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Abstract
Disease: Oculopharyngeal muscular dystrophy is a late onset muscular dystrophy char-
acterised by dysphagia, ptosis and limb weakness. The disease has a rate of occurrence
of 1 per 80,000 in the general population but a significantly higher incidence in the
Burkha-Jewish, French Canadian and Hispanic populations.
Therapeutic strateং: Numerous scientific reports have examined the effect of myo-
statin inhibitors in inherited and acquired muscular dystrophies, atrophies and my-
opathies. Here we evaluated the effect of treatment with the myostatin blocking an-
tibody RK35 on the disease progression of OPMD and associated muscle atrophy in
a murine model of OPMD. Subsequently, in order to facilitate disease diagnosis and
monitoring effectiveness of the treatment regimen, we evaluated select transcripts, pro-
teins and metabolites as possible biomarker candidates.
Methods: A17 OPMD mice at various ages were treated by intraperitoneal injection
with 10mg/kg of RK35 for 10 weeks weekly, and a range of physiological, histological,
mass spectrometric and biochemical parameters of disease progression monitored. Gas
chromatograpy based mass spectrometric analysis was then conducted in-order to iden-
tify possible markers of disease progression in mouse sera.
Results: Myostatin blockade in the A17 OPMD mice at an early stage of disease pro-
gression over a period of 10 weeks (12-22 weeks of age) significantly reduced loss of
body and muscle mass, increased muscle strength, increased myofibre diameter and
reduced expression of markers of muscle fibrosis. A similar treatment regimen in A17
OPMD mice at an advanced stage of disease progression (42-52 weeks of age) partially
restored body mass and increased muscle mass. A disease profile is subsequently pre-
sented from the perspective of potential biomarker candidates identified by serum mass
spectrometry.
Conclusion: Inhibition of myostatin by the clinically relevant monoclonal antibody
RK35 delays disease progression, muscle atrophy and fibrosis, in the early stages of
OPMD. In more advanced disease stages, RK35 treatment improved body and mus-
cle mass, but not myofibre diameter indicating a partial reversal of the muscle atrophy,
and amelioration of the disease phenotype.
iii
Contents
1 Introduction to biology, function and therapeutic application of
myostatin 1
1.1 The skeletal muscle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 Skeletal muscle histology . . . . . . . . . . . . . . . . . . . . . . 2
1.1.2 Skeletal muscle ultrastructure . . . . . . . . . . . . . . . . . . . . 3
1.2 Introduction to myostatin . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.3 Structure and regulation of myostatin gene and protein . . . . . . . . . . . 6
1.3.1 Structure of the myostatin gene . . . . . . . . . . . . . . . . . . . 6
1.3.2 Post-translational processing of the myostatin protein . . . . . . . 6
1.3.3 Regulation of myostatin expression . . . . . . . . . . . . . . . . . 8
1.4 Interaction of myostatin with cellular signalling pathways . . . . . . . . . . 11
1.4.1 Canonical myostatin signalling is effected through the ACTRIIB path-
way . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.4.2 SMAD4 as a limiting factor between canonical ACTRIIB and BMP
signalling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.4.3 Myostatin signalling interacts with IGF-1 pathway by forming a feed-
back loop with Akt . . . . . . . . . . . . . . . . . . . . . . . . . 14
1.4.4 Myostatin acts to arrest the cell cycle as an anti-proliferative agent . 14
1.4.5 Action of myostatin on oxidative stress of the cell and related path-
ways . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
1.4.6 Wnt signalling inhibits canonical myostatin pathway . . . . . . . . 16
1.4.7 Caveolins suppress myostatin signalling by receptor interaction . . 16
1.5 Evolutionary function of myostatin in invertebrate and vertebrates . . . . . 17
1.6 Effect of myostatin signalling on tissue systems . . . . . . . . . . . . . . . 19
1.6.1 Effect on skeletal muscles . . . . . . . . . . . . . . . . . . . . . . 19
1.6.2 Effect on cardiac muscles . . . . . . . . . . . . . . . . . . . . . . 21
1.6.3 Effect on skeletal framework . . . . . . . . . . . . . . . . . . . . 22
1.6.4 Effect on bioenergetics and metabolism . . . . . . . . . . . . . . . 24
iv
1.7 Commercial and clinical interest for myostatin inhibition . . . . . . . . . . 25
2 Introduction to oculopharyngeal muscular dystrophy and exper-
imental strategies towards amelioration of disease symptoms 29
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.2 Intra-nuclear inclusions as the hallmark of OPMD . . . . . . . . . . . . . 32
2.3 Disease models of OPMD . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.3.1 In vitromodels . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.3.2 Invertebrate models . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.3.3 Murine models . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.4 Therapeutic strategies towards treatment of OPMD . . . . . . . . . . . . 36
2.4.1 Surgical intervention . . . . . . . . . . . . . . . . . . . . . . . . 36
2.4.2 Pharmacological intervention . . . . . . . . . . . . . . . . . . . . 36
2.4.3 Molecular and cell therapy strategies . . . . . . . . . . . . . . . . 38
2.5 Need to identify disease biomarkers in OPMD . . . . . . . . . . . . . . . 43
2.6 Aims, objectives and hypotheses of current study . . . . . . . . . . . . . . 47
2.6.1 Aims and objectives . . . . . . . . . . . . . . . . . . . . . . . . . 47
2.6.2 Hypotheses: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3 Materials and methods 52
3.1 Animal handling and maintenance . . . . . . . . . . . . . . . . . . . . . 52
3.2 Genotyping of mice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.3 Intra-peritoneal injection procedures . . . . . . . . . . . . . . . . . . . . 54
3.4 Open field behaviour analysis . . . . . . . . . . . . . . . . . . . . . . . . 55
3.5 Forelimb grip strength analysis . . . . . . . . . . . . . . . . . . . . . . . 57
3.6 In-situmuscle electrophysiology . . . . . . . . . . . . . . . . . . . . . . . 57
3.7 Sample collection and processing . . . . . . . . . . . . . . . . . . . . . . 58
3.8 Immunohistochemical analysis . . . . . . . . . . . . . . . . . . . . . . . 59
3.9 Western blotting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.10 qPCR analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.11 Mass spectrometric analysis . . . . . . . . . . . . . . . . . . . . . . . . . 62
3.12 Statistical Techniques . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.12.1 Descriptive data analysis . . . . . . . . . . . . . . . . . . . . . . 63
3.12.2 Inferential data analysis . . . . . . . . . . . . . . . . . . . . . . . 63
3.12.3 Statistical packages employed . . . . . . . . . . . . . . . . . . . . 65
4 Treatmentwith anti-myostatin antibody RK35 ameliorates atrophic
symptoms at early stages of disease in the oculopharyngeal muscu-
lar dystrophy model mouse 66
v
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
4.2 Administration of RK35 prevents disease associated loss of body mass in early
stages of OPMD: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.3 Administration of RK35 prevents disease associated loss of muscle mass in early
stages of OPMD: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.4 Administration of RK35 antibody prevents disease associated reduction of my-
ofibre diameter in the OPMDmice: . . . . . . . . . . . . . . . . . . . . . 71
4.5 Increase in muscle mass of TA is accompanied by a decrease in expression of
collagen VI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4.6 Administration of RK35 antibody does not affect intranuclear inclusion den-
sity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
4.7 Increase in muscle mass is accompanied by an increase in muscle function . 78
4.7.1 Increase in muscle mass is accompanied by an increase in fore limb grip
strength. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
4.7.2 Administration of antibody RK35 results in no change in open field
behaviour test outcomes . . . . . . . . . . . . . . . . . . . . . . 79
4.7.3 Increase in muscle mass observed corresponds to an increase in max-
imal tetanic force . . . . . . . . . . . . . . . . . . . . . . . . . . 81
4.8 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
5 Treatmentwith anti-myostatin antibody RK35 partially ameliorates
atrophic symptoms at advanced stages of disease in the oculopharyn-
geal muscular dystrophy model mouse 91
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
5.2 Progression of disease results in lower initial body mass in 52-week old OPMD
mice: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
5.3 Administration of the RK35 antibody at advanced stages of disease progres-
sion restores muscle mass in the OPMDmice: . . . . . . . . . . . . . . . . 96
5.4 Increase in muscle mass is accompanied by a significant increase in myofibre
diameter in wild-type but not in OPMDmodel: . . . . . . . . . . . . . . 97
5.5 Increase in muscle mass of TA is accompanied by a decrease in expression of
collagen VI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
5.6 Administration of RK35 antibody does not affect intranuclear inclusion den-
sity in OPMDmuscle . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
5.7 Increase in muscle mass in OPMD treated with RK-35 antibody is accompa-
nied by no changes in muscle function . . . . . . . . . . . . . . . . . . . 103
5.7.1 Increase in muscle mass is accompanied by no change in forelimb grip
strength . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
vi
5.7.2 Administration of antibody RK35 does not affect open field behaviour
test outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
5.8 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
6 Treatmentwith anti-myostatin antibody RK35 partially reverses metabolic
dysregulation observed in energy production pathways of OPMD 115
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
6.2 Statistical analyses of serummetabolic profile of murine models of OPMD in
early stages of disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
6.2.1 Univariate statistical analyses reveal dysregulated metabolite features
due to the disease condition in the OPMDmice . . . . . . . . . . 117
6.2.2 Multivariate statistical models reveal distinct metabolic profiles for the
A17 mice from the FvB mice . . . . . . . . . . . . . . . . . . . . . 117
6.3 Functional analyses of serummetabolic profile . . . . . . . . . . . . . . . 125
6.3.1 Quantitative enrichment analyses reveal a dysregulation of energy pro-
duction pathways between the untreated A17 and FvB mice . . . . 125
6.3.2 Enrichment in predicted databases suggest dysregulation of enzymes
between the untreated A17 and FvB mice . . . . . . . . . . . . . . 126
6.3.3 Effect of anti-myostatin regimen on A17 metabolome . . . . . . . . 128
6.4 Change in metabolic profile is accompanied by alteration in expression levels
of select transcripts and proteins . . . . . . . . . . . . . . . . . . . . . . . 131
6.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
7 Discussion 144
References 155
Appendix A Additional data 201
vii
Listing of figures
1.1 Myostatin and BMP pathways jointly regulate muscle mass . . . . . . . . . 13
2.1 Strategies to ameliorate disease symptoms of OPMD . . . . . . . . . . . . 37
2.2 Myoblast transfer therapy to ameliorate disease symptoms of OPMD . . . . 42
4.1 Experimental design to test effect of RK35 antibody on muscle atrophy of 22-
week old OPMDmice . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
4.2 Effect of RK35 antibody on body mass of 22-week old OPMDmice . . . . . 70
4.3 Effect of RK35 antibody on muscle mass of 22-week old OPMDmice . . . . 72
4.4 Effect of RK35 antibody on myofibre diameter of 22-week old OPMDmice 74
4.5 Effect of RK35 antibody on collagen VI deposition in muscles of 22-week old
OPMDmice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4.6 Effect of RK35 antibody on INI in muscles of 22-week old OPMDmice . . 77
4.7 Effect of RK35 antibody on forelimb grip strength of 22-week old OPMDmice 80
4.8 Effect of RK35 antibody on open field behaviour of 22-week old OPMDmice 83
4.9 Change in tetanic force generated in TA of 22-week old OPMDmice admin-
istered with RK35 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
5.1 Experimental design to test effect of RK35 antibody on muscle atrophy of 52-
week old OPMDmice . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
5.2 Effect of RK35 antibody on body mass of 52-week old OPMDmice . . . . . 95
5.3 Effect of RK35 antibody on muscle mass of 52-week old OPMDmice . . . . 98
5.4 Effect of RK35 antibody on myofibre diameter of 52-week old OPMDmice . 100
5.5 Effect of RK35 antibody on collagen VI deposition in muscles of 52-week old
OPMDmice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
5.6 Effect of RK35 antibody on INI in muscles of 52-week old OPMDmice . . 104
5.7 Effect of RK35 antibody on forelimb grip strength of 52-week old OPMDmice 106
5.8 Effect of RK35 antibody on the open field behaviour of 52-week old OPMD
mice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
viii
6.1 Change in serummetabolite levels of 22-week old OPMDmice (fatty acids) 120
6.2 Change in serummetabolite levels of 22-week old OPMDmice (mitochondrial
intermediates) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
6.3 Change in serummetabolite levels of 22-week old OPMDmice (Amino acids
and misc.) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
6.4 PLS-DA of serummetabolite features from 22-week old OPMDmice . . . 123
6.5 Metabolic set enrichment analysis of serummetabolites from 22-week old A17
and FvB mice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
6.6 Metabolic set enrichment analysis of serummetabolites from 22-week old treated
A17 and FvB OPMDmice . . . . . . . . . . . . . . . . . . . . . . . . . . 130
6.7 Mitochondrial oxidative phosphorylation activity in TA of 22-week old OPMD
mice: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
6.8 Expression of select transcripts in TA of 22-week old OPMDmice . . . . . 134
6.9 Dysregulation of metabolites linked to mitochondrial shuttles in OPMD . . 140
A.1 Effect of RK35 antibody on minimum feret diameter of 22-week old OPMD
mice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
A.2 Effect of RK35 antibody on minimum feret diameter 52-week old OPMDmice 208
ix
List of Tables
3.1 Variables from open field behaviour analysis . . . . . . . . . . . . . . . . . 56
4.1 Open field behaviour of 22-week old OPMDmice does not change with treat-
ment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
5.1 Open field behaviour of 52-week old OPMDmice does not change with treat-
ment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
6.1 Change in serummetabolite levels of 22-week old OPMDmice . . . . . . . 118
A.1 Change in body mass of 22wk old OPMDmice . . . . . . . . . . . . . . . 201
A.2 Change in muscle mass of 22wk old OPMDmice . . . . . . . . . . . . . . 202
A.3 Change in minimum feret diameter of 22wk old OPMDmice . . . . . . . . 203
A.4 Change in collagen VI expression of 22wk old OPMDmice . . . . . . . . . 203
A.5 Change in INI density in TA of 22-week old OPMDmice administered with
RK35 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
A.6 Change in forelimb grip strength in 22-week old OPMDmice administered
with RK35 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205
A.7 Change in maximal force generated in TA of 22-week old OPMDmice admin-
istered with RK35 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205
A.8 Change in body mass of 52wk old OPMDmice . . . . . . . . . . . . . . . 205
A.9 Change in muscle mass of 52wk old OPMDmice . . . . . . . . . . . . . . 206
A.10 Change in raw muscle mass of 52wk old OPMDmice . . . . . . . . . . . . 207
A.11 Change in minimum feret diameter of 52wk old OPMDmice . . . . . . . . 209
A.12 Change in collagen VI expression of 52wk old OPMDmice . . . . . . . . . 209
A.13 Change in INI density in TA of 52-week old OPMDmice administered with
RK35 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
A.14 Change in forelimb grip strength in 52-week old OPMDmice administered
with RK35 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
x
Abbreviations
AAV Adeno-associated virus
ACTRIIB Activin receptor IIB
AON Antisense oligonucleotide
BMP Bone morphogenetic protein
BMSC Bone marrow derived mesenchymal stem cells
CDK Cyclin dependant kinease
DMD Duchenne muscular dystrophy
ECM Extracellular matrix
EDL Extensor digitor longus
FLRG Follistatin related gene
FSD Follistatin domain
GASP-1 Growth and differentiation factor-associated serum protein-1
GCMS Gas chromatography / Mass spectrometry
GDF Growth and differentiation factor
HSP Heat-shock protein
IGF-1 Insulin like growth factor-1
INI Intra -nuclear inclusions
LAP Latency associated peptide
LCMS Liquid chromatography / Mass spectrometry
LTBP Latent transforming growth factor beta binding protein
MRF Myogenic regulatory factor
mTOR Mammalian target of rapamycin
xi
NF-kB Nuclear factor kappa light chain enhancer of activated B cells
Normal QQ plot Normal quantile-quantile plot
OPMD Oculopharyngeal muscular dystrophy
PABPN1 Polyadenylate binding nuclear factor-1
shRNA Small hairpin RNA
siRNA Small interfering RNA
SNP Single nucleotide polymorphism
SPARC Secreted protein acidic and rich in cysteine
TA Tibialis anterior
TGF-beta Transforming growth factor β
TNF-alpha Tumour necrosis factor - alpha
xii
Dedicated to my mice.
May your legacy live on.
Except you number 42.
xiii
The evolution of life in different physicalhabitats across aerial, aquatic, fossorial and ter-restrial environments presents a unique challenge
and must be overcome by an organism to forage, mate,
shelter and to escape predators. Locomotion is essential
for survival, and as such over the course of time has been
under a strong selective pressure, with animals adapting
their musculo-skeletal structures to increase efficacy for
their most used behaviour; for example, migratory ani-
mals have adapted themselves to be energy efficient for
movement over large distances, whereas non-migratory
animals that require quick bursts of momentum to
escape predators are likely to have a costly but very fast
locomotion. Arthropods such as the crustaceans have a
greater need for muscle plasticity as they undergo a series
of atrophy and regrowth during their stages of moulting
and subsequently is essential for the growth and survival
of the species itself 244. Fishes on the other hand display a
remarkable control over the size of muscle fibres in order
to maximise energy efficiency and balance diffusional
constraints especially in Arctic habitats 193.
This versatility of the muscle cell is determined by many
factors that are intricately controlled from the onset of
myogenesis to adulthood (such as resistive/endurance
based activity, electrical simulation/denervation, a
heavy load/ microgravity, nutritional and calorific sup-
ply/hypoxia and calorie restriction) which results in
the muscle tissue to be highly responsive to functional
demands by bringing a change in the physiological prop-
erties of the muscle (twitch speed, specific and absolute
force, oxidative capacity and endurance) as well as the
intra-cellular and extra-cellular regulatory mechanisms
encompassed in the contractile apparatus 122. The discov-
ery, analysis and modification of these factors will have
numerous therapeutic and agricultural implications.
xiv
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Understanding the mechanism by which myostatin
regulatॽ muscle mass will be critical not only for under-
standing the control of tissue size in general but also for
developing new strategiॽ for increasing muscle growth
both for human therapeutic applications and for livestock
production.
Lee 224
Chapter 1
Introduction to biology, function and therapeutic ap-
plication of myostatin
1.1 The skeletal muscle
Muscles transform neural control signals into forces that act upon the body segments to ef-
fect a coordinated motor task. They represent the classic biological example of a structure-
function relationship and are primarily responsible for maintenance of and changes in pos-
ture, locomotion, as well as movement of internal organs, such as the contraction of the
heart and peristalsis. The muscle tissues are derived from the mesodermal layer of embry-
onic germ cells in a process known as myogenesis45. The processes involved in myogenesis
(the formation of skeletal musculature during embryonic development) is common among
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all vertebrates, and broadly involves the commitment of stem cells to myogenic precursor
cell (MPC) pools, followed by differentiation into myoblasts, migration and fusion to form
myotubes, while simultaneously undergoing a myogenic-lineage pathway to transform into
fusion competent myoblasts 195.
1.1.1 Skeletal muscle histology
The skeletal muscle structure integrates contractile and structural elements in-order to ef-
fect contraction. A layer of dense connective epimysieal tissue surrounds each muscle, and
is usually continuous with the tendon of a muscle 109. A muscle is composed of numerous
fascicles composed of bundles of muscle fibres separated by the perimysium (with arterioles
and veins running between the fascicles) 109. Another structure in the perimysial connective
tissue are the muscle spindle fibres which acts in a sensory capacity and is associated with
the coordination of muscle activity and stretch, and the maintenance of muscle tone. They
are found in all muscles except those of the face 109. Endomysium ultimately separates indi-
vidual muscle fibres from each other, and is usually associated with the extracellular matrix.
Transverse sections of muscles usually reveal multinucleated, polygonal fibres ranging be-
tween 40 to 80 microns in diameter 109. It is usually possible to differentiate one fibre from
the other, with the intramyofibrillar space often appearing as one continuous netweork un-
der the microscope 109. Skeletal muscle extracellular matrix (ECM) strongly affects muscle’s
normal function, its ability to adapt, and the biological reservoir of muscle stem cells that
it provides. Biomechanical studies support the idea the ECM bears the majority of muscle
passive load, which implies that clinical examination of patient range of motion and stiff-
ness primarily reflect their ECM properties. In addition, while muscle pathology is typically
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described in terms of altered fibre type, fibre size distribution or centralized nuclei, nearly
every pathological change reported in muscle is also associated to some degree with ECM
fibrosis 109.
Skeletal muscle fibres are divided into multiple types based on twitch speed. Type I my-
ofibers are the slow-twitch fibers, also referred to as slow-oxidative fibres. They are charac-
terised by a slow contraction time following electrical stimulation, are usually recruited first
in the henneman recruitment 24. They are ideally suited for sustained, low-level activity. To
accomplish this, they are equipped with numerous large mitochondria and relatively abun-
dant intracellular lipid for oxidative metabolism 165. In contrast to the type I fibres, the type
II fast-twitch muscle fibre has a predominant glycolytic metabolism, poor vasculature, rela-
tively abundant glycogen stores and decreased activity of oxidative enzymes resulting from
fewer mitochondria as compared to the slow-twitch muscles 165. The type II myofibres are
further divided into types IIa (fast aerobic or intermediate twitch myofibre), and IIb (fast
glycolitive or fast twitch myofibres). In small mammals, a fourth myosin heavy chain iso-
form, MHCIIx is present that has an intermediate contractile speed between the MHCIIa
andMHCIIb isoform 165. Muscle fibres of a single motor unit are uniform in their fibre
type, though randomly scattered 109. The proportion of each fibre type, however, varies
considerably between muscles and even in different regions of the same muscle.
1.1.2 Skeletal muscle ultrastructure
The basic contractile unit of the muscle fibre is the sarcomere. Three distinct regions are
observed, namely two Z-lines flanking ethe ends and oneM-line localized centrally in the
sarcomere. The Z-line is composed mainly of a-actin in and provides support for the hori-
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zontal thin filaments which are perpendicularly oriented towards the M-line in both sides
of the Z-line79. TheM-line is composed of myomesin, M-protein and creatine kinase and
provides support for the horizontal thick filaments which are perpendicularly oriented
towards the Z-line in both sides of the M-line79. Titin is a large elastic protein that spans
from the Z-line to the M-line and closely associates with the thick filaments, playing a major
role in the maintenance of the alignment and orientation of the thick filaments in the sar-
comere 383. Multiple helically oriented actin molecules form the F-actin. Tropomyosin and
troponin are attached to the thin filament at regular intervals to prevent “misfire” result-
ing in unwanted contractions. The length of the thin filament is thought to be controlled
by a giant protein, nebulin, although this function remains contentious 256. The thick fila-
ment is mainly composed of myosin molecules comprising two heavy chains and four light
chains, arranged as a a-helix, resulting in the rod-like structure of the thick filament. The
N-terminal region of the myosin molecule has actin-binding sites and ATPase properties.
Shortening of the sarcomere and muscle contraction is based on the sliding of the thick
and thin filaments which occurs through the interaction of the myosin head with the actin
molecule 182.
The sarcolemma has special membrane invaginations known as the t-tubules that assist
in expediting the transfer of the action potential (from the neuromuscular junction) to the
flanking sarcoplasmic reticulum (terminal cisternae) 181. The action potential (received from
a neuron) travels across the sarcolemma, through the transverse (t) tubules where it causes a
conformational change in the dihydropyridine receptors (DHP) , that are physically linked
to the ryanodine receptors (Ryr) resulting in the opening of the calcium channels of the sar-
coplasmic reticulum. The tropomyosin hinders the actin’s myosin binding sites, preventing
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muscle contraction in a resting muscle. The binding of troponin with the calcium ions (re-
leased from the sarcoplasmic reticulum) shifts the tropomyosin and allows actin to bind to
myosin for muscle contraction. This reaction is reversed when the sarcoplasmic concentra-
tion of calcium decreases 357.
1.2 Introduction to myostatin
Myostatin and the closely related growth differentiation factor 11 (GDF11) are believed to
have separated from the ancestral gene, after the divergence of the Piscॽ from the universal
common ancestor *, sharing similar hallmarks and displaying remarkable sequence homol-
ogy with up to 90% similarity in the mature region of the protein when comparing the
Piscॽ to mammals 131,238. Lee 224 proposes the physiological action of myostatin to be similar
to a chalone for skeletal muscle †, and numerous studies indeed demonstrate that increased
expression of myostatin does lead to reduced skeletal muscle mass caused by downregula-
tion of muscle specific genes and reduced cardiac integrity caused by atrophy 110,320,436. Con-
versely, a knock down or knock out of myostatin results in a hyper muscular characteristic
in animals and humans.
*InDrosophila melanogaster, there exists the ancestral myoglanin gene which is believed to be related to
myostatin
†Proposed by Bullough 51 , a chalone being tissue secreted chemical effector, which acts as a negative regula-
tor of tissue size by directly or indirectly influencing mitosis
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1.3 Structure and regulation of myostatin gene and protein
1.3.1 Structure of the myostatin gene
The myostatin gene (MSTN, 2q32.2) spans two introns and three exons with the last exon
coding for the (mature protein) bioactive domain 141. The myostatin promoter has several
muscle specific cis elements (E-box clusters) for the myogenic regulatory factors (MRF)
such as MyoD,Myf5, myogenin andMRF4 359. The expression profile of the MRFs todotypo
(MyoD, andMyf5 being expressed in the proliferating and fusing myoblasts and myotubes;
myogenin being expressed in differentiating myotubes; andMRF4 being expressed in ter-
minal myogenic differentiation) and the proximity of the clusters to the promoter suggests
a cooperative regulation of transcription and imply a high transcriptional control of myo-
statin during myogenesis 359. MSTN has three mRNA start sites at nucleotide positions
-76, -116 and -166 with the latter two start sites producing cDNAs of expected lengths 141.
Expression of myostatin though primarily found in skeletal muscle tissues 198,264, has also
been recorded in lower levels in other tissue types Deng et al. 98 , such as the adipose tis-
sues 264, mammary glands 190, Purkinje fibres and cardiomyocytes 351, spleen, lymphocytes 243,
placenta 277, and in the uterine gland during adenomyosis61.
1.3.2 Post-translational processing of the myostatin protein
The myostatin pre-protein (375 amino acid residues) consists of three regions (of the signal
peptide, pro-peptide and mature region), which are proteolytically cleaved to unmask the
mature protein. The first cleavage removes the 24 amino acid signal peptide region (respon-
sible for targeting protein to secretory pathway) from the N terminus of the protein 224,337.
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The ensuing secretion of myostatin is proposed to follow two distinct pathways (leading
to local and systemic pools of myostatin), which differ by the location of the subsequent
cleavage events of the pre-protein from the mature peptide.
The canonical pathway includes the processing of myostatin along the intra-cellular se-
cretory pathway. The pro-myostatin in the endoplasmic reticulum undergoes homodimeri-
sation during which the mature protein (C-terminal fragment at about 12 kDa), folds into
the classical hand architecture: each monomer having four β-sheet fingers, a cysteine knot
motif in the palm region, and a major helix at the wrist along with a pre-helix loop which
interacts with an anti-parallel monomer to form the dimer in a palm-to-palm orientation
by an intermolecular disulfide bond63. The N-terminal pro-peptide region also undergoes
a homodimerisation event and is separated from the mature protein by a tetrabasic cleavage
site. The second proteolytic event structurally separates the pro-peptide region from the
mature protein at the RSRR site and is believed to occur at the Golgi apparatus mediated
by furin pre-protein convertases48,258. The mature protein thus formed has distinct sur-
faces that render specificity to receptor binding sites, namely: two convex β-sheet (finger)
regions and two concave (finger-tip) regions. Subsequent to the cleavage event, the pro-
peptide re-associates with the mature protein in a non-covalent manner, regulating folding
and “activation” of the mature peptide, in a structure termed as the latancey associated pep-
tide (LAP)63. The LAP - myostatin complex is thus secreted by the cell and is abundant in
the serum, contributing to the systemic pool of myostatin 166,436. The final “activation” is
initiated by a cleavage event believed to be regulated by the BMP-1 metallo-proteases that
disrupts the bond between the pro-protein and the mature protein, releasing the latter and
permitting the subsequent initiation of signalling cascades 224.
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An alternative pathway for myostatin secretion was proposed by Anderson et al. 8 wherein
the second proteolytic event during myostatin processing (by the furin pre-protein con-
vertases) occurred in an extra-cellular environment (rather than at the intra-cellular golgi
apparatus). This was achieved by the latent TGF-β binding proteins (LTBP) which con-
tributed to a local pool of pro-myostatin that is present endogenously in skeletal muscle (in
addition to serummyostatin) regulating muscle physiology in specific muscle groups, and is
discussed later on in this chapter.
1.3.3 Regulation of myostatin expression
The regulation of myostatin signalling is achieved by multiple pathways including at the
level of the transcript by miRNAs 107,178,205,260,353, the level of the protein by different binding
factors and at the level of signalling pathways wherein myostatin cleavage from the pro-
peptide is controlled by the SMAD proteins 224. The major myostatin binding proteins
come from the follistatin domain family. The first subfamily includes binding proteins
such as follistatin and glycoproteins encoded by the follistatin-related gene (FLRG), and
the second subfamily consisting of secreted protein acidic and rich in cysteine (SPARC),
Growth and differentiation factor-associated serum protein-1 (GASP-1) and other proteins
associated with the extra-cellular matrix.
Follistatin binds with myostatin and prevents receptor association
Follistatin is a highly conserved secreted glycoprotein and acts as a broad spectrum antag-
onist for myostatin and Activin-a64. Follistatin has an N terminal domain which binds to
the concave surface of the myostatin protein, and two follistatin domains (FSD1 and FSD2)
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which bind the convex β-sheet fingers. Two follistatin proteins hence surround each myo-
statin ligand preventing receptor association64. The heparin binding domain in follistatin
also causes endocytosis of the bound myostatin ligand and eventual intra-cellular diges-
tion64.
FSTL-3 is another member of the follistatin family63. The role of FSTL-3 in the regu-
lation of muscle mass is currently unclear, as though FSTL-3 is shown to block myostatin
activity in vitro and increase muscle growth in vivo, reports have however also shown that
a homozygous FSTL-3 =  mouse possesses normal muscle mass and subsequent loss of
function studies reported no change in the anatomy and physiology of the model 226.
GASP-1 regulates myostatin signalling by steric inhibition and receptor as-
sociation
Growth and differentiation factor-associated serum protein-1 (GASP-1), is shown to bind to
myostatin at physiological conditions to regulate myostatin bio-availability in the serum 167.
It contains structural elements of whey acidic protein domain, an Ig domain, two tan-
dem Kunitz domains, a netrin domain and also contains a homologous domain to the cys-
teine repeat reminiscent of follistatin278. However, due to the absence of a characteristic
hydrophobic insertion at the C-terminal cysteine rich region (between cysteines 5-6, respon-
sible for the formation of the kazal protease inhibitor loop) which attenuates the protease
activity in other proteins of the subfamily (e.g. SPARC), GASP-1 retains and functions as a
protease inhibitor against serine proteases and metalloproteases 167. This is evidenced by the
complex series of interactions it participates in with myostatin in that the mature myostatin
protein and the myostatin pro-peptide independently compete to bind to GASP-1 167. The
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follistatin domain may regulate the binding of myostatin to GASP-1 in a manner consis-
tent with other binding proteins of the follistatin family and subsequently prevent receptor
association. Hill et al. 167 further suggest the possibility of GASP-1 regulating myostatin bio-
availability in a manner independent of the follistatin domain by antagonising the follow-
ing essential cleavage steps during protein processing: the processing of myostatin protein
by inhibiting the BMP-1 metalloprotease and the cleavage of the (non-covalently bound)
pro-peptide from the mature region of the protein.
LTBP binds secreted myostatin to extracellular matrix regulating bioavail-
ability
The LTBP are a family of four proteins that bind to TGF-β (via an 8-cysteine rich motif)
functioning as a chaperone during their respective secretory pathways 324 and associates with
both the pro-myostatin and the processed protein. Indeed, the pro-myostatin is linked non-
covalently to the LTBP, and enables the presence of an extra-cellular pool of myostatin.
On the contrary for the LAP-MSTN complex, the pro-peptide of myostatin is associated
with the LTBP by a disulfide bond, whereas the mature ligand interacts with the LTBP by
non-covalent means 8. Interestingly for a stable complex to form between the LTBP and
myostatin, the mature myostatin must be associated with the pro-peptide, as neither the
pro-peptide or the mature protein alone can associate with the LTBP8. Of the 4 proteins in
the LTBP family, LTBP-2 associates with non-glycosylated pro-myostatin that is retained in
the endoplasmic reticulum (and consequently not competent for secretion), while LTBP-
3 associates with glycosylated pro-myostatin that can be secreted 324,379. Once secreted, the
LTBP-myostatin complex covalently binds to the extra-cellular matrix, subsequently requir-
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ing a two-step activation process: the disassociation of the pro-myostatin protein from the
LTBP and further cleavage by extra-cellular furin protease to initiate the signalling cascade,
resulting in a tissue-level/local control of myostatin bio-availability8.
1.4 Interaction of myostatin with cellular signalling pathways
1.4.1 Canonical myostatin signalling is effected through the ACTRIIB path-
way
Canonical myostatin signalling relies upon the binding of C terminal dimers of the ma-
ture myostatin protein, to the Activin type II B receptor (ACTRIIB), a transmembrane
serine/threonine kinase and to a lesser degree ACTRIIA228,318. The binding to ACTRIIB
is facilitated by the convex surface of the mature myostatin protein 376 which stimulates re-
cruitment of an activin receptor like kinases (Alk), Alk 4 and 5 which bind to the wrist helix
and finger region of the mature myostatin protein 147,227. The recruitment of Alk 4/5 leads
to the activation of their latent kinase activity and results in the phosphorylation of serines
residues at the carboxy terminal domain of (receptor regulated) R-SMADs 2 and 3. The
phosphorylated R-SMAD complex SMAD 2/3 then forms a heterodimeric complex with
the co-SMAD 4, and translocates to the nucleus and effects transcriptional control of the
ubiquitin proteolytic pathways6,100,259. Within the SMAD signalling cascade, SMAD 7,
works as a negative feedback inhibitor by acting on the myostatin promoter 124. SMAD 7
also interrupts the association of the SMAD 2/3 and SMAD 4 by competitive binding, in-
hibiting the formation of the transcription factor complex 162,289. The inhibitory association
by SMAD 7 with R-SMADS further results in the recruitment of the E3 ubiquitin ligases
and eventual degradation of the (DNA binding) complex425.
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Recombinant mature myostatin has been shown to reversibly inhibit the myogenic dif-
ferentiation of myoblasts by downregulating MyoD,Myogenin, Myf5 and p21 via canonical
signalling 20,266,279. Myostatin has been shown to downregulate MyoD by a FOXO1 depen-
dent mechanism 20,259.
1.4.2 SMAD4 as a limiting factor between canonical ACTRIIB and BMP signalling
The bone morphogenetic proteins (BMPs) also form part of the TGF-β superfamily and
from two studies in 2013 were implicated to interact with myostatin signalling 340,419. The
binding of BMPs (such as BMP7 and BMP14) to their receptors and subsequent phospho-
rylation of R-SMADs 1/5/8 results in the formation of a hetero-trimeric complex (figure:
1.1). This complex binds to the co-SMAD SMAD 4 forming the transcription effecting
complex, which similarly translocates to the nucleus to effect transcription of target genes.
SMAD 4 forms the common link and limiting factor between canonical myostatin and
BMP signalling pathways (figure: 1.1). Sartori et al. 340 suggest that the muscle hypertro-
phy observed upon myostatin inhibition is not due to the absence of the synthesis of atro-
genes (genes that influence atrophy of muscle tissue) resultant from canonical myostatin
signalling, but rather due to an increased BMP signalling. The authors propose that it is
the balance of BMP and myostatin signalling that is crucial for maintaining muscle mass
(figure: 1.1) 340. The resultant BMP signalling causes an increase in cellular growth (without
associated satellite cell activation and nuclear accretion) in the skeletal muscle which leads to
the characteristic double-muscling phenotype in myostatin null mutants 340.
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Figure 1.1: Myostaধn and BMP pathways jointly regulate muscle mass: SMAD4 is the limiধng factor between myostaধn and BMP signalling.a Excessive
myostaধn signalling causes muscle atrophy as compared to (b) signalling effected in a healthy ধssue. However, (c) inhibiধon of myostaধn results in excessive
BMP signalling, leading to muscle hypertrophy.
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1.4.3 Myostatin signalling interacts with IGF-1 pathway by forming a feed-
back loop with Akt
Insulin like growth factor-1 (IGF-1) increases muscle growth via the IGF-1/PI3K/Akt/mTOR
pathway and is shown to interact with the canonical myostatin signalling via Akt. SMAD2/3,
which participates in the canonical myostatin signalling functions as an inhibitor of Akt
(which itself serves as an indirect activator of mTOR), whereas mTOR is an inhibitor
of SMAD2/3 in a feedback loop 157,186,339,382. Studies show IGF1 to be dominant over myo-
statin signalling in cultured muscle cells, however overexpression of myostatin has been
shown to inhibit IGF17, due to an increased Akt activity evidenced in in-vitro and in-vivo in
MSTN =  null models 236,283. It has been hypothesised that myostatin can switch between
the protein synthesizing pathways mediated by mTORC1 and mTORC2, to pathways in-
hibiting protein synthesis, possibly mediated by FOXO transcription factors and GSK3B,
resulting in muscular atrophy 114.
1.4.4 Myostatin acts to arrest the cell cycle as an anti-proliferative agent
The cell cycle consists of 2 main stages of cell division: mitosis and interphase, which is
further divided into: Gap phase 1 (G1), S phase and gap phase 2 (G2). Myostatin has been
shown to reversibly arrest the cell cycle in the G1 phase in cultured muscle cells such as
C2C12 myoblasts 255,333,374,375. The anti-proliferative effect of myostatin was found to corre-
late with the increased activity of the cyclin dependent kinase (CDK) inhibitor p21, and
therefore result in the downregulation of CDK2 and CDK4 255,374,375. CDK4 activity is also
downregulated by myostatin via increased cyclin D1 degradation, a protein vital to the reg-
ulation of the G1 phase of the cell cycle426. Interestingly, a model overexpressing myostatin
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has been shown to have pronounced atrophy of muscles and an increased myonuclear do-
main as compared to the wildtype animals, suggesting possible effects on satellite cell prolif-
eration in pre-natal stages of ontogeny 321.
1.4.5 Action of myostatin on oxidative stress of the cell and related path-
ways
Tumour necrosis factor - alpha (TNF-α) is a cytokine involved in the acute phase of sys-
temic inflammation, and initiates a signalling cascade via TNF receptor type 1 or type 2.
Upon binding, the receptor forms a homotrimer and undergoes conformational changes
to facilitates additional protein interactions following which signalling continues via three
potential cascades: activation of various MAPK cascades, induction of apoptotic signalling,
and activation of the transcription factor nuclear factor kappa light chain enhancer of ac-
tivated B cells (NF-κB)60,175,183,191,307,428. NF-κB has been implicated as an atrophy inducing
transcription factor in various studies, mediated via various catabolic pathways including
signalling influenced by TNF-α 54,104,180,232,285. ‡ Evidence has been presented implicating
myostatin signalling via a TNF-α/NF-κB to NADPH oxidase pathway in the production
of reactive oxygen species (ROS) in skeletal muscle. TNF-α has been shown to strongly in-
duce myostatin expression via NF-κB signalling, and in a feed forward manner, higher levels
of TNF-α stimulate further expression of myostatin. As the presence of myostatin activates
secondary messenger ROS via a TNF-α/NADPH oxidase mechanism, increased levels of
myostatin lead to increased levels of ROS and therefore oxidative stress in the cellular sys-
tem 362.
‡TNF-αmediated activation of NF-κB has been shown to downregulate the expression of differentiation
factors such as Myogenin and Akt, vital factors in the myogenesis and promoting IGF1/Akt pathway 151
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1.4.6 Wnt signalling inhibits canonical myostatin pathway
Wnt signalling is most commonly known for its role in asymmetric division, cell prolifera-
tion and fate determination during embryonic development 134. Studies have shownWnt4
to have the strongest inhibitory effect on myostatin, due to its negative effects on SMAD
signalling via the activation of the β-catenin pathway in early differentiating cells 363,365.
Takata et al. 365 suggestedWnt4 mediates its effects on myogenesis by inducing effects op-
posite to those of myostatin, and downregulate myostatin expression in myoblasts. Inter-
estingly, Bernardi et al. 30 hypothesise either Wnt4 inhibits SMAD signalling independently
of myostatin or Wnt4 lies upstream of myostatin.
1.4.7 Caveolins suppress myostatin signalling by receptor interaction
Caveolin proteins which mediate cell membrane invaginations, have been shown to regu-
late many cellular mechanisms, such as vesicular trafficking and signal transduction 237,300,301.
Caveolin 3 is a muscle specific membrane protein and several mutations have been shown
to cause limb girdle muscular dystrophy275. Caveolin 1 interacts with TGF-β type I and II
receptors, as well as type I and II receptors of the BMPs, indicating caveolin regulation of
TGF-β superfamily signalling at receptor level 222,349,432. Studies have shown that caveolin
3 interacts with and eventually suppressed intracellular myostatin signalling by decreasing
phosphorylation of SMAD 2 as well as transcription levels of SMAD 294.
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1.5 Evolutionary function of myostatin in invertebrate and vertebrates
Myostatin is expressed in skeletal muscles from somitogenesis into adulthood 141. The evo-
lution of myostatin is interesting in that the gene for myostatin diverged from the ances-
tral gene recently and has since been under strong stabilising selection pressure 1,131,224,295.
Though seemingly counter-intuitive for natural selection, myostatin may have been se-
lected for: it drives more efficient oxidative (fatty-acid) based metabolism (as compared
to less efficient glycolytic metabolism), and subsequently allows long-distance based en-
durance activities 284; Studies have also shown that myostatin plays a role in cell-fate deter-
mination of precursor cells of the muscular and adipose tissue systems 177,412.
As discussed previously, expression of myostatin is actively regulated and is suggested
to interact with protein cascades controlling muscle growth 135,293,325. For organisms such as
the crustaceans who undergo a moult-dependant discontinuous growth process, muscles
undergo a reversible atrophy to detach and subsequently exuviate body parts from the old
exoskeleton. This process is marked by significant changes in the expression and abundance
of Mstn/Gdf-1195. Interestingly, a relatively high amount of putative myostatin transcripts
were also observed during the intermolt stage where the growth of the muscle is restricted
by a rigid exoskeleton95. The multiple genome duplication events in the Piscॽmay suggest
that myostatin plays a crucial role in embryonic development in fishes (after the events of
gastrulation), with studies in the rainbow trout (a salmonid) indicating the transcripts of
mstn-1a andmstn-1b being observed in the developing somite (with an increase in transcript
levels being observed during the progression of somitogenesis) possibly to regulate myogen-
esis, a function which has been well conserved. In contrast however,mstn-2 transcripts were
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reported to be not well expressed till adulthood, wherein the only correctly spliced tran-
script ofmstn-2a is expressed predominantly in the brain, adding a layer of redundancy to
the functions of gdf-11.
In contrast to the Piscॽwho posses multiple copies of the gene due to whole genome
duplication events 131,135, the mammals only possess one copy of the myostatin gene (though
different splice variants have been indicated 190). Analysis of bovine and porcine tissues in-
dicate that myostatin transcripts were detected consistently from prenatal stages, charac-
terised by a notable increase in transcript levels early in development sustained until late
gestation, and then reduction of transcript levels at birth 190,198. This pattern was found to
coincide with the progression of primary and secondary myofibrillogenesis 190. Further-
more, the expression of myostatin is majorly restricted to the skeletal muscles (specifically to
the developing muscle fasciculi rather than the ancillary cells), but has also been observed
(albeit at low levels) in mammalian cardiac muscles (playing a role in morphogenesis),
mammary gland, adipose tissues, serum and the brain 190,325. When considering the expres-
sion pattern of GDF-8 and GDF-11 taken together, in mammals, different spatiotemporal
expression patterns restricts primary GDF-11 functions on the neural system, and primary
myostatin functions on the musculoskeletal system. This suggests that myostatin may have
had a role as a general differentiation factor in non-mammalian vertebrates (evidenced by
the ubiquitous presence of receptors), and the limited roles in mammals being a recent evo-
lution of myostatin 325.
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1.6 Effect of myostatin signalling on tissue systems
1.6.1 Effect on skeletal muscles
Studies have shown that the level of expression of myostatin inversely correlates with mus-
cle mass and subsequently results in numerous anatomical, physiological and metabolic
modifications in the skeletal muscle. The inhibition of myostatin in mammals show an in-
crease in muscle mass by hypertrophy (in the event of a postnatal knockdown) or by both
hypertrophy and hyperplasia (in the case of a genetic knockdown)224. Evidence from stud-
ies in animals such as the mouse, cow, sheep and humans indicate that myostatin also func-
tions in a dose dependant manner with heterozygous and homozygous (null) mutants of
myostatin having significantly more skeletal muscle mass than wild-type 263,269. Within the
muscles, type II fibres were reported to be more susceptible/responsive to the myostatin
signalling pathways than the type I fibres (due to the presence of additional ActRIIB recep-
tors relative to type I fibres)410.
Myostatin appears to act in two distinct phases dependant on gestational age and tar-
get tissue: myostatin appears to regulate satellite cell proliferation during primary myoge-
nesis influencing the cyclin kineases (resulting in hyperplasia and hypertrophy) in a pre-
natal organism; postnatal myostatin knockdown however is unable to bring about de-
novomyofibrillogenesis, and the hypertrophy observed in a post-mitotic fibre is primar-
ily caused by cytoplasmic growth (rather than by nuclear accretion) mediated by non-
canonical pathways264,340. Myostatin null animals also exhibit a fibre type shift towards
the fast glycolytic from the slow oxidative type 263,415, but not in healthy mice subject to
postnatal anti-myostatin strategies, andMouisel et al. 284 postulate a role for myostatin in
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regulating the delicate balance between muscle mass, strength, and oxidative / glycolitive
capacity in the skeletal muscle. Interestingly, myostatin has been demonstrated to increase
glucose uptake in muscle cells76,171. Disruption of myostatin in null mutants though result-
ing in an increased muscle growth, comes at a cost of decreased specific force, and increased
muscle fatigue (contributed to by a reversible fibre type shift towards glycolytic phenotypes,
which was reported to be attenuated by an endurance exercise regime 253). The hypertrophic
response in the null mutants was also correlated to a reduction in the mitochondrial con-
tent and subsequent oxidative phosphorylation (OXPHOS) activity, increased intolerance
to exercises, frequent muscle cramps, vulnerability to lactic acidosis and rhabodomyoly-
sis 284,312.
Muscle fibrosis is an essential step for resolution of acute injuries to permit myofibre
stumps to reform the contractile unit, subsequent to which the fibroblasts undergo apop-
tosis 233. Myostatin is reported to directly simulate proliferation of muscle fibroblasts and
subsequent expression of extra-cellular matrix proteins like collagen. While a study by Li
et al. 234 implies that myostatin protects muscle fibroblasts from apoptosis, further analysis
(especially in loss of function model systems) will provide insight into possible therapeutic
targets.
We must be careful when interpreting results from early in-vitro studies on myostatin,
which provided inconclusive and often contradictory conclusions regarding the effect of
myostatin inhibition on satellite cell proliferation. Rodgers & Garikipati 325 suggests that
research groups standardise the source of the recombinant myostatin protein, to be from
an eukaryotic expression system. Though a prokaryotic expression systemmay be used,
lack of an oxidative environment and the absence of folding enzymes unique to the eukary-
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otes reportedly caused minor protein mis-folding, and subsequently required significantly
higher biological concentrations than that found in the serum. We must also consider the
fact that the myostatin genetic knockout is essentially a different phenotype when com-
pared to an adult mouse treated with an agent to knockout myostatin. A muscle undergo-
ing some form of atrophy has a markedly different micro-environment than a healthy mus-
cle. Thus, therapeutic conclusions from studies that use the myostatin null mouse must be
drawn carefully, and additional studies must be conducted to validate the therapeutic agent
in relevant models.
1.6.2 Effect on cardiac muscles
Myostatin, though acting primarily in the hypertrophic and growth pathways in skeletal
muscles, has also been implicated in maintaining the structural integrity of the cardiac tis-
sues48. In brief, the expression of myostatin in cardiomyocytes is characterised by a spike
in transcriptomic and proteomic expression levels in early embryonic and neonatal stages,
subsequent to which the expression declines in a healthy tissue 261. It has also been reported
that over expression of myostatin contributes to sarcopenic cardiac fibrosis and subsequent
inhibition of cardiac tissue function 283. Curiously, different ventricles of the heart display
varying levels of myostatin inhibition with the left ventricle displaying a significantly higher
expression of transcripts compared to the right ventricle 381. Furthermore, the expression
of myostatin rises again in an ischemic heart (especially in the peri infract zone) or from
other bio-events resulting in an increased cardiac load 351. Interestingly, cardiac myostatin is
released into the serum consequent to pathological cardiac loading (where the myostatin
can act on skeletal muscles), thereby linking cardiomyopathies with general muscle weak-
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ness 163,229,282,351,356.
The heterogeneous cell types present in the heart (cardiomyocytes and fibroblasts) are
believed to participate in interactions responsible for maintaining cardiac structure, by
forming an interconnected regulatory network 34. While overexpression of myostatin has
been demonstrated to inhibit cardiac growth, genetic inactivation of myostatin specifically
in adult cardiomyocytes while initially results in cardiac hypertrophy and heart failure, sub-
sequently results in a compensatory increase in myostatin production by the fibroblasts in
the cardiac tissue 34,35. While Heineke et al. 163 report that no effect was observed in terms
of cardiac function/survival by the administration of the first generation anti-myostatin
antibodies, it remains to be seen if newer and more efficacious candidates may be able to
ameliorate cardiac fibrosis.
1.6.3 Effect on skeletal framework
The increased muscle mass caused by a myostatin antagonist does naturally lead to ques-
tion the effect of an increased stress on the load bearing structures of the skeletal system (of
the bones and tendons). Indeed, the masses of the bones and muscle positively correlate,
and a dystrophic (or sarcopenic) muscle is usually accompanied by an osteopenic bone 113.
The effect of myostatin on the regulation of bone development may involve a complex se-
ries of direct (effect of myostatin signalling on bone marrow stem cells) and indirect (effect
of phenotype change caused by myostatin signalling on bone structure) interactions. The
postnatal developmental pathways followed by the skeletal system lends itself to be influ-
enced by muscle strength 156. The resultant increased muscle mass in myostatin null mice
display increased sizes of bones (especially at sites of muscle insertions) and the spine lead-
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ing to an increased bone mass, an increased bone mineral content (especially of the hyaline
end plate in the spine; a symptom associated with spinal osteoarthritis/lumbar spondylitis),
and also of increased bone mineral density 153,154,155.
Myostatin is proposed to influence bone marrow stem cells (BMSC) which express the
ACTRIIB receptor, whereas mature bone cells do not 156. Furthermore, as these mesenchy-
mal stem cells can either differentiate into adipocytes or osteoblasts, the effect of adipocyte
formation is tightly interlinked with osteoblast formation. Hamrick et al. 156 summarises
that myostatin null mutants experience an altered mechano-sensitivity of BMSCs leading to
an increased (load-dependant) osteogenic differentiation, and conversely tail-unloading of
myostatin null mice did result in increased quantities of bone marrow adipocytes. BMSCs
in null mutants are adapted to the increased muscle load of the null mutants and atten-
uation of this load may result in an increased adipogenic response 156. A similar trend of
increased bone mass was also observed in short term studies utilising postnatal means of
myostatin knockdown (using soluble receptors72 and monoclonal antibodies 33). It has also
been reported that myostatin deficiency in mice increases osteogenic response in exercise,
along with an increased fracture callus 155,156.
Studies suggest that myostatin plays a crucial role in early fracture healing, by regulating
the recruitment of progenitor cells to the site of injury73,113,203. In a further study by Guo
et al. 150 , the authors report that 12-15-month-old myostatin null mice displayed degenerative
processes in the Achilles tendon-bone insertion resulting in bone dis-organisation, extra os-
sification (thickening and calcification) of tendons, synovial thickening and inflammation
causing impaired mobility and performance, highlighting the need to study the long term
effects of various myostatin inhibitors on the skeletal system during stages of drug transla-
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tion and in clinics.
The series elastic component of the muscles formed by the intramuscular tendons and
tendons composed of the type I and III collagens form a crucial component of the muscu-
loskeletal system269. Studies have reported that myostatin is an essential pro-fibrotic fac-
tor, with administration of exogenous recombinant myostatin resulting in an increased
tendon cross-sectional area and increased extra-cellular matric (ECM) in tendons and liga-
ments 113,130. Myostatin null mice display hypocellular, brittle, stiff and smaller tendons 270.
Indeed, Eliasson et al. 112 suggests that myostatin plays a crucial role in maintaining tendon
structure with myostatin being highly expressed in a loaded intact tendon, and also plays a
positive role in early tendon repair. The effect of administration of a short termmyostatin
antagonist on the permanent structure of the tendon remains yet to be investigated.
1.6.4 Effect on bioenergetics and metabolism
Skeletal muscles form the most abundant tissue in the body and maintains the energy bal-
ance of the organism. Indeed, muscles absorb glucose which is then stored or oxidised sub-
sequent to a contraction induced / (postprandial secreted) insulin induced signals. Mus-
cles use both glucose and fatty acids as fuel, and serves as a source of amino acids for fuel
utilisation by other tissues during starvation. Several studies have shown a negative corre-
lation between insulin sensitivity and myostatin expression in muscles 169,170,332,418. On the
corollary, studies in the myostatin null mouse, have shown that peripheral tissues are more
sensitive to insulin, and take up a larger quantity of glucose in response to insulin signalling
when compared to controls74,149,265,418. The skeletal muscles, brown and white adipocytes
and the liver also display an increased activation of Akt, suggesting elevated insulin sig-
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nalling 126,149,263. An increased muscle mass in the null mouse also results in an increased
rest energy expenditure, leading to myostatin null mutants having lesser adipose tissue (and
increased glucose tolerance) than wild-type models74.
Myostatin null mice on the whole gain less weight from a high fat diet than controls,
and also display decreased serum cholesterol, leptin, triglycerides, reduced quantity and
area of artherosclerotic plaques, reduced pro-inflammatory cytokines, and reduced TNF-α
signalling 263,265,418.
Transgenic mice over-expressing myostatin display immature adipocytes that have in-
creased glucose uptake and increased insulin sensitivity 121,231,364,434, and on the corollary
myostatin inhibition has been suggested to promote the browning of adipocytes46,430.
McPherron 262 postulates myostatin may regulate adipogenesis to maintain a propor-
tion of insulin sensitive adipocytes at an early stage of differentiation, and hence a systemic
knockdown of myostatin may be less efficient than a muscle specific knockdown of myo-
statin in-order to increase muscle specific insulin sensitivity 263.
1.7 Commercial and clinical interest for myostatin inhibition
Since the discovery of myostatin in 1997 264, more than 2000 scientific articles have been
published §, with a great many more clinically unproven products on the market claiming
to inhibit myostatin. Rodgers & Garikipati 325 in their seminal review on the evolution of
myostatin state that the scientific and cultural popularity of myostatin is due to the com-
mercial potential of the use of myostatin inhibitors in animal breeding, biomedicine as well
as performance enhancement in sports. The latter is not surprising as the use of anabolic
§data retrieved from PubMed with the search term of “myostatin”
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steroids by athletes does pose long-term risks including sterility, cardiac hypertrophy, and
neuropsychiatric disorders. Rodgers & Garikipati 325 argue that myostatin inhibitors may
revolutionise aquaculture, as the muscle mass to body mass ratio is markedly higher in fish
than mammals, leading to more increase in muscle mass per increase in body weight. In the
case of mammals, myostatin inhibitors leads to more lean mass in cattle (with piedmontese
meat being “particularly tender”). This however presents a complication in the birth of the
calf (due to increased size) in the case of the piedmontese cattle, offsetting the profit margin
from a myostatin null mutant, on a per cattle basis 325.
In biomedicine, the use of myostatin inhibitors remains particularly appealing and nu-
merous studies have been conducted to assess the effect of myostatin inhibition on several
pathological diseases including myopathies. Though myostatin inhibition does not present
a solution for the underlying cause of the disease itself, it may lead to an improvement in
quality of life whenever the disease induces a pathological muscle atrophy phenotype. Sev-
eral direct and indirect inhibition strategies have been attempted to inhibit the myostatin
pathway with some successfully progressing from a preclinical stage to the clinical settings
although no approved drugs are yet on the market. Therapeutic strategies to inhibit myo-
statin include:
Recombinant anti-myostatin antibodies and peptibodies The first generation
myostatin antibody did not meet the primary clinical endpoint and then it was discontin-
ued (Myo-029 fromWyeth for muscular dystrophies 399). Newer recombinant myostatin
antibodies are currently set to be tested in clinical settings (Pfizer’s PF-06252616: clinical
trial phase II for DMD - NCT02310763, Bristol Myers-Squibb’s BMS-986089: clinical
trial phase II for DMD - NCT02515669, Lily Oncology’s Ly2495655: clinical trial phase
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II for pancreatic cancer resultant cachexia – NCT01505530, Novartis’ Bym338: clinical
phase II for sporadic inclusion body myositis – NCT02573467; for hip fracture surgery –
NCT02152761; and for sarcopenia - NCT02333331). A myostatin peptibody ¶ (AMG 745)
has furthermore been tested in clinic to counteract muscle loss and increased body fat due
to androgen deprivation in patients affected by prostate cancer 297.
Soluble ACTRIIB receptors Ace-031 (Acceleron, NCT01099761) was a soluble form
of the myostatin receptor ACTRIIB and while providing promising results in preclinical
models of disease, it was discontinued due to minor bleeding and dilation of blood ves-
sels in the skin found during a clinical trial for DMD 56. Other soluble ACTRIIB has been
tested in preclinical study for Type 1 or insulin dependent diabetes mellitus where it in-
creased the muscle mass but failed to improve blood glucose407 and for DMDwith or with-
out dystrophin restoration 174,281. Fakhfakh et al. 118 reports that administration of a soluble
form of ACTRIIB improves myoblast transplantation in cell transplantation inmdxmice.
An increase in muscle mass was also observed when the reagent was administered to mice
with spinal cord injury 143, though no beneficial effect was observed in associated paralysed
muscles.
Myostatin propeptide Myostatin propeptide expressed by adeno-associated viral
vectors delivered by systemic administration has been used as a preclinical strategy in ani-
mal models of type 2 diabetes to improve glucose disposal in muscles76,and in aged mice to
counteract age-related loss of muscle mass through sarcopenia 16.
¶Peptibodies are an alternative therapeutic reagent to monoclonal antibodies that consist of biologically
active peptides grafted onto a Fc domain resulting in an increased apparent affinity and long plasma reten-
tion 354.
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Follistatin Follistatin has been used to counteract the effects of type 1 Diabetes (by
either injecting the recombinant protein 188 or by expressing the protein by AAV vectors433).
Delivery of follistatin by AAV vectors has been used to improve muscle repair in either a
mouse model of Pompe disease 123, or DMD 326 and it is currently in a clinical trial for Becker
and Duchenne muscular dystrophy (NCT01519349, NCT02354781) 268.
Gene therapy approaches The second approach targeting myostatin aims to inhibit
the cellular expression of the protein by using antisense oligonucleotides interfering with
the normal splicing process of the pre-mRNA and so induce exon skipping with subse-
quent formation of a stop codon and truncated out of frame non-functional protein that
is degraded by non-sense mediated decay. Antisense oligonucleotides designed to skip spe-
cific exons of dystrophin pre-mRNA and re-frame the mutated RNA has been extensively
tested in DMD and they are currently in phase II clinical trial (NCT02310906). Preclini-
cal studies of myostatin exon skipping to increase muscle size of animal models of DMD
have been successfully carried out with or without the combination with dystrophin exon
skipping 31,200,204,240,241,245,246.
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She first noticed a tendency to drooping of the eyelids
about four years ago. Following thॾ at an interval of
about a year, she began to have difficulty in swallowing.
Both of these conditions had grown gradually worse so
that at the present time she swallows with very consider-
able difficulty and ॾ only able to take solid food with a
large amount of water or tea.
Taylor 373
Chapter 2
Introduction to oculopharyngeal muscular dystrophy
and experimental strategies towards amelioration of dis-
ease symptoms
2.1 Introduction
Myopathies represent a large class of skeletal muscle diseases usually characterised by muscle
weakness. Myopathies in systemic disease results from several different disease processes
including endocrine, inflammatory, paraneoplastic, infectious, drug- and toxin-induced,
critical illness myopathy, metabolic, collagen related, and myopathies with other systemic
disorders 397. Patients with systemic myopathies often present acutely or sub acutely whereas
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familial myopathies or dystrophies generally present in a chronic fashion with exceptions of
metabolic myopathies where symptoms on occasion can be precipitated acutely70.
Oculopharyngeal muscular dystrophy (OPMD; OMIM 164300) is primarily an auto-
somal dominant (with rare instances of recessive inheritance have been evidenced252,361),
late-onset, slow-progressing degenerative muscle disorder that presents in the fifth or sixth
decade of life 158. The disease is mainly characterised by progressive eyelid drooping (pto-
sis) which may also lead to diplopia, swallowing difficulties (dysphagia due to severe my-
opathy in the pharyngeal and cricopharyngeal muscles) and proximal limb weakness 158.
Though the disease is reported to have global prevalence (with cases being reported in at
least 33 countries), the larger clusters are in the Bukhara Jewish population in Israel (1/700),
and in the French Canadian population (1/1000 in Quebec), and recently diagnosed in the
Hispanic and Chinese populations 26,71,81,350. It affects around 1/100,000 individuals in Eu-
rope 38,47,93.
Biopsy of the deltoid muscles from patients suffering fromOPMD reveal a variation
in myofibre diameter. Though fibre necrosis is rare, ragged red fibres (Caused by the ac-
cumulation of abnormal mitochondria below the plasma membrane of the muscle fibre
under a Gomori trichrome stain) were observed. Characteristic histopathological hallmarks
of OPMD comprise of the presence of rimmed vacuoles (usually containing cytoplasmic
debris and myelin bodies) and intranuclear inclusion bodies. Other dystrophic features
observed were extensive endomysial fibrosis (upto 40% of fibrotic tissue area), central nu-
cleation resulting frommyofibre regeneration, and marked atrophy of myosin heavy-chain
IIa fibres in the cricopharynx 136,380.
The polyadenylate-binding nuclear protein 1 (PABPN1) gene (14q11.2, NC 000014.9) is
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mutated in patients affected by OPMD. PABPN1 is an ubiquitously expressed polyadeny-
lation factor localised in nuclear speckles, which binds with high affinity to poly(A) tails
of mRNAs and plays crucial roles in modulating their fate47. It promotes interactions be-
tween the poly(A) polymerase, the cleavage and polyadenylation specificity factor, and con-
trols the length of the poly(A) tail during transcription4. PABPN1 also contributes to the
export of mRNA from the nucleus to the cytoplasm4. More recently, new biological func-
tions for PABPN1 have been proposed including the modulation of alternative cleavage and
polyadenylation sites 187,315,322, synthesis of non-coding RNAs and mRNA biogenesis and
myogenesis 12,13 and regulation of calcium homeostasis 133.
OPMD is caused by an abnormal expansion of an alanine (GCG) trinucleotide repeat
in the coding region (exon 1) of the PABPN1 gene. An addition of 2-7 alanine amino acids
in mutants (10 repeats in wild-type, 12-17 repeats in mutants), leads to an expanded poly-
alanine tract at the N-terminal of the PABPN1 protein, resulting in protein aggregation.
Malerba et al. 246 propose that the expanded protein in the murine model undergoes both
a gain of toxic function and a loss of physiological function, resulting in OPMD patho-
genesis. PABPN1 is prone to aggregation and mutant expanded PABPN1 (expPABPN1) in
OPMD has a higher rate of aggregation than that of the wild-type protein 3. In line with
other neurodegenerative and myodegenerative diseases, an improper folding of expPABPN1
results in the accumulation of scattered rim vacuoles and intranuclear inclusions (INIs).
INIs are insoluble, 8.5 nm polymeric fibrillar aggregates inside nuclei of affected cells and
they are considered the major histopathological hallmark of the disease 102,372. However un-
like most myopathies there is an absence of fibre necrosis. It is still unclear whether nuclear
aggregates in OPMD have a pathological function or a protective role as a consequence of
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a cellular defence mechanism. In fact, INIs are found in 25% and 10% of skeletal muscle nu-
clei of heterozygous and homozygous OPMD patients, respectively4. It has recently been
proposed that the pathogenesis of OPMD (in terms of molecular and proteomic profiles) is
similar to a muscle undergoing sarcopenia and it is believed that the molecular changes asso-
ciated with sarcopenia may trigger symptoms associated with OPMD in the later decades of
life 317.
2.2 Intra-nuclear inclusions as the hallmark of OPMD
Several well-known diseases (e.g. Huntington’s disease, spongiform encephalopathies,
Alzheimer’s and Parkinson’s diseases) derive from changes in the native conformation of
protein folding 239. Histochemical analyses of biopsy material fromOPMD patients have
indeed shown that expansion of the poly-alanine tract of PABPN1 induces protein aggre-
gation in the nucleus 55. These inclusions are characteristic of OPMD and contain numer-
ous molecules, including PABPN1, poly(A)-containing RNA, various transcription factors
of the proteasome ubiquitin pathway (ubiquitin and 20S catalytic proteasomal subunit),
molecular chaperones (HDJ-1, HSP70), HNRPA1 and arginine methyltransferares, all of
which are sequestered and trapped 22,55,78,119,372,380. It has been proposed that the transcrip-
tomic dysregulation observed in OPMDmay be the result of the decrease of the wild-type
soluble form of the protein 316. Furthermore, it should be noted that intranuclear inclusions
of wild-type PABPN1 have also been described 28,395. Though similar to the INIs found in
OPMDmyofibres (similar fibrillar structure), these INIs are not associated with disease.
Recently increased association of INIs with HSP70 chaperones and type I arginine methyl
transferases has been demonstrated in biopsies fromOPMD patients. This suggested that
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sequestration of these proteins in aggregates may induce cellular defects in pathways where
chaperone activity or proteins modified by arginine methylation are involved 372. Interest-
ingly in all these cases a decrease in aggregates in these cell culture models was directly cor-
related to a decrease in cell death. On the other hand recent evidences suggest that loss of
muscle function and degeneration in OPMD is related to the levels of soluble PABPN1 ar-
guing against old assumptions of a gain of function mechanism from the mutant PABPN1
(de Klerk and others 2012). This was further validated by the observation that depleting
PABPN1 levels in muscle cells dramatically affects myogenesis 13.
2.3 Disease models of OPMD
Models of OPMD have been generated both in vitro and in the classical biological systems
of theDrosophila melanogoster, C. elegans and theMॿ musculॿ. The underlying approach
to the development of all models exhibit a common trend and involves the introduction of
an expanded (mutated) PABPN1 (expPABPN1), which in the case of the in vivomodels is
expressed specifically in muscles.
2.3.1 In vitro models
Several in vitromodels have been developed to study OPMD. The COS-7 (African green
monkey kidney) cell line was transfected with plasmids coding for bovine expPABPN1
(pEGFPC1–PABPN1–A17) or wild-type bovine PABPN1 (as a control, using a construct
expressing 10 alanines)406. The C2C12 (murine myoblast) cell line as well as the Primary
mouse myoblasts (clone IM2) transfected with FLAG-tagged expPABPN1 316 have also been
modified including a full-length human PABPN1 flagged cDNA driven by either a CMV
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promoter or a Desmin promoter respectively208,316. While a good correlation between pro-
tein aggregation and cellular toxicity has been observed in the in vitromodels of OPMD 3,
no such relation has been found in humans 239,388.
2.3.2 Invertebrate models
TheDrosophilamodel was developed with an expPABPN1 of 17 alanines (or 10 in the con-
trol) in skeletal muscle, which manifests in the phenotype as an abnormal wing posture.
The progression of disease was found to be correlated with the length of the expPABPN1
introduced (aggregation was most prevalent in the expPABPN1 with 17 repeats) with for-
mation of INI very similar to human pathology (including expPABPN1 resistant to salt-
extraction)66. However it must be noted that as theDrosophila does not mirror human
physiology, the pharmacokinetics of drugs tested in this model (e.g. chemotherapeutic
agents such as doxycycline or substances as trehalose and ibuprofen) differ, and hence trans-
lation to a higher model is required before clinical applications69.
The C. elegans is a unique model for the study of neuromuscular diseases as the muscle
cells in the animal are mono-nucleated. A C. elegansmodel of OPMDwas generated by ex-
pressing a version of human PABPN1 including 13 alanines in muscles. Although the model
exhibited impaired mobility, progressive atrophy and PABPN1 aggregations, nuclear in-
clusions were not observed65. The C. elegansmodel has been used extensively to study the
effect of drugs acting on the Histone deacetylases such as sodium butyrate 208 and sirturin-
based drugs 302. The genetic tractability of the C. elegansmodel allowed research groups
to explore the role of the Wnt and sirturin/FoxO pathways, and led to β-catenin being de-
scribed as a therapeutic target for OPMD, allowing the development of drugs such as the
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GSK3-β inhibitor to be explored as a possible candidate 303.
2.3.3 Murine models
Mouse models of OPMD that have been generated utilise an expPABPN1 expressed either
ubiquitously or specifically in muscles. It must be noted that early mouse models that were
developed to ubiquitously express expPABPN1, led to phenotypes that were not reported
for the human pathology (early mortality and growth retardation) 168,248. Davies et al. 92 gen-
erated a widely accepted mouse model of OPMD expressing expPABPN1 with 17 alanines
by a muscle specific HSA1 promoter. The model (A17.1 or alternatively A17) displayed a
progressive atrophy which becomes evident at 16-18 weeks and developed KCL-insoluble
PABPN1 aggregates in the myonucleus which quantitatively increased with age. Centrally
located nuclei and vacuoles, (characteristic of a dystrophic phenotype at a cellular level)
were also observed, however the clinical symptoms of ptosis and dysphagia does not de-
velop in this model91. Trollet et al. 384 reported that the atrophy in the A17 model was re-
stricted to fast glycolytic fibres and as such, the mouse model of OPMD appears to be pre-
ferred among research groups, with numerous candidate drugs and strategies tested in the
system 89,91,92.
However analyses of the transcriptomic profile in the A17 mouse model must account
for the variability from the overexpression of mutant PABPN1 in addition to the regu-
lar expression of endogenous PABPN1 393. In order to accurately model the genotype of
the disease, Vest et al. 393 recently generated a heterozygous mouse model with one ala-
nine expanded allele and one wild-type allele, both under control of the native promoter
at the native locus displaying small but significant muscle-specific and age related muscle
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histopathology.
2.4 Therapeutic strategies towards treatment of OPMD
2.4.1 Surgical intervention
Medical intervention is only symptomatic and surgical techniques are used to correct the
ptosis and improve swallowing in moderate to severely affected individuals. Two tech-
niques are mainly employed to surgically correct ptosis: the resection of the levatorpalpe-
brae aponeurosis, and frontal suspension of the eyelids, and are usually recommended
when ptosis interferes with vision or due to increasing discomfort caused by compensatory
neck postures. A cricopharyngeal myotomy is performed to alleviate the symptoms of dys-
phagia, however there exists a risk of recurrence 387. Recently, the safety of cricopharyngeal
dilatation was reported in a trial, with patients reporting a sustained improvement in qual-
ity of life. Cricopharyngeal dilatation has an inherent advantage in that the procedure is
repeatable in case of recurrence of symptoms, however further studies are required to fully
explore this technique 247.
2.4.2 Pharmacological intervention
The use of chemical (Me2SO) and molecular chaperones including heat shock proteins such
as HSP40, HSP70, yeast HSP104 and a bacterially derived mini-chaperone were shown to
reduce mutant PABPN1 aggregates, which correlated with decreased toxicity in cell culture
models of OPMD 21. The use of HSP70 inducing pharmacological agents such as ZnSO4,
8-hydroxyquinoline and anti-inflammatory drugs (ibuprofen and indomethacin) was also
shown to reduce cell death in mutant alanine-expPABPN1 expressing cells in vitro409. Fur-
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Figure 2.1: Strategies to ameliorate disease symptoms of OPMD: These include approaches to knock down PABPN1
(e.g.,anধsense oligonucleoধdes (AONs), short hairpin RNA (shRNA)-mediated knockdown of mutant expanded
PABPN1 (expPABPN1)); the over-expression of BCL2 to aħenuate the effects of the mitochondrial-mediated apopto-
sis pathway; and the delivery of genes expressing intrabodies to reduce nuclear inclusions and the over-expression of
wild-type PABPN1 by viral vectors(e.g., adeno-associated viral vectors). Pharmacological strategies include the use of
anধ-aggregate-forming drugs such as doxycycline, trehalose,and guanabenz. Reproduced from Harish et al. 158
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thermore, the use of anti-prion drugs (6-aminophenanthridine and Guanabenz) previously
shown to prevent prion protein-associated amyloid fibres formation in vitro, proved effec-
tive in theDrosophilamodel of OPMD. The alleviation in muscle degeneration and nu-
clear aggregates formation in this model was attributed to a specific action of these drugs
on domain V of the large ribosomal RNA, hence preventing its protein folding activity
without interfering with its protein synthesis function 23). The disaccharide trehalose 115 has
been demonstrated to either induce autophagy 216,338 or proteosomal degradation62 to tar-
get misfolded proteins, though the mecanism of action in OPMD remains unclear92. It
has been further suggested that trehalose may act act as a chaperone for the misfolded pro-
tein resulting in protein stabilisation and inhibition of aggregate formation 184,413. Argov
et al. 15 initially demonstrated safety of trehalose in human patients, and recently reports the
administration of 300cc trehalose IV weekly for 24 weeks , increases muscle function in a
Phase II trial 14. The study promisingly reports a 35% improvement in swallowing times in
the the 80ml drink test, accompanied by improvements observed in various quantitative
and qualitative tests of muscle strength in human patients 14.
2.4.3 Molecular and cell therapy strategies
Intrabodies
Intrabodies are small antibody fragments (of about 200 amino acids) designed to target in-
tracellular proteins coding for the Fv variable region of an antibody. They display increased
specificity and affinity, and present a promising safety profile as they lack the inflamma-
tion causing Fc region 59,106. While initially applied in the fields of infectious diseases and
oncology 84,146,250,367, therapeutic applications of intrabodies was soon expanded to protein
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misfolding diseases such as Huntington’s, Alzheimer’s and Parkinson’s disease 58,272,273,274.
Naturally occurring heavy-chain-only antibody fragments called nanobodies were tested
as therapeutics for OPMD both in cellular models and inDrosophila 159,329. The intracellu-
lar expression of intrabodies in in vitromodels prevented the aggregation of PABPN1 in a
dose-dependent manner and reduced existing aggregates68. Expression of this intrabody in
Drosophilamodels decreased the presence of mutated PABPN1 derived intranuclear inclu-
sions and restored the wild-type transcriptomic expression profile 392. Although promising,
this approach needs further validation in mammalian models with therapeutically relevant
method of administration and doses.
Gene Therapy
The application of gene therapy in muscular dystrophy is a well-established approach, with
proof-of-principle validated both in vivo and in clinical trials 268. Increased levels of apop-
tosis were previously reported in in vivomodels 89,168. Expression of molecular chaperons
(HSP70) and the anti-apoptotic protein p35 efficiently reduced pathology in aDrosophila
model of OPMD66. Over-expression of BCL2 in vivo also resulted in an improved phe-
notype with reduced apoptosis in muscle fibres and improved muscle strength. This im-
provement, however, was limited to the early stages of the disease. A correlation between
reduction in levels of observed apoptosis (quantified by TUNEL-positive nuclei, immuno-
histochemical stains for levels of caspase 3 and cytosolic cytochorme C) and improved mus-
cle function (grip strength, wire manoeuvre and vertical gripping tasks) was observed in
A17 mice over-expressing BCL2, between 4 and 8 months of age90. This suggests the molec-
ular complexity of OPMD pathology and the need for gene therapeutic strategies acting
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upstream of apoptosis and modulating both protein degradation (ubiquitin-proteasomal)
and energy production (mitochondrial) pathways.
The fact that some pathological features of the disease (as loss of muscle function and
degeneration) are related to the levels of soluble PABPN1 and that muscle regeneration
can be worsened by depleting PABPN1 levels in muscle cells 13 clearly suggest the poten-
tial of a replacement gene therapy approach in OPMD, whereby a functional PABPN1 is
transferred into the affected muscles to replace the depleted soluble protein (figure: 2.1).
However, a successful gene replacement approach would not be fully therapeutic with-
out an aggregates-dismantling approach. While a number of pharmaceuticals have been
proposed and shown to exert anti-aggregate properties through different mechanisms of
actions 23,89,91,92,405 none of them specifically target the underlying molecular defect behind
OPMD.
Gene therapy in this regard offers an appealing alternative to small drugs with the phe-
notype that is improved at both histological (reduction of pathological aggregates) and
molecular levels (abrogation of mutant PABPN1 expression). Strategies to knockdown
PABPN1 include: anti-sense oligonucleotides (AONs) and small interfering RNA (siRNA)/short
hairpin RNA (shRNA). For instance, the use of AONs has gained a lot of interest in mus-
cular dystrophy over the past years with proof-of-principles already demonstrated in Duchenne
muscular dystrophy, Fukuyama congenital muscular dystrophy, myotonic dystrophy,
spinal muscular atrophy, dysferlinopathy and amyotrophic lateral sclerosis 223. With only
two to seven extra GCG residues in the mutant allele of PABPN1 compared with wild type
PABPN1, allele-specific silencing of expPABPN1 could be achieved by single nucleotide
polymorphisms (SNP) targeting or through the direct targeting of the expanded GCNmoi-
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ety. The efficacy of this approach was successfully demonstrated in similar disease models
of misfolded proteins 36,103,132,176. While expPABPN1 knock-down approach could be of great
clinical significance in OPMD, the risk of silencing the wild type protein hampers these
approaches. A fully restorative therapeutic strategy in OPMDwould therefore need to
combine an expPABPN1 knock-down approach with gene replacement. Care would need
to be taken when selecting the optimal replacement gene (PABPN1) prior to delivery. Stud-
ies in our lab have shown the feasibility of the knock-down and replacement approach by
exploiting the redundancy of the genetic code 246.
Cell therapy
The muscle stem cell pool of unaffected muscles in OPMD remains intact and myogenic
(as compared to the affected muscles whose satellite cells show reduced myogenicity). This
allowed to test autologous myoblast transplantation as a therapeutic approach. Although
the genotype is not corrected, an autologous myoblast transplantation has inherent bene-
fits in the reduced rate of rejection of the graft, as evidenced by pre-clinical testing in animal
models 306. The concept was advanced to a Phase I/II clinical trial in which myoblasts de-
rived from the quadriceps and the sternocleidomastoid muscles were implanted into the
constrictor muscles of the pharynx, and the patients were followed for a minimum of two
years (figure: 2.2). The transplantation was well tolerated, and the patients reported an
average 16.6% improvement in the 80ml drink test, along with reported improvement in
quality of life. Interestingly, it was shown that the amelioration of dystrophic symptoms
was directly correlated with the amount of cells injected 306.
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Figure 2.2: Myoblast transfer therapy to ameliorate disease symptoms of OPMD: (a)Myoblasts from donor muscles
(sternocleidomastoid or quadriceps) are biopsied (b) and myogenic cells are isolated. (c) Ex vivo gene correcধon may
be employed by convenধonal gene therapy strategies in order to correct the mutaধon. (d) The myoblasts are allowed
to proliferate and (e) are injected into the cricopharynx, one of the muscles affected in OPMD. (f)Myoblasts integrate
in the host ধssue, amelioraধng disease symptoms. Reproduced from Harish et al. 158
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2.5 Need to identify disease biomarkers in OPMD
Despite recent advances in molecular techniques and elucidation of disease mechanism, the
low rate of prevalence in OPMD coupled with its variable age of onset has resulted in the
disease to be underdiagnosed or misdiagnosed (for example as myasthania gravis or mito-
chondrial disorders) in populations considered canonically not at risk 17,242. Other factors
such as non-familiarity of the disease and lack of genetic testing facilities to confirm the
disease has only recently lead to the identification of cohorts in the Chinese and Hispanic
populations, with smaller rates of incidence identified in other countries71,242,330. Further-
more, the validation of disease appropriate outcome measures in clinical trials for OPMD
remains challenging. It remains critical that these outcome measures possess independence
from other co-morbidities, exhibit sensitivity and specificity to disease progression, and dis-
play a response to a therapeutic regimen. Current methods which utilise endoscopy based
swallowing studies and direct observation of muscle function, score based rankings of mus-
cle function using the Salassa or McHorney rankings, and the 80ml drink test are relatively
time and labour intensive 306.
The vascular system transports dissolved gases, nutrients, hormones, metabolites, reg-
ulates pH, restricts fluid loss at sites of injury, assists in thermoregulation and forms the
primary site of action for the immune system 313. It stands to reason that dysfunction in any
major tissue system due to stress, disease conditions, or organ damage will directly or indi-
rectly impact the biochemical composition of the blood serum 313. The characterisation of
circulating molecules in blood serum will present an easily accessible, minimally invasive,
high throughput and rapid method of sample collection and analysis, utilising a widely ac-
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cepted and studied technique in clinical diagnosis (classical examples include tests for blood
glucose, serum cholesterol etc.) 313.
Metabolites encompass small biochemical molecules (usually below 1.5 kd) found in in-
tracellular and extracellular spaces and metabolic biomarkers play a crucial role in clinical
diagnosis of human diseases 127. Metabolomic analysis includes the study and characterisa-
tion of metabolic phenotypes under a particular set of conditions, and assist to sub-classify
disease states, elucidate disease aetiology and mechanisms 396. Metabolomic analysis can be
performed without apriori knowledge of the metabolome composition (via metabolite
fingerprinting) to generate hypotheses or utilising pre-existing datasets in-order to test spe-
cific hypotheses. Metabolic fingerprinting (or untargeted metabolomic analysis) further
involves the comparison of patterns of changes in response to disease, environmental or ge-
netic changes 101. The efficacy of treatment strategies can also be monitored if the metabolic
phenotype shifts back to the wild-type state. The analysis of metabolite identity and con-
centration will provide information which can be interpreted in the light of biochemical
pathways 101.
Mass spectrometry allows quantitative, selective and sensitive analyses to identify metabo-
lites 101. Mass spectrometry used in conjunction with gas chromatography (GCMS) and liq-
uid chromatography (LCMS) assists investigators in the identification of distinct changes
brought about in a biological system either due to disease conditions or due to a therapeu-
tic regimen, by assisting the investigator to resolve the mass spectra 280. Indeed, chromato-
graphic resolution reduces complexity of mass spectra observed by effecting metabolite
separation with respect to time, isobaric separation with respect to isotopes, and provides
other additional information on the physio-chemical properties of the metabolites 101. How-
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ever current chromatography techniques are limited by the heterogeneity of the metabolome,
and multiple supplementary techniques are required to capture the entire metabolome
complement 280,304,327.
Mass spectrometric techniques have been used before as a non-invasive analytical method
in humans and animal models for studying cardiovascular diseases 50, myocardial ischemia 334,
type 2 diabetes405, ovarian cancer99, kidney cancer 209, Huntington’s disease 386, Parkinson’s
disease40, schizophrenia 172,385, cystic fibrosis 196, and cancer cachexia296. Screening and vali-
dation of potential biomarker candidates remains challenging as ideal biomarker candidates
present a panel of robust and reproducible biomarkers in order to improve disease speci-
ficity (than a single biomarker candidate); can serve as pharmodynamic markers to monitor
safety and efficacy of treatment; can act as surrogate markers to predict future benefit of
clinical intervention; can inform pathophysiological pathways and novel therapeutic tar-
gets 161.
While the serummetabolic profile of either OPMD patients or animal models remains
to be investigated, recent efforts have elucidated the metabolic components across a wide
range of muscular dystrophies in humans 39,360. In a recent LCMS based study by Spitali
et al. 360 , the cross-sectional matabolomic profile of human patients suffering fromDMD
was initially examined, with the metabolites subsequently examined in samples from BMD,
LGMD 2A and 2B, myotonic dystrophy 1, and FSHD.The metabolites were linked to en-
ergy production, amino acid metabolism,testosterone metabolism and response to treat-
ment with glucocorticoids. For example, creatinine levels were comparatively low in BMD,
LGMD2A and 2B; creatine was elevated in DM1, LGMD2A and 2B; imidazole acetate
lower in LGMD2A and 2B, guanidineacetate lower in BMD,MD1, and LGMD 2A 360.
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Though study is however limited, due to low sample sizes used in patient samples, espe-
cially in non-DMD related myopathies, it offers a broad overview of metabolic signatures
observed in muscular dystrophies, and will serve as an useful tool to further isolate, identify
and characterise biomarker panels.
GCMS is used to analyse thermally stable, volatile, polar and non-polar metabolites 280,
and was used as an analytical platform in this report in-order to elucidate the serummetabolomic
component of the OPMDmice. In brief, a mass spectrometric analysis occurs in multiple
stages: Samples are first subject to chemical derivatisation in order to extend the range of
compound classes detected to include monosaccharides, disaccharides, amines, amino and
organic acids 152. The initial chromatographic resolution involves the separation of con-
stituent components of the sample based on their (thermal) volatility through a specialised
column (stationary phase) assisted by a fluid (mobile phase; inert gas in case of GCMS) 101.
The interaction of the constituent parts with the column results in sample separation via
adsorption which is quantified as sample retention time. Mass spectrometers then ionise
samples and accelerate the ions through an electromagnetic field where the ions are sep-
arated based on their mass to charge (m/z) ratio, which are then detected 101, and subse-
quently analysed. GCMS analyses were performed for this study, while considering costs
of machine operation, availabilty of downstream analytical tools such as curated and com-
mercial databases (NIST) of known compounds.
46
2.6 Aims, objectives and hypotheses of current study
Central to an atrophic phenotype (which may arise due to dystrophy, cachexia, sar-
copenia or atrophy) is the gradual and progressive loss of whole body mass, muscle mass
and muscle function leading to disability by loss of ambulation. The use of blocking an-
tibodies to inhibit a negative regulator of muscle mass (myostatin) presents a clinically
relevant strategy and has been tested before in other mouse models401. In this report we
propose to examine the therapeutic effect of post-natal inhibition of myostatin by the
use of the anti-myostatin (blocking) IgG1 hybridoma RK35 on the progression of disease
in murine models of OPMD at two time-points. By examining the mice at the during
early stages of disease progression and at advanced stages of disease progression, we pro-
pose to examine the efficacy of the antibody on rescuing muscle mass in different micro-
environments.
2.6.1 Aims and objectives
We propose to examine the effect of inhibition of myostatin on two different age groups
in order to assess the therapeutic efficacy of the antibody RK35. We further propose to per-
form the first characterisation of the serummetabolome of the OPMDmouse model in
order to elucidate the impact of the disease state on the metabolomic profile of the animals.
We aim to achieve this by:
• Examination of the therapeutic effect of the antibody RK35 on mice during early
stages of disease progression:
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– Examination of the effect of the antibody on the body mass and muscle mass in
the A17 mice
– Examination of the effect of the antibody on muscle function
– Examination of the effect of the antibody on histological parameters such as the
myofibre diameter, collagen VI deposition, and INI density
– Characterisation of the serummetabolomic profile in the A17 mouse, and sub-
sequent examination of the effect of the antibody on the metabolome of the
A17 mice.
• Examination of the therapeutic effect of the antibody RK35 on mice during advanced
stages of disease progression:
– Examination of the effect of the antibody on the body mass and muscle mass in
the A17 mice
– Examination of the effect of the antibody on muscle function
– Examination of the effect of the antibody on histological parameters such as the
myofibre diameter, collagen VI deposition, and INI density
2.6.2 Hypotheses:
Inhibition of myostatin during early stages of disease progression in the OPMDmodel
system will delay disease progression, and that inhibition of myostatin in advanced stages
of disease progression may rescue the atrophic phenotype in the animals. The mice for the
”early stage” cohort were aged for 12 weeks prior to the treatment regimen whereas the mice
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in the ”advanced stage” cohort were aged for 40 weeks. Each cohort was treated for 10 weeks
(dosed at 10 mg/kg IP) on a weekly basis with the antibody RK35. We hypothesise:
1. Inhibition of myostatin will ameliorate disease symptoms in the
OPMDmouse model
(a) Inhibition of myostatin will lead to an increase in whole body
mass: Previous studies have shown that the natural growth related gain of
body mass in the A17.1 disease model will be lower than the healthy controls92.
We hypothesise that the increase in rate of growth and subsequent increase in
body mass caused by the inhibition of myostatin will be significantly higher
in the mice treated with the antibody than the mice treated with saline. This
gain of mass will subsequently ameliorate the weight-loss associated with an
atrophic phenotype in the ”early stage” and ”advanced stage” cohorts.
(b) Inhibition of myostatin will rescue the loss of muscle mass: Due
to the atrophic nature of the disease model, we expect that the muscle masses
of the A17.1 disease model will be significantly lower than the respective mus-
cle masses of the control mice. Previous studies by Trollet et al. 384 have indeed
indicated that the glycolytic muscle fibres are more susceptible to the atrophy
observed in the OPMDmodel system. We propose that treatment with the an-
tibody will increase the muscle mass of the A17 mouse, and as such ameliorate
the atrophic phenotype. Due to the fibre type specificity of both the disease
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and myostatin, we hypothesise that the proportional increase in muscle mass
observed will be highest in the fast glycolytic muscles such as those found in
the TA and EDL and the least in the slow oxidative fibres such as those in the
soleus. Due to disease progression, we speculate that the efficacy of myostatin
inhibition by the antibody to be attenuated in the ”advanced stage” cohort,
when compared to the ”early stage” cohort.
(c) Increase in muscle mass will be accompanied by an increase in
muscle fibre diameter: Previous studies in other mouse models subject to
an anti-myostatin regimen have indicated an increase in muscle fibre diameter
which correlates to an increase in muscle mass. We propose that the increase
in muscle fibre diameter will offset the atrophy in the muscles of the A17 mice.
Additionally we speculate that the relative increase in muscle fibre diameter to
be lower in the ”advanced stage” cohort than the ”early stage” cohort due to
irreversible damage resulting frommuscle dystrophy.
(d) Inhibition of myostatin will not affect density of intranuclear
inclusions (INIs) in myonuclei of the OPMDmodels: Inhibition of
myostatin does not correct the disease genotype in the OPMDmodels. While
we expect the A17 mice to have a significantly higher density of INIs, we pro-
pose myostatin inhibition will not affect the density of INI observed in the
”early stage” and ”advanced stage” cohorts of treated mice.
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(e) Inhibition of myostatin will restore muscle function in the at-
rophic phenotype: We propose that inhibition of myostatin will also result
in an increase in muscle functional characteristics in the atrophic model sys-
tem. Specifically we expect the restoration of muscle strength of the A17 mice
to non-atrophic levels in the disease model. We also propose to examine the
general locomotor activity of the atrophic mice. We speculate the voluntary
locomotor activity of the A17 mice to be lower than the healthy FvB mice. Ad-
ditionally myostatin inhibition has not been previously shown to have an effect
on voluntary muscle function.
2. To test the metabolomic profile (serum) of the OPMDmodel system
We propose to test the relationship between the disease progression and metabolomic
profile in serum samples collected in objective 1 to suggest possible candidates to
act as biomarkers in the OPMDmodel system. The mass spectrometric analysis of
serummarkers will enable researchers to follow disease progression and treatment
response. Furthermore, the usage of metabolomics as a functional genomics tool will
enable the generation of hypotheses regarding disease mechanism, and subsequent
generation of alternative therapeutic targets.
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I am unable to find any reference in the literature of the
family hereditary affections to thॾ disturbance... Thॾ
disorder ॾ particularly remarkable in that although
hereditary in type, it hॼ not been known to occur early
in life, and must therefore be regarded ॼ superinduced
in predisposed persons by conditions arising in the
degenerative period of life
Taylor 373
Chapter 3
Materials and methods
3.1 Animal handling and maintenance
The A17 model mice was generated by Davies et al. 91 by expressing a bovine expanded
PABPN1 transgene driven by a muscle specific human skeletal actin promoter, in the FvB
mice. The model mice though does not present an accurate genocopy of the disease, does
indeed model it at a tissue level and expresses the presence of characteristic intranuclear in-
clusions, muscular atrophy, fibrosis, transcriptomic dysregulation and subsequently has
been used to test therapeutic agents that reduce the intranuclear aggregates. The model
mice used in this experiment was heterozygous for the transgene, bred by mating a het-
erozygous female A17 mouse with a healthy male FvB mouse, with the litters either being
A17 or FvB in expected mendellian ratios (1 in every 2 pups has a high probability of bearing
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transgene). Only male mice were utilised for this expeirment, with the FvB littermates serv-
ing as background / strain controls for the A17 mice. All mice were bred internally and all
mice were housed individually with food and water ad libitum in a minimal disease facility
at Royal Holloway, University of London. Individual mice were identified by ear-notching
at about 4 weeks of age, and each mouse was monitored as per the recommendations of
Animals (Scientific Procedures) Act (1986).
3.2 Genotyping of mice
Due to the heterozygous nature of the disease model, the OPMDmice were analysed to
confirm the genotype. In short, ear notches from the mice were digested to extract genomic
DNA and a PCR was performed, with primers directed against the bovine PABPN1 insert.
50μl of 10x PCR homogenization buffer (500 mMKCl, 100 mMTris-HCl (pH 8.3),
0.1mg/ml Gelatin, 0.45% v/v Tween 20, 0.45% v/v Nonidet P40, 5 mg/ml Proteinase K)
was added to the ear notch, and the samples were digested at 55C for 5 hours. After the
digestion, proteinase K was heat inactivated by subjecting the sample to 100C for 10 min-
utes. The samples were cooled on ice to room temperature and were genotyped by a PCR
using the primers 5’ - GAACCAACAGACCAGGCATC - 3’ and 5’ - GTGATGGTGAT-
GATGACCGG - 3’. In short, 1 μl of the DNA sample was mixed along with 12.5 μl of 2x
PCRMaster Mix (Genesys Ltd., Surrey, UK), 0.5 μl of forward and reverse primers (10
pm/μl amplifying a 300 bp product) , or 18s primers as positive control for each reaction (
5’ - TTGACGGAAGGGCACCACCAG - 3’ and 5’ - GCACCACCACCCACGGAATCG -
3’; 10 pm/μl amplifying a 100 bp product), and the final volume was made up-to 25 μlwith
ddH2O.
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The PCR cycle implemented initial denaturation at 95C for 2 minutes, followed by 40
cycles of 95C denaturation, 60C for annealing and 72C for extension with each step
lasting for 30 seconds. The final extension was conducted at 72C for 10 minutes, and the
samples were cooled down to 4C. The samples were run on 2% agarose gel in TBE buffer
(0.11M Tris; 90 mMBorate; 2.5mM EDTA; pH 8.3) at 100V till product separation using
Hyperladder IV (Bioline, London, UK). The absence of a band at 300 bp indicated that the
mouse being genotyped does not contain the insert, and hence is of the FvB strain. Presence
of a band at 300 bp, indicates the probability of the mouse of the A17 genotype. This am-
biguity is resolved and the correct strain is verified by cross referencing the genotype of the
breeder pairs.
Initial body weights were used to evenly distribute animals among cohorts to ensure
equivalent average body-weights prior to the commencement of experimental protocols.
After the commencement of the experiment the mice were monitored daily, with their
weights recorded every week.
3.3 Intra-peritoneal injection procedures
All injection procedures were performed at the same time of day (between 12pm and 2pm,
selected based on brightest lighting conditions in the procedure room) . Mice were weighed
prior to each injection. To administer material in the peritoneal cavity, mice were restrained
and held in a manner that exposes their ventrum. To mitigate the chances of accidental
puncture, care was taken to ensure that their head was lower than their lower body to en-
sure freely movable abdominal organs to move towards the diaphragm. A 29G  12 needle
is inserted into the abdominal cavity in the lower quadrant, in a manner to avoid the ce-
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cum, urinary bladder and the liver. The needle was directed towards the animal’s head at an
angle of 15 - 20 degrees and inserted. Aspiration was attempted to ensure that an abdomi-
nal viscus has not been penetrated. In this experiment, we administered the murine anti-
myostatin blocking antibody RK-35 (Pfizer, USA; diluted in sterile saline (Sigma Aldrich,
UK) for a final volume of 200 μl) which was injected at 10mg/kg weekly for 10 weeks into
the A17 mouse (disease model for OPMD) and FvB (strain control) mice. The dosing regi-
men was optimised based on observed pharmacokinetic profile and serum half life measure-
ments along with dose response studies performed in the C57 model mice (private commu-
nication, Carl Morris, Pfizer, USA; confidential data not shown).
3.4 Open field behaviour analysis
Animals were tested in IR Locomotor Activity Monitors systems as provided by Linton
Instrumentation (Norfolk, UK). The analysis was undertaken in two phases. The initial
phase involved acclimatising the mice in the system, and leaving them undisturbed for an
hour each day for five consecutive days. The final phase involved acclimatisation in the test
cages half hour prior to commencement of data collection, followed by primary data collec-
tion every 10 minutes for 60 minutes every day for five consecutive days. All open field tests
were conducted within the same time period (afternoon) , in-order to minimise impact of
the circadian rhythm in behavioural analyses. Additionally, the order of mice analysed was
randomised each day, along with randomisation of cages used to measure behavioural activ-
ity. The output variables are highlighted in Table: 3.1. All analyses were performed blinded
.
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Table 3.1: Variables from open field behaviour analysis: Open field behaviour analysis is performed and summarised
by a funcধon of count data, ধme data and distance captured in 10 minute intervals over a period of an hour. Count
data is categorised as either fast or slow based on a funcধon of the mobile threshold (set as 20 breaks) and fast
threshold (40 breaks).
Behavioural parameter Units Description
Total Activity Fast Activity Count Fast Beam Breaks
Slow Activity Count Slow Beam Breaks
Total Static Counts
Fast Static Count Beam breaks (Δposition) lower thanCounts mobile threshold but higher than fast threshold
Slow Static Count Beam breaks (Δposition) lower thanCounts mobile threshold and fast threshold
Total Mobile Counts
Fast Mobile Count Beam breaks (Δposition) higher thanCounts mobile threshold and fast threshold
SlowMobile Count Beam breaks (Δposition) higher thanCounts mobile threshold but lower than fast threshold
Total Rearing Counts Fast Rearing Counts Count Fast beam breaks in upper frame
Slow Rearing Counts Count Slow beam breaks in upper frame
Total Center Rearing Counts
Fast Center Count Fast beam breaks in upper frameRearing Counts at the centre of the cage
Slow Center Count Slow beam breaks in upper frameRearing Counts at the centre of the cage
Active Time Static Time Seconds Time spent in static activity (slow and fast)
Mobile Time Seconds Time spent in mobile activity (slow and fast)
Innactive Time Seconds Time spent inactive
Rearing Time Seconds Time spent in rearing
Front To Back Counts Count No of traverses along the length of the cage
Distance Travelled Meters The distance covered by the mouse in the cage
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3.5 Forelimb grip strength analysis
To assess the forelimb grip strength of the animals, mice are allowed to rest on an angled
mesh assembly, facing away from the meter (Linton Instrumentation, Norfolk, UK) and
with its hind limbs not in contact with the mesh. A pulling force was exerted on the tail
of the mouse parallel to the angle of the mesh, causing the animal to resist with both fore-
limbs. The maximal force was recorded as the force before the release of any limb from the
transducer mesh. To prevent habituation of the mice, the test was performed over three
days in 30 second intervals of data collection and rest, over five observations per day. All
grip strength analyses were conducted at the same time of day (afternoon) , with randomi-
sation of order of mice analysed. All analyses were performed blinded .
3.6 In-situ muscle electrophysiology
Muscle in-situ electrophysiology surgery and measurement were performed by Drs. Ornella
Cappelari and Alberto Malerba. Data analysis was performed by Pradeep Harish . At the
end of the experiment muscle function was assessed using the right tibialis anterior (TA)
muscle. A17 and FvBMice were deeply anesthetized by using pentobarbital solution (in-
traperitoneally, 60 mg/ kg) and were carefully monitored throughout the experiment to en-
sure that there was no reflex response to toe pinch. The distal tendon of the TAmuscle was
dissected from surrounding tissue and tied with 4.0 braided surgical silk (Interfocus, Cam-
bridge, UK). The sciatic nerve was exposed and superfluous branches axotomized, leaving
the TAmotor innervation via the common peroneal nerve intact. The foot was secured to a
platform and the ankle and knee immobilized using stainless steel pins. The TA tendon was
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attached to the lever arm of a 305B dual-mode servomotor transducer (Aurora Scientific,
Ontario, Canada) via a custommade steel s-hook.
TAmuscle contractions were elicited by stimulating the distal part of common peroneal
nerve via bipolar platinum electrodes, using supramaximal square- wave pulses of 0.02 ms
(701A stimulator; Aurora Scientific). Data acquisition and control of the servomotors were
conducted using a Lab-View- based DMC program (Dynamic muscle control and Data Ac-
quisition; Aurora Scientific). Optimal muscle length (Lo) was determined by incrementally
stretching the muscle using micromanipulators until the maximum isometric twitch force
was achieved. Maximum isometric tetanic force (Po) was determined from the plateau of
the force–frequency relationship following a series of stimulations at 10, 30, 40, 50, 80, 100,
120, and 150 Hz. After tetanic stimulation via sciatic nerve, TAmuscle contractions were
elicited by a direct stimulation of the muscle. The specific force (N/cm2) was calculated by
dividing Po by TAmuscle cross-sectional area. the largest obtainable cross sectional area
of muscle was estimated using the following formula 352 : Muscle weight(g)TA fiber length(cm)1:06(g=cm3) . All
analyses were performed blinded .
3.7 Sample collection and processing
Mice were euthanised in accordance with schedule 1 procedures , and blood extracted by
cardiac puncture. Blood samples were allowed to clot overnight at 4°C, and spun down at
2000 rpm (Heraus biofuge 13; Marshall scientific, NewHampshire, USA) for 20 minutes.
The supernatent was extracted, and spun again at 4000 rpm for 20 minutes. Sera samples
were aliquoted and stored at −80°C.
Tibialis Anterior (TA), Extensor Digitor Longus (EDL), and soleus were harvested,
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weighed and mounted in O.C.T. compound (Thermo Fisher Scientific, Leicestershire, UK),
frozen in 2-methylbutane (isopentane) chilled with liquid nitrogen, and stored at −80°C.
3.8 Immunohistochemical analysis
10 μm transverse sections of the whole tissue were sectioned at intervals of 200 μm along
the whole muscle for all muscles analysed , and the sections were mounted on coated slides
(VWR International, Leicestershire, UK).
Transverse sections of the TA and EDL were air-dried, fixed either in methanol or 4%
formaldehyde, washed thrice in phosphate-buffered saline (PBS) with 0.1% (v/v) Tween-
20 (PBS-T) for 5 minutes. The sections were incubated at room temperature for 1 hour in
a blocking solution (1% normal goat serum in 0.1 m PBS, 0,1% Triton X100). For PABPN1
immunodetection, sections were then incubated in 1 m KCl, 30 mmHEPES, 65 mm PIPES,
10 mm EDTA, 2 mmMgCl2, pH 6.9, for 1 h prior to the immunolabelling, to remove any
soluble proteins. Sections were then incubated with the primary antibody (anti-PABPN1
(rabbit monoclonal, diluted 1:100, Abcam ab75855, overnight at 4 °C), anti-laminin (rat
monoclonal; diluted 1:800; Sigma-Aldrich L0663, 1 hour at room temperature) and anti-
collagen VI (rabbit polyclonal, Abcam ab6588, 1:200, 1  hour at room temperature ). Sec-
tions were washed as before and flurophore-labelled secondary antibodies (Alexa fluor
conjugated to 488 or 594 fluorochromes) were applied for 1 hour. Slides were stained with
DAPI Slides were stained with DAPI (0.1 μg/ml for 3 minutes) to visualise nuclei and cov-
erslips were mounted using the mounting medium (Vector Labs, California, USA). Whole
muscle images (for laminin based fibre morphometry and collagen VI based stains) or ran-
dom fields (for PABPN1 immunostaining) were captured using a microscope (Zeiss, Cam-
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bridge, UK). Sections from both left and right muscles for the TA and EDL were analysed,
with statistical analyses performed on the average value between the muscles . The feret di-
ameter was obtained by manufacturer provided software (Zeiss, Cambridge, UK). The area
of collagen VI and quantification of PABPN1 immunostaining was performed by ImageJ .
All analyses were performed blinded .
3.9 Western blotting
Muscle tissues were homogenised in RIPA buffer (NaCl 0.15 m; HEPES 0.05 m; NP-40 1%;
sodium dehoxycholate 0.5%; SDS 0.1%; EDTA 0.01 m) and with protease inhibitor cocktail
(Roche diagnostics, Risch-Rotkreuz, Switzerland). The protein content of the sample was
quantified by BCA assay (Pierce, Massachusetts, United States). Proteins were denatured
at 70°C for 10 minutes, loaded and separated on pre-cast 4–12% Bis–Tris gel (Invitrogen,
California, United States) and transferred onto a nitrocellulose membrane using a semi-
dry transfer method (Trans-Blot turbo transfer pack, Bio-Rad, California, United States).
The membrane was blocked by incubation in 5% milk in 0.1 m PBS, 0.1% Tween-20 for 1
hour. The membrane was probed with primary antibodies (OXPHOS Rodent WB An-
tibody Cocktail; Abcam ab110413; diluted 1:200) overnight, washed and further incubated
with flurophore-attached secondary antibodies. The membranes were directly imaged by
the Odyssey system (LI-COR Biosciences, Nebraska, United States), and area of band was
quantified using manufacturer provided software. All analyses were performed blinded .
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3.10 qPCR analysis
RNA extraction and qPCR analysis was performed in collaboration with Dr. Capucine
Trollet 384. Total RNAwas extracted from frozen skeletal muscles biopsies using Trizol (In-
vitrogen, California, United States) according to the manufacturer’s instructions. RNA
samples were quantified using a ND-1000 NanoDrop spectrophotometer (NanoDrop
Technologies, Massachusetts, United States).
RNA (50-250ng for muscle biopsies) was reverse transcribed using M-MLV reverse tran-
scriptase (Invitrogen) according to the manufacturer’s instructions. cDNAwas used for
quantitative PCR reaction using SYBR green mix buffer (LightCycler® 480 Sybr green
I Master) in a total of 9ul reaction volume. PCR reaction was carried out as follows: 8
minutes at 95°C followed by 50 cycles: 15 seconds at 95°C, 15 seconds at 60°C and 15 sec-
onds at 72°C. Specificity of the PCR products was checked by melting curve analysis us-
ing the following program: 65°C increasing by 0.11°C/second to 97°C. Transcripts mea-
sured in this study include MyHC IIa (Myh2; 5’ - ACTTTGGCACTACGGGGAAAC -
3’ and 5’ - CAGCAGCATTTCGATCAGCTC - 3’ ), MyHC IIb (Myh4; 5’ - CTTTGCT-
TACGTCAGTCAAGGT - 3’ and 5’ - AGCGCCTGTGAGCTTGTAAA - 3’) andMurf1
(5’ - CGACCGAGTGCAGACGATCATCTC - 3’ and 5’- GTGTCAAACTTCTGACTCAGC
- 3’)The expression level of each mRNAwas normalized to that of murine Rplp0mRNA
(large ribosomal protein, subunit P0; 5’ - GAGGACCTCACTGAGATTCGG - 3’ and 5’
- TTCTGAGCTGGCACAGTGAC - 3’) expression. Expression levels were calculated ac-
cording to the DDCt method. All analyses were performed blinded .
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3.11 Mass spectrometric analysis
Mass spectrometric analysis was performed in collaboration with Prof. John Halket 152.
Data files were provided to and analysed by Pradeep Harish. 50 μl serum and 10μL tride-
canoic acid solution (as an internal standard) was vortexed for 10 seconds. 0.5 mLmethanol/chloroform
(3:1, v/v) was added and vortexed for 30 seconds and spun down at 3000 rpm (Heraus
biofuge 13; Marshall scientific, NewHampshire, USA) for 10 minutes. The top (organic)
layer was carefully transferred to a glass vial and dried down under N2 at room temperature.
30 μl methoxyamine HCl solution (20 mg/mL in dry pyridine) was then added and the
vial was tightly capped, vortexed and heated at 60°C for 15 minutes. After cooling, 70 μL
BSTFA (1% TMCS) and 30 μL heptane were added, vortexed, tightly capped and heated at
70°C for 30 minutes. After cooling the samples were transferred to microvials for GC/MS
analysis. The samples were analysed in the following order: A17+ Saline, FvB, A17 + RK35 .
An Agilent 5973 quadrupole MSD system with a 6890 GC using a 30 m x 0.25 mm i.d.
fused silica capillary column. 1 μl of serum sample was injected on to the column pro-
grammed on an increasing temperature gradient from 50°C (1 minute) at 10°C/minute to
300°C (held 5 minutes) for a total time of 31 minutes. The helium carrier gas was set at a
constant flow of 1 ml/minute. The interface to the mass spectrometer was maintained at
280°C. The mass spectrometer was calibrated using the instrument Autotune procedure
and standard 70 eV electron impact spectra scanned fromm/z 35-600 with a solvent delay
of 5.5 minutes.
Rawmass data was utilised to create peak table using XCMS online 371, to perform initial
statistical filtering, ion peak filtration and retention time alignment. Mass data deconvolu-
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tion was then carried out on changed ion concentrations using MS ChemStation v6.9 (Ag-
ilent, California, United States) to obtain feature ions and mass spectrum of each metabo-
lite. Metabolite signatures were then compared against NIST v11 library. Subsequently, the
raw peak area in the peak table was normalised to that of tridecanoic acid. Data files were
then uploaded toMetaboanalyst v4.0 for statistical analysis422. All analyses were performed
blinded .
3.12 Statistical Techniques
3.12.1 Descriptive data analysis
All descriptive data in this document are represented as the mean of the distribution
standard error of distribution. In the event of comparison during hypothesis testing, the
data are represented as percentage differences between the groups being compared. Unless
mentioned explicitly, the conventional statistical parameters are used for hypothesis testing
(α = 0.05, β = 0.2). Normality of the distribution was assessed by a shipro-wilks, and the
distribution was assumed to be normally distributed if the p value was0.05. Normality
was also visually verified by the use of Normal QQ plots and histograms. Homogeneity of
variance was assessed by Levene’s test, and if p0.05, the distribution was assumed to be
homoscedastic (homogeneous variance). In the event that p0.05, the distribution was
assumed to be heteroscedastic (heterogeneous variance).
3.12.2 Inferential data analysis
Comparison of two groups If the conditions of normality and homoscedasticity
were met in the distribution, a students t-test was performed between the groups. If the
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condition of normality was not met in a homoscedastic distribution, a Mann-Whitney
U test was performed. In the case of violation homogeneity of variances, a two sample
Kolmogorov–Smirnov test was performed.
Comparison of multiple groups If the conditions of normality and homoscedastic-
ity were met, a oneWay ANOVAwas performed to compare multiple groups. In the case
of a normally distributed heteroscedastic distribution, Welch’s ANOVAwas performed.
Multiple comparison analysis were also independently performed with the Benjamini,
Hochberg, and Yekutieli correction for the false discovery rate (FDR). If the condition
of normality was not met in a homoscedastic distribution, a Kruskal-Wallis ANOVAwas
performed with the comparison of medians. In the case of violation of normality and het-
eroscedasticity, and if the distribution shapes were equivalent, a Kruskall-Wallis ANOVA
was performed, with the comparisons of mean ranks. Multiple comparison analysis for the
Kruskal Wallis ANOVAwere performed with Dunn-Bonferroni correction for family wise
error rates.
Fibre morphometry analysis To compare the distribution of muscle fibre size, a
kernel density estimate was used to fit smoothed probability density functions to 1000 ran-
domly selected measurements of minimal feret diameter per animal for the TA or 400 for
the EDL 193 . The kernel density estimate has an inherent advantage of smoothness, as com-
pared to a histogram and hence models the underlying distribution more accurately. Once
two probability density functions corresponding to the treatment groups were obtained,
the median of the distributed was compared using the appropriate method. The minimal
feret’s diameter is defined as closest possible distance between the two parallel tangents of
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an object (i.e. muscle fibre)Dubach-Powell, and was used to determine fibre diameter .
3.12.3 Statistical packages employed
Unless specifically stated, all descriptive statistical techniques were performed using Graph-
Pad Prism v7.00, (GraphPad Software, California, USA). Hypothesis testing and Kernel
density estimation used to analyse the muscle fibre minimum feret diameters and was per-
formed in R (Version 3.2.1, R Foundation for Statistical Computing, Austria).
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Taylor’s original report attracted little notice or wॼ soon
forgotten … yet we have continued to see examplॽ of it
from time to time … and such casॽ have nearly always
been misdiagnosed by the referring physician. Because
of its apparent rarity and lack of general recognition,
and also for the purpose of presenting new data … we are
prompted to place the following observations on record.
Victor et al. 394
Chapter 4
Treatment with anti-myostatin antibody RK35 amelio-
rates atrophic symptoms at early stages of disease in the
oculopharyngeal muscular dystrophy model mouse
4.1 Introduction
Myostatin acts as a negative regulator of muscle mass, and has been investigated
as a therapeutic target to ameliorate symptoms in cases of cachexia, sarcopenia, muscular
atrophy and muscular dystrophy41,137,211,358,417,431. Inhibition of myostatin has been reported
to increase muscle mass and myofibre size (by cytoplasmic growth) 340, which though does
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not target the underlying disease state may lead to an improvement in the quality of life
of patients by delaying the onset of locomotion/atrophy related disability. While several
proof-of-concept studies and clinical reports exist in severe muscular dystrophies 399,401, to
our knowledge this is the first report to examine the effect of myostatin in oculopharyngeal
muscular dystrophy (OPMD).
The OPMDmodel system involves the A17 OPMD transgenic mice which express bovine
expanded polyadenylate-binding nuclear protein 1 (PABPN1) protein containing a patho-
logical polyalanine tract specifically expressed in skeletal muscle92. The FvB mice (which
form the background strain for the A17 mice) were used in this model system as a strain and
littermate control . The OPMDmodel exhibits loss of body mass, muscle mass, decreased
specific force in skeletal muscle, transcriptomic dysregulation and significant accumulation
of intranuclear inclusions (INI) in myonuclei91,384 . Studies suggest that the disease progres-
sion and atrophy in the model system is prevalent in fast glycolytic fibres found for example
in the tibialis anterior (TA) and the extensor digitorum longus (EDL) muscles, with the ox-
idative fibre types such as those found in the soleus being less affected, inspite of equivalent
transgene expression between the muscles 384. Specifically, there was a decrease in myofibre
cross-sectional area of MyHC-IIB fibres, with an increase in the area of MyHC-IIA fibres.
This change in the myofibre morphology is accompanied by a significant loss of muscle
mass in the TA (upto 40%) and EDL (upto 20%), which corresponds to a loss of maximal
force in both muscles (upto 20%) at 26 weeks of age. The soleus remains unaffected . 246,384.
Previous analysis by Trollet et al. 384 have demonstrated that the atrophy in the OPMD
model system is most apparent from the 18th week of age. To monitor the effects of in-
hibiting myostatin in the early stages of OPMD (before the onset of visible atrophy) , male
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Figure 4.1: Experimental design to test effect of RK35 anধbody on muscle atrophy of 22-week old OPMD mice:Mice
(9 male A17 + RK35, 10 male A17 + saline, 8 male FvB + RK35, 10 male FvB + saline mice) were administered a
weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 12th week of age, and
body mass, muscle mass and histology, select proteins, metabolites and transcripts were analysed.
A17 and FvB mice at 12 weeks of age were administered RK35 antibody (10 mg/kg IP) or an
equivalent volume of saline weekly for 10 weeks (9 male A17 + RK35, 10 male A17 + saline, 8
male FvB + RK35, 10 male FvB + saline mice) . Mice were then assayed for muscle function,
and muscle sections from TA and EDL were histologically analysed (figure: 4.1).
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4.2 Administration of RK35 prevents disease associated loss of body mass in
early stages of OPMD:
Body mass index has been correlated to muscle strength 160, presenting measurement of
body mass as a rapid and longitudinal method to follow disease progression. The progres-
sion of the disease at 22 weeks of age results in a difference in body mass of 8% (p < 0.05)
when comparing the untreated A17 mice with the untreated FvB control mice (figure: 4.2).
The administration of the antibody (10mg/kg IP, weekly for 10 weeks) resulted in an in-
crease of 11% (p < 0.01) in the body mass of the treated A17 mice when compared to the
untreated A17 mice.
This increase in body mass in treated A17 mice is also normalised to the untreated FvB
control mice, with a negligible difference of 3% (p > 0.05) reported. The data are sum-
marised in figure: 4.2. A descriptive statistical summary is presented in table: A.1.
4.3 Administration of RK35 prevents disease associated loss of muscle mass
in early stages of OPMD:
Measurement of muscle mass is used as a canonical indicator for progress of neuromuscular
diseases in various preclinical models. While certain disease profiles (such as those observed
in themdxmodels) may involve an initial pseudo-hypertrophic response, most myopathies
involve varying degrees of muscular atrophy215. Different mammalian muscle fibre types
possess varying sensitivity to pathophysiological atrophy signals underlining the need to
examine muscles across the fibre types in preclinical studies410. Three distinct muscles, the
TA, EDL and, the soleus comprising mixed, type IIb, and type I fibre types respectively
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Figure 4.2: Effect of RK35 anধbody on body mass of 22-week old OPMD mice: Mice (9 male A17 + RK35, 10 male
A17 + saline, 8 male FvB + RK35, 10 male FvB + saline mice) were weighed and administered a weekly regimen of
either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 12th week of age. (a) The average body mass
per group is ploħed against weeks since commencement of experiment (b) The average body mass from the final
week is represented across all groups. Data presented as mean SEM, with p-values obtained by mulধple t-tests
ađer a FDR correcধon.
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were examined, to encompass disease progression and therapeutic response across canonical
myofibre metabolic profiles 343.
TA, EDL and soleus from 22-week old A17 mice with FvB mice subsequent to the treat-
ment regimen (10mg/kg IP RK35, weekly for 10 weeks) were collected, weighed and frozen.
The raw muscle masses (figure: 4.3 d,e,f) were normalised to the initial body mass of the
mice. The muscle masses (normalised to the initial body mass) of TA and EDL were de-
creased by 29% (p < 0.001 ) and 20% (p < 0.001 ) respectively (figure: 4.3 a,b). Administra-
tion of RK35 antibody to A17 mice caused an increase of 19% (p < 0.01 ) and 41% (p < 0.001
) in the mass (normalised to the initial body mass) of TA and EDLmuscles respectively
when compared to untreated A17 mice. The muscle masses of the treated A17 mice when
compared to those of the healthy FvB controls, resulted in a difference of 9% (p > 0.05 )
and 14% (p < 0.05 ) in the TA and EDL (fig:4.3 a,b). No change in the muscle mass of the
soleus was observed across all groups (figure:4.3 c). The data are summarised in figure: 4.3.
A descriptive statistical summary is presented in table: A.2.
4.4 Administration of RK35 antibody prevents disease associated reduction
of myofibre diameter in the OPMDmice:
Myofibre diameter and shape is often correlated to general health of the muscle fibre411.
A dystrophic phenotype results in the gradual replacement of healthy myofibres by either
fibres undergoing increased proteolysis / reduced proteogenesis, necrosis, regeneration, de-
position of connective tissue and fat deposits. These processes over the course of the disease
causes considerable variation in muscle fibre morphometry in a dystrophic muscle403,411.
A17 and FvB mice were subject to an anti-myostatin treatment regimen (weekly 10mg/kg
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Figure 4.3: Effect of RK35 anধbody on muscle mass of 22-week old OPMD mice:Mice (9 male A17 + RK35, 10 male
A17 + saline, 8 male FvB + RK35, 10 male FvB + saline mice) were administered a weekly regimen of either saline or
the RK35 anধbody (10mg/kg IP) for 10 weeks from the 12th week of age. TA (a,d), EDL (b,e) and soleus (c,f) were
sampled and mean mass of all muscles were either normalised to the iniধal body mass (a,b,c; A.U being arbitrary
units) or are presented as is (d,e,f).Data presented as mean SEM, with p-values obtained by mulধple t-tests ađer a
FDR correcধon.
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IP for 10 weeks), following which whole muscle sections were stained for laminin, imaged,
blinded and analysed for the minimum feret * diameter. Median fibre diameters from the
kernel density estimate of 1000 random fibres or 400 random fibres per mouse were se-
lected from the TA and EDL respectively and analysed (figure: A.1) .
The reduction of muscle mass in the TA and EDL of A17 mice was accompanied by a
reduction in the average myofibre cross-sectional area by 28% (p < 0.001 ) and 22% (p <
0.001 ) respectively, when compared to FvB mice (figure: 4.4). Administration of the RK35
antibody resulted in a significant increase of 17% (p < 0.01 ) and 44% (p < 0.001 ) respec-
tively, in the TA and EDLmuscles when compared to untreated A17 mice (figure: 4.4).
The soleus was not histologically analysed as reports indicate the minimal effect of inhibi-
tion of myostatin on soleus contractile properties 269, sparing of oxidative fibres in OPMD
models 384, and minimal change in muscle mass observed after myostatin inhibition by
RK35 (figure: 4.3). The data are summarised in figure: 4.4. A descriptive statistical sum-
mary is presented in table: A.3.
4.5 Increase in muscle mass of TA is accompanied by a decrease in expression
of collagen VI
Muscle fibrosis is a distinct histopathological feature of OPMD in humans 136. Muscle sec-
tions from 22-week old A17 mice were stained for collagen VI, imaged, blinded, and anal-
ysed for the area of collagen VI deposition. Evidence of disease associated muscle fibrosis
exists in the form of a 56% (p < 0.001 ) increased area of collagen VI deposition when com-
pared to untreated FvB mice (figure: 4.5). Inhibition of myostatin by administered RK35
*The minimal feret’s diameteris defined as closest possible distance between the two parallel tangents of an
object (i.e. muscle fibre)Dubach-Powell.
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Figure 4.4: Effect of RK35 anধbody on myofibre diameter of 22-week old OPMD mice: Mice were administered a
weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 12th week of age. Mus-
cle samples from 5 randomly selected mice per group were secধoned and stained for laminin. (a) 1000 fibres were
randomly selected for the TA, (b) whereas 400 fibres were randomly selected for the EDL, and the median minimum
feret diameter was analysed. The average median minimum feret diameter per group was ploħed, bars represenধng
SEM, with p-values obtained by mulধple t-tests ađer a FDR correcধon.
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antibody (10mg/kg IP, weekly for 10 weeks) reduced deposition of collagen VI in the TA
muscle by 40% (p < 0.001 ) when compared to untreated A17 mice (figure: 4.5). Surpris-
ingly, no significant change in collagen VI levels were however observed for EDLmuscle.
The data are summarised in figure: 4.5. A descriptive statistical summary is presented in
table: A.4.
4.6 Administration of RK35 antibody does not affect intranuclear inclu-
sion density
The characteristic hallmark of the OPMD protein expansion is the aggregation of the exp-
PABPN1 in the nucleus 158. The disease phenotype causes the sequestration of essential tran-
scripts and proteins, compromising the transcriptomic profile of the cell and subsequently
the muscle 158,246. While strategies are being developed by research groups to target these in-
tranuclear inclusions 246, we report that an acute anti-myostatin treatment employed on a
post-natal mouse model does not quantitatively affect the density † of INI observed. Mus-
cle sections from 22-week old OPMDmice treated with RK35 (weekly at 10mg/kg IP for
10 weeks) were stained for PABPN1 after a KCl wash 384, co stained with DAPI, imaged,
blinded and analysed. The total nuclei, and the nuclei positive for PABPN1 were counted,
and averaged across fields of view per mouse, and analysed.
The absolute INI density while negligible in the untreated FvB control mice (0% 0%
of observed nuclei), is significantly higher in the untreated A17 mice (36% 0.79%, p <
0.001 ; figure: 4.6). Administration of the antibody (10mg/kg IP, weekly for 10 weeks) re-
sults in a negligible change in the density by 4.5% (p > 0.05 ), with the treated A17 mice
†The percentage of nuclei with INI to the total number of nuclei in a field of view
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Figure 4.5: Effect of RK35 anধbody on collagen VI deposiধon in muscles of 22-week old OPMD mice: Mice were
administered a weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 12th week
of age. 5 randomly selected whole muscle secধons from all groups for (a) TA and (b) EDL were stained for collagen VI,
and 5 random fields were imaged and analysed for the percentage area of collagen VI staining. The average area per
group is ploħed, bars represenধng SEM, with p-values obtained by mulধple t-tests ađer a FDR correcধon.
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Figure 4.6: Effect of RK35 anধbody on INI in muscles of 22-week old OPMD mice: Mice were subject to a weekly regimen of either saline or the anধ-
myostaধn RK35 anধbody IP for ten weeks from the 12th week of age ধll the 22nd week of age. 5 randomly selected muscle samples per group from all
groups were stained for bovine PABPN1 ađer a KCl wash, and 5 random fields were imaged and analysed for the percentage number of posiধve PABPN1
stains to all myonuclei. The average density is ploħed, bars represenধng SEM, with p-values obtained by mulধple t-tests ađer a FDR correcধon
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having an absolute 34% 2.7% of observed nuclei with INI. The data are presented in fig-
ure: 4.6, and a statistical summary is presented in table: A.5.
4.7 Increase in muscle mass is accompanied by an increase in muscle function
Muscle strength is often correlated to muscle size, fibre type and excitation-contraction cou-
pling processes, subsequently linked to impaired locomotion with increased mortality, and
serves as a crucial indicator in phenotypes linked to muscular dystrophy43. Muscle function
testing permits the analysis and quantification of the strength of either individual mus-
cles or whole muscle groups43. Three distinct types of muscle function, the forelimb grip
strength, open field activity behaviour and an in-situmuscle electrophysiological assay were
analysed in this study. In order to obtain measures of muscle function, the experiment was
repeated with a n = 10 per group. The measures of change in body mass and muscle mass
were identical to the previous experiment (data not shown; see figure: 4.1) .
4.7.1 Increase in muscle mass is accompanied by an increase in fore limb grip
strength.
Forelimb grip strength measurements allows evaluation of in-vivomuscle performance in
a non-invasive manner. The forelimb grip strength encompasses measurement of peak
resistive force as the animal is pulled away from a grid, with studies in OPMDmodels re-
porting a correlation of grip strength with disease progression92,384. 22-week old OPMD
mice treated weekly with 10mg/kg IP RK35 were assayed, 15 measurements over four days
(with upto five measurements per day) in 30 second intervals were recorded and median
grip strength per mouse was analysed.
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The grip strength (normalised to initial body mass) of the untreated A17 mice was 13%
(p < 0.05 ) lower than the untreated FvB control mice, which may indicate an atrophic loss
of muscle function due to dystrophy, and a compromise of muscle structure due to fibrosis
(figure: 4.7). The administration of RK35 causes an increase of normalised grip strength by
23% (p < 0.001 ) when compared to the untreated A17 mice. This increase in normalised
grip strength results in there being a 8% (p > 0.05 ) difference when compared to the un-
treated FvB control mice (figure: 4.7). While an increase in (and subsequent normalisation
of) grip strength in the treated A17 mice is observed, the forelimb grip strength of treated
FvB control mice remain statistically homogeneous to the untreated FvB control mice (fig-
ure: 4.7). This is surprising, and may indicate that inhibition of myostatin in a healthy an-
imal systemmay not necessarily be correlate an increase in muscle strength to an increased
muscle mass. The data are summarised in figure: 4.7, and a descriptive statistical summary
is presented in table: A.6
4.7.2 Administration of antibody RK35 results in no change in open field be-
haviour test outcomes
Open field behaviour analysis enables the assay of voluntary motor activity within the con-
text of locomotor impairment in murine models of muscular dystrophy, and subsequent
efficacy of therapeutic regimen to ameliorate loss of muscle function 370. Different from
the grip strength which measures muscle strength, open field behaviour analysis demon-
strates the effect of the disease and therapeutic agents on whole body systems, making it
a beneficial auxiliary outcome measure in preclinical studies 370. Though previous and pi-
lot experiments show no differences in locomotor activity between the A17 and FvB mice,
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Figure 4.7: Effect of RK35 anধbody on forelimb grip strength of 22-week old OPMD mice: Mice (9 male A17 + RK35,
10 male A17 + saline, 8 male FvB + RK35, 10 male FvB + saline mice) were administered a weekly regimen of either
saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 12th week of age. Forelimb grip strength was anal-
ysed and the average of 15 measurements per mouse, per group is ploħed, bars represenধng SEM, with p-values
obtained by mulধple t-tests ađer a FDR correcধon.
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open field analyses were performed in this study to quantify the effect of increased muscle
mass brought about by myostatin inhibition in the A17 disease model; especially as the ther-
apeutic administration of myostatin brought about an increase in muscle force . 22-week
old OPMDmice treated weekly with 10mg/kg IP RK35 were observed for 1 hour per day,
over 4 days . 22 variables were recorded in each observation, and average measurement per
mouse was analysed. No overt difference exists in the voluntary locomotor activity mea-
sured between the untreated A17 mice, treated A17 mice and untreated FvB control mice.
While minor trends observed wherein the untreated A17 mice display a difference in mean
compared to the other groups, for example in select cases of ”fast activity” (figure: 5.8 a),
”total activity” (figure: 5.8 b), and ”total static count” (figure: 5.8 c), ”total centre rearing
count” (figure: 5.8 d), these differences however remain statistically homogeneous. A de-
scriptive statistical summary of the data are presented in table: 4.1. A description of terms
used in analysis is presented in table: B1.
4.7.3 Increase in muscle mass observed corresponds to an increase in maximal
tetanic force
Evaluation of muscle mechanical function allows examination of disease progression and
the effect of therapeutic regimens administered. Performed on a terminally anaesthetised
mouse, in-situ electrophysiological techniques have inherent advantages over other non-
invasive or ex-vivo techniques 246. Non-invasive tests such as grip strength provide valu-
able longitudinal information, but are susceptible to central fatigue, cooperation of animal,
and animal learning requiring a large number of replicates. On the other hand, ex-vivo as-
says while providing information on muscle contraction do not permit the examination of
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Table 4.1: Open field behaviour of 22-week old OPMD mice does not change with treatment: Mice (n = 10 per
group) were administered a weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from
the 12th week of age. Open field behaviour was analysed over an hour over four days, and the average measure-
ments of 20 observaধons per group is represented below.
Activity A17 + Saline A17 + RK35 FvB + Saline FvB + RK35Mean SEM Mean SEM Mean SEM Mean SEM
Active time (s) 203 10 237 6 225 9 228 11
Distance travelled (m) 15 1 17 1 16 1 16 1
Fast activity (bks) 43 4 51 4 49 4 56 5
Fast centre rearing count 12 3 13 3 10 2 13 3
Fast mobile count 29 3 35 4 33 3 39 4
Fast rearing count 78 19 104 20 95 19 92 20
Fast static count 14 1 17 1 17 2 17 2
Front To Back count 21 1 23 1 23 1 25 2
Inactive Time (s) 398 10 363 6 375 9 372 11
Mobile Time (s) 37 3 43 3 40 2 46 4
Rearing Time (s) 232 19 269 13 238 14 261 19
Slow activity (bks) 254 14 294 9 282 13 294 17
Slow centre rearing count 11 1 11 1 8 1 10 1
Slow mobile count 41 4 47 3 44 3 54 5
Slow rearing count 60 4 69 3 60 3 68 4
Slow static count 213 12 247 8 238 12 240 14
Static Time (s) 166 9 194 6 185 9 182 10
Total activity (bks) 297 16 345 11 331 15 350 20
Total centre rearing count 23 3 23 3 18 3 23 4
Total mobile count 70 6 82 6 77 5 92 9
Total rearing count 138 19 172 20 156 19 160 21
Total static count 227 13 264 8 254 13 257 15
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Figure 4.8: Effect of RK35 anধbody on open field behaviour of 22-week old OPMD mice: Mice (n = 10 per group)
were administered a weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 12th
week of age. Open field behaviour was analysed over an hour over four days, and the average measurements of 20
observaধons per group is ploħed, bars represenধng SD. (a) total acধvity represents average total beam breaks, (b)
front-to-back counts represents the number of ধmes mouse crossed the length of the cage (c) total mobile counts
and (d) total centre rearing count. Staধsধcal analyses were conducted, with values obtained by mulধple t-tests ađer a
FDR correcধon
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muscle contraction under neural stimulus 366. The analysis of maximal force generation on
tetani at a series of increasing stimulation frequencies on a per muscle basis, provides infor-
mation on muscle strength, Henneman recruitment of motor units in disease and treated
conditions 24, and enables assessment of force per unit area of the muscle 246. The maximal
tetanic force produced by the untreated A17 mice at an excitation frequency of 180Hz , was
55% (p < 0.001 ) lower than the untreated FvB controls (figure: 4.9 a,b). Administration of
the antibody to A17 mice caused an increase of 21%(p < 0.05 ) when compared to the un-
treated A17 mice. This results a difference of 28%(p <0.01 ) between the treated A17 and
untreated FvB control mice (figure: 4.9 a,b) for the maximal tetanic force. Surprisingly, no
change in maximum tetanic force between the untreated FvB mice and treated FvB mice
was observed. Specific force was calculated as a function of muscle mass, length of mus-
cle and muscle specific gravity to approximate muscle cross sectional area 246. Surprisingly,
specific force of all groups remain statistically homogeneous (figure: 4.9, c,d). The data are
summarised in figure: 4.9. descriptive statistical summary is presented in table: A.7.
4.8 Discussion
OPMD is modelled in various in-vitro and in-vivomodel systems. In this study, the A17
mammalian model system which co-expresses an expanded bovine PABPN1 construct in
skeletal muscles to recreate the disease at a tissue level was utilised to examine the thera-
peutic effects of myostatin blockade in early stages of disease. As established 384, we report
that A17 disease model (untreated A17) mouse at 22 weeks of age possesses a lower body
and muscle mass resultant from the dystrophy as compared to the FvB controls. The lower
muscle mass was accompanied by an atrophy of the muscle fibres (evidenced by a decreased
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Figure 4.9: Change in tetanic force generated in TA of 22-week old OPMD mice administered with RK35: Mice (n =
10 per group) were administered a weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks
from the 12th week of age. The leđ TA from all groups were mounted on a mechanotransducer and the sciaধc nerve
was excited (a) average max. force generated at increasing frequencies is ploħed. (b) The average max. force gen-
erated at 180Hz is ploħed, with bars represenধng SEM. (c)Maximal force values were normalised with the muscle
cross-secধonal area to obtain specific force (d) Specific force of TA at 180Hz is ploħed is ploħed. Data presented as
mean SEM, with p-values obtained by mulধple t-tests ađer a FDR correcধon
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myofibre diameter), an increased level of observed fibrosis (evidenced by collagen VI de-
position), and lower functional quality of muscles (evidenced by grip strength and in-situ
muscle physiology) as compared to the untreated FvB control mice. Analysis of INI density
(which serve as the pathological hallmark of the disease) revealed that at 22 weeks of age, the
A17 mice have a significantly higher proportion of INIs in the myonuclei of TA, confirm-
ing that animals used model OPMD on a tissue level.
The inhibition of myostatin increases muscle mass by driving cytoplasmic growth of the
muscle fibre 340. The efficacy of myostatin blockade by the monoclonal antibody RK35 has
been examined in the murine models of amyotrophic lateral sclerosis (ALS), Duchenne
muscular dystrophy(DMD) and nemaline myopathy9,173,378, and is currently in phase II
clinical trial as PF-06252616 for DMD (NCT02907619,NCT02310763 and Bhattacharya
et al. 32). Other similar reagents include recombinant antibodies (e.g. JA-1641), myostatin
propeptide42 and a monoclonal antibody (REGN1033 220). It was hypothesised that the in-
hibition of myostatin before pathological onset, or during the early stages of disease would
delay disease progression.
Supporting the hypothesis, a treatment associated reversal of loss of body mass and mus-
cle mass by an increase in muscle fibre diameter of the OPMDmodel was observed. The
increase in body mass by 11% in treated animals was most evident during the first 5 weeks
of the 10 week treatment regimen, after which the difference was maintained. A similar ef-
fect was observed by Andre et al. 9 and Tinklenberg et al. 378 wherein the greatest increase in
body mass is observed within 5 weeks of treatment. Increase in body mass of 3%-14% was
observed for other antibody based reagents41,220, and a 24% increase in body mass by the use
of a propeptide42.
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The increase in muscle masses (by 19% and 41% in TA and EDL) and muscle fibre diam-
eter (by 17% and 44% in TA and EDL) observed in this study is promising, as it indicates
that inhibition of myostatin may be a valid strategy to counteract the loss of body mass and
muscle mass in the OPMDmodel mice at early stages of disease progression. Other studies
employing an anti-myostatin regimen reported an increase in muscle mass of hind-limb
muscles by 13%-35% depending on muscle and disease model examined9,41,42,220,378.
No loss in the mass of the soleus was reported in this study. The muscle fibre type com-
position between the TA, EDL and soleus differ, with the EDL primarily composed of
glycolytic fast-twitch fibres, the TA composed of mixed fibres, and the soleus primarily ox-
idative slow twitch fibres. The increased response to the antibody as observed in the EDL
compared to the TA and soleus was hypothesised as studies report that the myofibrillar
metabolic profile of a glycolytic fast-twitch fibre causes an increased production of myo-
statin transcripts and an increased density of the ACTRIIB receptors to be present in the
EDL 269,424. This observation is most promising as OPMD disease progression is reported
to be more specific in fast-twitch muscle fibres like the EDL 384, and the specific response
expected and observed with the antibody RK35 on the EDL complements the aetiological
profile of the disease. No changes were also observed in the density of INI in the TA, sup-
porting our hypothesis that inhibition of myostatin does not affect disease phenotype.
Muscle fibrosis forms an essential step which culminates in the reforming of the con-
tractile unit frommyofibre stumps 233. Collagen VI is implicated in tissue remodelling and
wound healing, as variations in collagen VI expression have been reported in many patho-
logical conditions, like muscle and liver fibrosis 128. Fibrosis is the most conspicuous patho-
logical change in dystrophic muscles; it is characterized by excessive accumulation of colla-
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gens and other ECM components, including collagen VI429. Wagner et al. 401 reported a
decrease in fibrosis inMstn = =mdxmodels. Studies inmdxmodels administered with an
anti-myostatin agent report that pharmacological inhibition of myostatin reverses muscle
fibrosis in the triceps (29% reduction in the area of collagen VI 234). Analysis of area of colla-
gen VI deposition in this study, revealed a reduction in the area in the TA of the treated A17
mice, but not the EDL by 40% and a non-significant 8% , respectively. Though further ex-
periments need to be performed to analyse why a decrease in area of collagen VI expression
in the EDL was not observed, we speculate that the difference in muscle fibre type may alter
susceptibility of the fibre to fibrosis dependant on relative stage of disease progression. The
reduction in the area of collagen VI in the TA however remains promising and indicates a
partial rescue of the structural integrity of a myofibre compromised by disease progression.
This increase in muscle mass is also correlated to an increase in grip strength and max-
imal tetanic force observed, corresponding to an increase in gross muscle function in the
treated A17 mice. Indeed, an increase in grip strength by 23% and maximal tetanic force of
TA by 21%is observed. Other reports indicate that an anti-myostatin regimen induces an
increase in grip strength by 21%9,378, maximal force by 16% and 19%-47% in the TA and EDL
respectively9,220,378.
Though studies in myostatin null animals have reported an increase in maximal force
but a decrease in specific maximum force of the muscle 271, it must however be noted that a
genetic knockout model of myostatin is inherently different from a post-natal knockdown
regimen and presents a different histopathophysiological profile. Pharmacological /post-
natal myostatin inhibition strategies as employed with the antibody RK35 does not result
in the characteristic ”double-muscling” response observed in a knockout mouse9,41,173,220,378.
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Though an increase in muscle strength in the treated A17 mice was observed, no such in-
crease was evident in the treated healthy FvB control mice (in-spite of an increase in muscle
mass), a pattern also observed by Andre et al. 9 .
While experiments need to be conducted to identify and elucidate this trend, we spec-
ulate that a supra-maximal increase in myofibre diameter in a healthy model systemmay
lead to an increased nuclear domain and place constraints on oxygen diffusion from the
membrane to the centre of the fibre leading to fibre asphyxiation, and a minimal increase
in strength observed 194. We also speculate that the minimal response observed in muscle
strength of the treated FvB mice (which does not correlate to the increased muscle mass)
might indicate a different -omic profile in the healthy FvB mice. This suggests the disease
profile may influence action and efficacy of the antibody and requires further investigation.
Most surprisingly, the specific force across all A17 and FvB groups remain homogeneous.
We speculate that the ratio of increased maximal force observed to the increased muscle
mass in the treated A17 mice mathematically correlates with the decreased maximal force to
the decreased muscle mass in the untreated A17 mice resulting in similar maximal specific
forces for the two treatment groups. However, this hypothesis does not explain the mini-
mal change in specific force and maximal force in-spite of an increase in muscle mass in the
treated FvB mice. Similar patterns were also observed in reports by other anti-myostatin
antibody based studies9,220,378, though a propeptide based inhibition strategy does result in
an increased specific force42. The difference in mechanism of action and efficacy between
propeptide based and antibody based approaches presents a singular opportunity to inves-
tigate and inform development of next generation of blocking antibodies.
Open field behaviour tests form an auxiliary test to test voluntary locomotion based on
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the exploratory drive of the organism 370. Routinely used to test anxiety related behaviour
of mice, the assay has also been used to inform researchers of voluntary locomotor activity
in a dystrophic environment240. No change in the voluntary locomotor activity between all
groups was observed. To minimise variability, the assay was carried out in a quiet, tempera-
ture controlled and well lit room with negligible human presence during the assay. Another
source of variability that traditionally applies to the assay involves changes in behaviour in
the activity cages subsequent to separation from litter mates, which however does not apply
to this study as all animals were individually housed after weaning. It must be noted that
while the assay was carried out in the same lighting conditions for all groups, differences in
circadian patterns over the whole day/night cycle was not measured, and further studies can
be conducted can explore the activity of the mice through longer periods in adapted cages.
Though it was not examined if this increase in muscle morphometry would be protected
against atrophy as the disease continues to progress, we can speculate that this increase in
muscle quality would delay the progression of the disease by the reduction of the net atro-
phy experienced.
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Taylor did not ascertain the pathological basॾ of the
syndrome but believed it ॼ a degeneration of neural
nuclei ... prevailing opinion at that time. The idea that
ptosॾ wॼ but a fragment of a progressive paralysॾ of
striated ocular musclॽ ... due to a primary degeneration
of the muscle fibrॽ ... hॼ only gained general acceptance
since the critical study of Kiloh and Nevin in 1951.
Victor et al. 394
Chapter 5
Treatment with anti-myostatin antibody RK35 partially
ameliorates atrophic symptoms at advanced stages of dis-
ease in the oculopharyngeal muscular dystrophy model
mouse
5.1 Introduction
Oculopharyngeal muscular dystropy (OPMD) primarily remains a late onset
muscle wasting disease, whose clinical diagnosis is often compounded by the onset of sar-
copenia associated muscle loss 317. A combined sarcopenic and dystrophic phenotype may
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irreversibly alter muscle structure and attenuate the efficacy of the therapeutic regimen as
compared to models in earlier stages of the disease 117,197,217,218,323,331,384.
Myostatin is a known regulator of muscle mass 264, and has been examined as a therapeu-
tic target to ameliorate symptoms of dystrophy, cachexia, and sarcopenia 263,325,399. Studies
in myostatin null mice report an increased bone mineral density, ejection fraction, resis-
tance to diet induced obesity, dyslipidemia, atherogenesis, hepatic steatosis, macrophage
infiltration, besides a substantial improvement in muscle mass416, which remain important
sarcopenia associated clinical features. Inhibition of myostatin on disease progression has
been studied in agedmdxmodel and C57 model systems utilising various strategies 16,221,288,
and report variable levels of efficacy. However reports on serummyostatin levels in aged
human populations remain inconclusive and is a crucial variable to consider when develop-
ing a related therapeutic regimen *.
To monitor the effects of inhibiting myostatin in advanced stages of OPMD, 8-10 A17
and FvB mice at 42 weeks old (age chosen dependant on home office regulations ; 9 male
A17 + RK35, 8 male A17 + saline, 10 male FvB + RK35, 10 male FvB + saline mice) were
weighed and administered the anti-myostatin antibody RK35 (10 mg/kg IP) or an equiv-
alent volume of saline weekly for 10 weeks. Mice were then assayed for muscle function,
and muscle sections from TA and EDL were histologically analysed (figure: 5.1).
*A cross-sectional study in aged (sarcopenic) patients suggested that serummyostatin levels increase with
advancing age and is inversely correlated with muscle mass427. Subsequent studies however report no age
related difference in myostatin protein or transcript levels 314,414. Meanwhile recent reports have speculated
a natural and compensatory decrease in serummyostatin levels during later stages of atrophy and disease
progression 251.
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Figure 5.1: Experimental design to test effect of RK35 anধbody on muscle atrophy of 52-week old OPMD mice:Mice
(9 male A17 + RK35, 10 male A17 + saline, 8 male FvB + RK35, 10 male FvB + saline mice) were administered a
weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 42nd week of age, and
body mass, muscle mass and histology were analysed.
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5.2 Progression of disease results in lower initial body mass in 52-week old
OPMDmice:
Skeletal muscle accounts for 40% of mammalian body weight, and substantial quantita-
tive and qualitative deterioration in skeletal muscle mass (due to dystrophy, or other sub-
clinical or clinical features) may be correlated to loss of body mass in murine models of
muscular dystrophy207, and allows the investigator to rapidly and longitudinally assess dis-
ease progression. 52-week old A17 and FvB mice were weighed and administered 10mg/kg
IP RK35 or saline, weekly for 10 weeks from 42 weeks of age.
A 15% (p < 0.01 ) difference in body mass exists, when comparing the A17 mice to the
FvB mice at the start of the experiment (figure: 5.2 b). This difference is maintained through-
out study (figure: 5.2 a,c). The treatment with the antibody causes an increase in final body
mass of 6% (p > 0.05 ) when compared to the untreated A17 mice, which trends to the
body mass of the FvB mice (maintaining a difference of 9% , p < 0.05 , to the FvB mice)
during the experiment (figure: 5.2 b). This increase in body mass results in a change of 9%
(p < 0.05 ) when compared to untreated FvB mice at the end of the experiment. A descrip-
tive statistical summary is presented in table: A.8.
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Figure 5.2: Effect of RK35 anধbody on body mass of 52-week old OPMD mice: Mice (9 male A17 + RK35, 8 male A17 + saline, 10 male FvB + RK35, 10 male
FvB + saline mice) were weighed and administered a weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 42nd week
of age. (a) The change in body mass per group is ploħed against weeks since commencement of experiment (b) The average iniধal body mass and (c) The
average final body mass is represented across all groups. Data presented as mean SEM, with p-values obtained by mulধple t-tests ađer an FDR correcধon.
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5.3 Administration of the RK35 antibody at advanced stages of disease pro-
gression restores muscle mass in the OPMDmice:
The loss of muscle mass is often used as a canonical indicator to follow progress of neu-
romuscular diseases in animal models. Age related muscle loss and dystrophic muscle loss
share clinical features such as fibrosis, myofibre irregularity in shape and heterogeneity in
size, and muscle weakness which may manifest as a loss in muscle mass 29,164,335,336,390,411. A17
and FvB mice were subject to an anti-myostatin treatment regimen (weekly 10mg/kg IP
RK35 for 10 weeks) from 42 weeks of age, following which the TA, EDL and soleus was
weighed and frozen.
A decrease in the muscle masses (normalised to the initial body mass) was observed, in
the TA and EDLmuscles by 23% (p < 0.01 ) and 16% (p > 0.05 ) respectively when A17 mice
were compared to FvB mice (figure: 5.3 a,b). Administration of RK35 antibody increased
muscle mass (normalised to the initial body mass) of the TA and EDL by 14% (p < 0.05 )
and 32% (p < 0.05 ) respectively, in the treated A17 mice when compared to the untreated
A17 mice. This increase results in an 8% (p > 0.05 ) and 12% (p > 0.05 ) difference in nor-
malised muscle masses in the TA and EDLmuscles when the treated A17 mice were com-
pared to FvB mice (figure: 5.3 a,b). A significant change in the muscle mass of the TA and
EDL by 15% (p < 0.01 ) and 26% (p < 0.05 ) was observed (figure: 5.3 a,b), when comparing
FvB mice against the treated FvB mice. The data are summarised in figure: 5.3. a descriptive
statistical summary is presented in table: A.9.
The normalisation ratios of the muscle mass by the (variable) initial body masses be-
tween the atrophic A17 mice and the healthy FvB mice correlate and may statistically mask
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the changes observed in the raw muscle masses. † To further elucidate the effect of the treat-
ment regimen, we next compared the change in non-normalised muscle mass (raw muscle
mass). The raw muscle mass of the TA and EDL were 40% (p < 0.01 ) and 16% (p < 0.05 )
lower respectively in the A17 mice than FvB mice (figure: 5.3 d,e). The treatment with RK35
antibody resulted in an increase of 12% (p < 0.05 ) and 14% (p < 0.05 ) in raw muscle mass of
the TA and EDL in the treated A17 mice when compared to the untreated A17 mice. This
increase in the muscle mass results in there being a 25% (p < 0.001 ) and negligible 2% (p
> 0.05 ) difference in raw muscle mass of the TA and EDL between the treated A17 mice
and FvB mice (figure: 5.3 d,e). A significant change in the raw muscle mass of the TA and
EDL by 15% (p < 0.001 ) and 26% (p < 0.001 ) was also observed, when the FvB mice were
compared against treated FvB mice. A significant increase in the mass of the soleus brought
about by the treatment in the 52-week old A17 mice was observed (figure: 5.3 c,f). The ad-
ministration of the antibody to the A17 mice resulted in a significant 28% (p < 0.005 ) in-
crease in normalised muscle mass (26% , p < 0.05 , an increase in raw muscle mass) when
compared to the untreated A17 mice. The data are summarised in figure: 5.3. A descriptive
statistical summary is presented in table: A.10 .
5.4 Increase in muscle mass is accompanied by a significant increase in myofi-
bre diameter in wild-type but not in OPMDmodel:
Decrease in myofibre diameter is directly correlated to a decrease in muscle mass and func-
tion411. Selective atrophy of type II myofibres in murine models of OPMDwas first de-
†This occurs as the ratio of the (higher) muscle mass from the healthy FvB controls to their (higher ini-
tial) body mass correlates to the ratio of the (lower) muscle masses from the atrophic A17 controls to their
(significantly lower initial) body mass.
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Figure 5.3: Effect of RK35 anধbody on muscle mass of 52-week old OPMD mice:Mice (9 male A17 + RK35, 8 male
A17 + saline, 10 male FvB + RK35, 10 male FvB + saline mice) were administered a weekly regimen of either saline
or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 42nd week of age. TA (a,d), EDL (b,e) and soleus (c,f) were
sampled and mean mass of all muscles were normalised to the iniধal body mass (a,b,c; A.U. being arbitrary units) or
are presented as is (d,e,f). Data presented as mean SEM, with p-values obtained by mulধple t-tests ađer an FDR
correcধon.
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scribed by Trollet et al. 384 , a disease profile shared with muscles undergoing sarcopenia 197.
42-week old A17 and FvB mice were subject to an anti-myostatin treatment regimen (weekly
10mg/kg IP RK35 for 10 weeks), following which whole muscle sections were stained for
laminin, imaged, blinded and analysed for the minimum feret ‡ diameter. Median fibre di-
ameters from the kernel density estimates of 1000 random fibres or 400 random fibres per
mouse were selected from the TA and EDL respectively and analysed (figure: A.2) .
The reduction of muscle mass in the A17 mice was accompanied by a reduction of myofi-
bre diameter in the TA and EDLmuscles by 18% (p < 0.05 ) and 6% (p < 0.05 ) respectively
when compared to FvB mice (figure: 5.4 a,b). The administration of RK35 to A17 mice re-
sults in an increase in myofibre diameter of 4% (p > 0.05 ) and 2% (p > 0.05 ) in both the
TA and EDLmuscles when compared to the untreated A17 mice (figure: 5.4 a,b). To de-
termine if the age of the organism played a role in the attenuated efficacy of the antibody,
the myofibre diameter in age-matched healthy FvB controls were compared. The myofibre
diameter of the treated FvB mice had increased by 13% (p < 0.05 ) and 14% (p < 0.05 ) in the
TA and EDL when compared against the untreated FvB mice. See figure: 5.4, and table:
A.11.
5.5 Increase in muscle mass of TA is accompanied by a decrease in expression
of collagen VI
The inflammatory components of a dystrophic muscle and activity of auxiliary cell media-
tors such as fibroblasts lead to muscle fibrosis which compromises muscle plasticity, muscle
structure and serves as a major histopathological hallmark of disease progression in mus-
‡The minimal feret’s diameter is defined as closest possible distance between the two parallel tangents of
an object (i.e. muscle fibre)Dubach-Powell.
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Figure 5.4: Effect of RK35 anধbody on myofibre diameter of 52-week old OPMD mice: Mice were administered a
weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 12th week of age. Mus-
cle samples from 5 randomly selected mice per group were secধoned and stained for laminin. (a) 1000 fibres were
randomly selected for the TA, (b) whereas 400 fibres were randomly selected for the EDL, and the median minimum
feret diameter was analysed. The average median minimum feret diameter per group was ploħed, bars represenধng
SEM, with p-values obtained by mulধple t-tests ađer an FDR correcধon.
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cular dystrophies 206. Whole muscle sections from 52-week old OPMDmice treated with
RK35 (weekly at 10mg/kg IP for 10 weeks) were stained for collagen VI, imaged, blinded
and analysed. The total area of collagen VI staining to the total imaged area of the muscle
was calculated.
In the 52-week old A17 mice there is evidence of disease associated muscle fibrosis in the
form of a 12.01% 1.05% and 11.29% 1.45% area of collagen VI deposition in the TA and
EDL when compared to the 4.54% 0.35% and 6.05% 0.70% area of collagen VI depo-
sition in the healthy FvB mice. This. This computes to a 32% (p < 0.001 ) and 52% (p <
0.001 ) percentage change when compared to untreated FvB mice. Inhibition of myostatin
by administered RK35 antibody reduced deposition of collagen VI in the TAmuscle by
40% (p < 0.001 ) when compared to untreated A17 mice, resulting in a total 7.16% 0.58%
area of collagen VI deposition in the treated mice.
This reduction in collagen VI area in the treated A17 mice was partially normalised to the
FvB controls, resulting in a 37% (p < 0.01 ) difference when compared to the untreated FvB
control mice. No treatment associated statistically significant change in collagen VI levels
were observed for EDLmuscle (a 8% difference in means was observed in the A17). The
data are summarised in figure: 5.5 and table: A.12.
5.6 Administration of RK35 antibody does not affect intranuclear inclusion
density in OPMDmuscle
OPMD is characterised by the accumulation of intranuclear inclusion (INI) bodies in the
myonuclei. Studies have proposed that the severity of disease is dependant on the extent of
INI accumulation, with homozygous genotypes associated with a corresponding increased
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Figure 5.5: Effect of RK35 anধbody on collagen VI deposiধon in muscles of 52-week old OPMD mice: Mice were
administered a weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 42nd week
of age. 5 randomly selected whole muscle secধons from all groups for (a) TA and (b) EDL were stained for collagen VI,
and 5 random fields were imaged and analysed for the percentage area of collagen VI staining. The average area per
group is ploħed, bars represenধng SEM, with p-values obtained by mulধple t-tests ađer an FDR correcধon.
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density of INI bodies across all myonuclei 384. Muscle sections from 52-week old OPMD
mice treated with RK35 (weekly at 10mg/kg IP for 10 weeks) were stained for polyadenylate-
binding nuclear protein 1 (PABPN1) after a KCl wash 384, co stained with DAPI, imaged,
blinded and analysed. The total nuclei, and the nuclei positive for PABPN1 were counted,
averaged across fields of view per mouse, and analysed.
The absolute INI density while negligible in the untreated and treated FvB control mice
(0% 0% of observed nuclei), is significantly higher in the untreated A17 mice (37%
1.76%, p < 0.001 ; figure: 5.6). Administration of the antibody (10mg/kg IP, weekly for
10 weeks) results in a negligible change in the density with the untreated and treated A17
mice having an absolute 37% 1.07% of observed nuclei with INI. The data is presented in
figure: 5.6, and a descriptive statistical summary is presented in table: A.13.
5.7 Increase in muscle mass in OPMD treatedwith RK-35 antibody is accom-
panied by no changes in muscle function
Muscle function analyses allows correlation of neuromuscular function degeneration, ex-
ercise tolerance, biochemical profile and maximal muscle strength. Studies in patients have
reported strong associations between loss of muscle strength, muscle mass and muscle qual-
ity in both atrophic conditions and advancing age. While select measurements in animal
models can be directly correlated to humans, care must me taken to account for variables
such as deterioration of cognitive function, fatigue, and other socio-economic factors which
may confound direct correlations between aged animal models and older patients.
103
Figure 5.6: Effect of RK35 anধbody on INI in muscles of 52-week old OPMD mice: Mice were subject to a weekly regimen of either saline or the anধ-
myostaধn RK35 anধbody IP for ten weeks from the 42nd week of age. 5 randomly selected TA muscle samples per group from all groups were stained for
bovine PABPN1 ađer a KCl wash, and 5 random fields were imaged and analysed per sample for the percentage number of posiধve PABPN1 stains to all
myonuclei. The average density is ploħed, bars represenধng SEM, with p-values obtained by mulধple t-tests ađer an FDR correcধon
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5.7.1 Increase in muscle mass is accompanied by no change in forelimb grip strength
Forelimb grip strength presents a non-invasive, longitudinal low-stress method to assay de-
generation of neuromusculoskeletal systems over disease progression. 42-week old A17 and
FvB mice were treated weekly for 10 weeks with 10mg/kg IP RK35 and assayed. 15 measure-
ments over four days (with upto five measurements per day) in 30 second intervals were
recorded and median grip strength per mouse was analysed. Normalised grip strength (to
the initial body mass) of the untreated A17 mice was minimally lower by 14% (p > 0.05 )
than the untreated FvB control mice (figure: 5.7 a). The administration of RK35 resulted
in a non-significant change of 3% (p > 0.05 ) in normalised grip strength when compared
to the untreated A17 mice. Difference in grip strength between the untreated FvB control
mice and treated FvB mice remain statistically homogeneous (figure: 5.7 a).
As noted previously, the difference in initial body mass results in there being a differ-
ence between normalised grip strength and the non-normalised grip strength values. The
normalised ratio of the grip strength to the initial body mass of the A17 model mice (with
a lower body mass and lower grip strength) to the healthy FvB controls (with a higher
body mass and higher grip strength) remain similar. In order to elucidate the effect of the
change in grip strength in advanced stages of the disease progression and amelioration of
symptoms by the administration of the antibody, we next examined the change in non-
normalised (raw) grip strength.
A difference of 31% (p < 0.001 ) exists, in non-normalised (raw) grip strength of un-
treated A17 mice than the untreated FvB control mice (figure: 5.7 b). The administration
of RK35 resulted in an increase of 5% (p > 0.05 ) in raw grip strength when compared to
the untreated A17 mice. This increase in raw forelimb grip strength of treated A17 mice re-
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Figure 5.7: Effect of RK35 anধbody on forelimb grip strength of 52-week old OPMD mice: Mice (n = 5) were admin-
istered a weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 42nd week of
age. (a) The grip strength normalised to the iniধal body mass or (b) raw grip strength was analysed and the average of
15 measurements per mouse, per group is ploħed, bars represenধng SEM, with p-values obtained by mulধple t-tests
ađer an FDR correcধon.
sults in a 25% (p < 0.001 ) difference when compared to the untreated FvB mice (figure: 5.7
b). The raw grip strength of the treated FvB mice remains homogeneous to the untreated
FvB mice. The data is summarised in figure: 5.7, and a descriptive statistical summary is
presented in table: A.14.
5.7.2 Administration of antibody RK35 does not affect open field behaviour
test outcomes
The open field behaviour test represents an auxiliary test for muscle function which exam-
ines the effect of whole body systems in a dystrophic environment. The ultimate objective
of assessing open field behaviour is to correlate identified genetic, biochemical and cellular
observations to changes in voluntary muscle function and disease progression. 42-week old
106
OPMDmice treated with 10mg/kg IP RK35 weekly for 10 weeks were observed for 1 hour
per day, over 4 days . Average measurements from 15 behavioural parameters were recorded
and analysed.
No overt difference was detected in the voluntary locomotor activity measured between
the untreated A17 mice, treated A17 mice and untreated FvB control mice. While minor
trends observed wherein the treated A17 mice display a difference in mean compared to the
other groups, for example in select cases of ”total activity” (figure: 5.8 a), ”front-to-back
count” (figure: 5.8 b), ”mobile time” (figure: 5.8 c), ”distance travelled” (figure: 5.8 d), these
differences however remain statistically homogeneous. A descriptive statistical summary
of the data is presented in table: 5.1. A description of terms used in analysis is presented in
table: B1.
5.8 Discussion
Screening of therapeutic reagents in relatively younger murine models of diseases presents
challenges in translating into clinical trials, as OPMD is usually medically diagnosed in the
later stages of life. Furthermore, pathogenesis of disease in OPMDmice is markedly differ-
ent from disease progression in human patients. The disease profile in the model is early
onset and induced in all skeletal muscles 384, whereas the aetiological profile in humans
involves a late onset dystrophy in the extraocular and pharyngeal muscles, with proximal
limb muscles also selectively affected dependant on disease progression and severity 158. The
similarities in clinical presentation of sarcopenia and late onset muscular dystrophies also
present unique challenges in disease diagnosis and treatment. In order to comprehensively
assess therapeutic efficacy, it is hence essential to examine the effect of any proposed reagent
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Table 5.1: Open field behaviour of 52-week old OPMD mice does not change with treatment: A17 and FvB mice
were administered a weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 42nd
week of age. Open field behaviour was analysed for a subset of mice (n = 5) over an hour over four days, and the
average measurements of 20 observaধons per group is represented below.
Activity A17 + Saline A17 + RK35 FvB + Saline FvB + RK35Mean SEM Mean SEM Mean SEM Mean SEM
Active time (s) 84 6 44 4 122 8 114 7
Distance travelled (m) 9 1 5 0 13 1 14 1
Fast activity (bks) 13 1 6 1 23 2 22 2
Fast mobile counts 10 1 5 1 20 2 20 2
Fast static counts 3 0 1 0 3 0 3 0
Front-to-back counts 13 1 8 1 19 1 22 1
Innactive time (s) 500 8 556 4 465 9 486 7
Mobile time (s) 33 3 17 2 57 5 57 4
Slow activity (bks) 93 7 49 5 137 9 127 7
Slowmobile counts 32 3 18 2 58 5 57 4
Slow static counts 61 5 31 3 79 4 70 4
Static time (s) 51 4 27 2 66 3 57 3
Total activity (bks) 106 8 55 5 160 11 149 9
Total mobile counts 43 4 23 2 78 7 77 6
Total static counts 63 5 32 3 82 5 73 4
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Figure 5.8: Effect of RK35 anধbody on the open field behaviour of 52-week old OPMD mice: A17 and FvB mice
were administered a weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 42nd
week of age. Open field behaviour was analysed for a subset of mice (n = 5) over an hour over four days, and the av-
erage measurements of 20 observaধons per group is ploħed, bars represenধng SD. (a) total acধvity represents aver-
age total beam breaks, (b) front-to-back counts represents the number of ধmes mouse crossed the length of the cage
(c) mobile ধme represents the amount of ধmes the mouse crossed a minimum distance threshold and (d) Distance
travelled. Staধsধcal analyses were conducted, with p values obtained by mulধple t-tests ađer an FDR correcধon, and
no significant change was found across all groups.
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on aged disease models to elucidate and model the interaction between disease phenotype,
and pharmacokinetic effects of the candidate drug.
Inhibition of myostatin has been shown to increase muscle mass, muscle fibre diameter,
decrease fibrosis and increase maximal force; all clinically relevant endpoints which may as-
sist in ameliorating symptoms of sarcopenia and muscular dystrophy. While the effect of
anti-myostatin regimens on murine models of muscular dystrophy have been investigated,
there exists minimal evidence on the effect of myostatin inhibition on late onset muscular
dystrophies. While in an early study, Wagner et al. 400 reports that long-term loss of myo-
statin in agedMstn = =mdxmice display decreased fibrosis, decreased myosteatosis, and
maintained their muscle mass, a myostatin null animal presents a markedly different phe-
notype than a model administered with a post-natal myostatin blocker. On the other hand
a study by Parsons et al. 299 reported minimal effect of the anti-myostatin antibody JA-16
on 32 month old murine models of LGMD2F. Other studies have included the analysis of
anti-myostatin antibodies (PF-354 221,288, RK359, ATA 842 57), or use of propeptide based
reagents 16,72, on aged mice to evaluate rescue of sarcopenic symptoms which we propose to
correlate with the effect of RK35 on 52-week old A17 mice 317.
The OPMDmodel mice at 52-weeks of age posses a lower body and muscle mass than
the FvB controls. The inhibition of myostatin presented strong trends to restore disease
associated loss of body mass (a non-significant 6% increase observed mainly in the first
five weeks of the treatment regimen). Other antibody based treatment strategies similarly
produced either non-significant9 or 5%-7% increase in body mass in aged non-dystrophic
mice 57,288. The treatment associated increase in muscle masses (by 14% and 32% in TA and
EDL) observed is promising, as it indicates that inhibition of myostatin may be a valid
110
strategy to ameliorate loss of muscle mass in advanced stages of disease progression. Other
strategies report similar scale of increase in muscle mass, ranging from 10%-20% for strate-
gies that directly inhibit myostatin 57,220,221,288, and 25%-30% when an activin receptor IIB
(ACTRIIB) soluble receptor was used72. In 1 year old C57/BL10 mice administered a short
term (4 weeks) treatment regimen with RK35, a 26% and 17% change in muscle masses of
the TA and the quadriceps were reported9. Interestingly in the same study, no significant
change in the gastrocnemius was observed for the 1 year old mice, though an significant
increase was indeed reported for a younger cohort9. Myostatin signalling is canonically
achieved by two distinct pathways, the ACTRIIB pathway and the bone morphogenetic
protein (BMP) pathway224,340. We speculate fast muscle fibres such as those in the EDL
to be more sensitive to myostatin signalling than other muscles (and consequently more
sensitive to inhibition of myostatin), as type II myofibres display an increased density of
ACTRIIB receptors 269,424, displaying an increased response to the administered RK35 anti-
body.
A significant increase in the mass of the soleus by 28% was observed in this study. Previ-
ous reports though indicate that inhibition of myostatin minimally influences contractile
properties on the soleus in-spite of an increase in the mass of theMSTN =  mice 202,269,
other reports also support a 20% increase in the muscle mass of the soleus observed in aged
mice when administered an anti-myostatin regimen 288, and in younger mice administered
with a propeptide reagent 125,281 whereas Morine et al. 281 reports no change in the mass of
the soleus when using a novel gene therapy based inhibitor. No change in the mass of the
soleus was observed for the age-matched healthy FvB control mice in this study.269,424.
While appreciating that type I myofibres in muscles remain mostly unaffected during the
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ageing process, and the overall percentage of type I myofibres undergo enrichment due to
motor unit remodelling of type II myofibres 52,53,86,97,185,391, we speculate that the disease pro-
gression may alter metabolism of slow-twitch myofibres, increasing their sensitivity to an
anti-myostatin reagent, which is not observed in age-matched controls in the OPMDmod-
els at 52-weeks of age.
Different muscle fibres display varying responses to inhibition of myostatin (for example,
the fast twitch IIB fibres display increased density of the ACTRIIB receptors as compared
to the slow twitch type I fibres). This fibre type specific response can perhaps be further
elucidated by correlating and measuring the increase in muscle fibre diameter on a per fibre
type basis, to specifically characterise the effect of the antibody on the aeitological profile
of the disease. Furthermore, the histological profile can can be quantified in the soleus, to
analyse the increase in muscle mass observed .
The OPMDmice at 52-weeks of age display a disease associated reduced muscle strength
(possibly resulting from the decreased muscle mass; evidenced by forelimb grip strength).
While other anti-myostatin strategies in aged non-dystrophic mice present a 12%-20% in-
crease in grip strength or other measures of muscle function (such as running time on
treadmills) 57,221,358, The increase in muscle mass for the treated mice in this study however
did not correlate to an associated increase in muscle strength. While the open field test is
routinely used to analysemdxmodels of Duchenne muscular dystrophy where the predic-
tive validity of certain aspects of the assay correlates to the 6 minute walk test, assessing
clinical endpoints in cases of OPMDmodels remains complex, and presents an opportu-
nity for further study. In this study, no difference in voluntary locomotor activity between
the mice was reported, though a longer period of analysis might attenuate the variability
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associated with circadian rhythms. Another accurate measurement of muscle function can
be achieved via in-situ electrophysiological assays and may elucidate if disease associated
changes in fibre metabolism and consequent pattern of motor unit recruitment remains
affected.
The increase in muscle mass was not accompanied by a significant increase in myofibre
diameter (a non-significant increase by 4% and 2% in TA and EDL was observed). The at-
tenuated response of the antibody thus observed is surprising as it does not correlate with
the increase in muscle mass observed (figure: 5.3). The observed non-significant increase
in myofibre diameter may result frommyofibres attaining maximal fibre diameter at 52-
weeks of age. However, this does not explain the increase in myofibre diameter in the FvB
controls (13% and 14% in TA and EDL), nor the 12%-15% increase in myofibre diameter ob-
served in aged non-dystrophic mice 16,288,358. This may suggest that the response to the anti-
body observed in the soleus (and by extension the efficacy of the antibody) correlates more
to disease progression than the age of the animals themselves.
The untreated A17 mice displayed a marked increased collagen VI deposition when com-
pared to the untreated FvB controls in the TA and EDL, which was reduced by 40% and a
non-significant 8% in the TA and EDL when administered with the antibody. Pathophys-
iological age / dystrophy associated fibrosis and consequent scarring results in sarcolem-
mal fragility, disturbances in calcium ion homeostasis, inflammation, reduction of motile
and contractile functions, and reduction of available tissue for therapeutic intervention249.
Myostatin is a known regulator of fibroblast activation and apoptosis, with anti-myostatin
agents shown to have an anti-fibrotic effect in other models of muscular dystrophy233,234.
While the minimal treatment associated anti-fibrotic response in the EDL is surprising, the
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partial reduction in area of collagen VI deposition observed in the TA is promising, as it
shows that an anti-myostatin regimen in advanced stages of disease progression can partially
reduce expression of collagen VI. It remains to be investigated if an increased dose might
cause a concordant increase in myofibre diameter, and the effect of a dose-response in aged
OPMDmice.
As hypothesised, no change in myonuclear INI density was observed when the A17 mice
were administered with the antibody, underlining a need for a combinatorial approach for
myostatin knockdown with a gene therapy based strategy to effect a long-term solution
to the disease phenotype. For example, Malerba et al. 246 reports that a knockdown of en-
dogeneous PABPN1 by a shRNA, and simultaneous replacement of a (codon optimised)
human PABPN1 improved muscle transcriptional and histological profile, and ameliorated
atrophic symptoms. Though an increase in muscle mass was not reported in the study 246,
a combinatorial approach with a myostatin inhibitor and a gene therapy reagent may assist
in ameliorating muscle atrophy and correcting the disease genotype. We further speculate
that disease progression at 52-weeks of age in the A17 OPMDmodel to have compromised
the muscle structure, causing an attenuation of the therapeutic effect observed at the ad-
ministered dose of the antibody 344. This attenuated response to the treatment regimen per-
haps additionally indicates the need for a modified therapeutic regimen, to correct atrophic
symptoms and restore muscle function in advanced stages of disease progression.
114
Although large clusters of victims can be found, OPMD
ॾ so rare, ॼ to be neglected by some popular neurologic
text books. Besidॽ, its cardinal clinical featurॽ are non-
specific manifestations; misinterpreted ॼ other ageing
disorders. The crucial diagnostic facilitiॽ of OPMD,
EM and genetic analysॾ, are not widely available in
developing countriॽ.
Chien 71
Chapter 6
Treatment with anti-myostatin antibody RK35 partially
reverses metabolic dysregulation observed in energy pro-
duction pathways of OPMD
6.1 Introduction
Mass spectrometric profiles of a number of muscular dystrophies have been investigated in
various studies 2,39,144,145. Qualitative and quantitative metabolomic analyses of Duchenne
muscular dystrophy (DMD), Becker’s muscular dystrophy (BMD), facioscapulohumeral
muscular dystrophy (FSHD), and limb girdle muscular dystrophy (LGMD) (2A and 2B),
myotonic dystrophy - 1 (MD-1) found significant increases in glycogen and energy related
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pathways, dysregulation in metabolism of fatty-acids, amino acids and corticosteroids 360.
The characterisation of the serummetabolome would assist in elucidating possible biomarker
candidates which can serve as diagnostic, prognostic and surrogate markers to aid in clinical
and pre-clincial trials.
Due to limited data available in the oculopharyngeal muscular dystrophy (OPMD)
model system or patient samples, a non-hypothesis driven pilot study was performed in-
order to generate data to inform future studies. The serummetabolite levels of 5 male A17
OPMDmurine model (untreated A17 mice), 5 male A17 mice treated systemically with an
anti-myostatin antibody (10mg/kg IP weekly for 10 weeks from 12 weeks of age; in-order to
gauge response to a therapeutic increase of muscle mass) and 5 control male FvB mice were
analysed by GCMS to propose new diagnostic criteria for OPMD 291 . The mice used in this
expeirment were the same mice used in Chapter 4 (figure: 4.1), however the FvB + RK35
group was not analysed due to limited sample availability .
Mice were fasted overnight, serum samples extracted after cardiac puncture, were sub-
ject to liquid-liquid extraction, chemical derivatisation and GCMS analysis. Grouped data
files were uploaded to XCMSOnline 371 for alignment, and then the data were uploaded to
Metaboanalyst 4.0422 to perform univariate (t-test) statistics, multivariate (PLS-DA) analy-
sis of variance, and pathway enrichment analysis.
6.2 Statistical analyses of serummetabolic profile of murine models of OPMD
in early stages of disease
Serum samples from 12 week old A17 and FvB mice subject to a weekly anti-myostatin treat-
ment regimen with the antibody RK35 (10mg/kg IP) or saline for 10 weeks was subject to
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GC/MS analysis. In order to obtain a snapshot of metabolite flux, identify important fea-
tures and assess differences between phenotypes, metabolite features were examined by
univariate analysis of variance (ANOVA), and a supervised multivariate partial least square
discriminant analysis (PLS-DA) were performed * .
6.2.1 Univariate statistical analyses reveal dysregulated metabolite features
due to the disease condition in the OPMDmice
An ANOVAwas performed in-order to determine metabolites changed in the untreated
A17 and treated A17 from the healthy untreated FvB controls. To determine significant fea-
tures, a cut off value for the false discovery rate (FDR) was set to 0.1, and p value for the
ANOVA F-test set to 0.05. Of 48 metabolites detected (40 of which were identified by the
national institute of standards and technology (NIST)) 20 metabolites displayed signifi-
cant differences between at least two of the groups analysedMultiple t-tests were then con-
ducted, and significance values adjusted with Tukey’s HSD (cut off at p < 0.05) to elucidate
differences between groups. The results are summarised in table 6.1.
6.2.2 Multivariate statistical models reveal distinct metabolic profiles for
the A17 mice from the FvB mice
Amultivariate PLS-DA analysis reported that the first two principal components accounted
for over 50% of the variability between the samples. The model produced a distinct separa-
tion of the FvB and A17 groups (figure: 6.4 (a)), suggesting a unique metabolic profile for
*The PLS-DA sharpens the separation between groups of observations by rotating principal components
to attain maximal separation and provide information to which variables contribute to the separation. A
variable importance projection (VIP) score summarises the variable influence across all component dimen-
sions 298,422
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Table 6.1: Change in serum metabolite levels of 22-week old OPMD mice: Mice were administered a weekly regimen of either saline or the RK35 anধbody
(10mg/kg IP) for 10 weeks from the 12th week of age, fasted and sera extracted by cardiac puncture. GCMS analysis was performed on sera and an ANOVA
was performed in-order to detect significant differences between groups.Baseline effect of disease represents change observed when the untreated A17
mice are compared to the FvB mice. Effect of the treatment regimen represents the change observed when the treated A17 mice are compared to the un-
treated A17 mice. (↑), (↓) and (=) indicate significant upregulaধon, downregulaধon, and change change in the treated A17 mice that is restored to the levels
of FvB controls, unless specified otherwise. No change indicates no significant differences or trends observed between groups being compared.
Name Type Figure Baseline effect of disease Effect of treatment regimen
3-Hydroxyadipic acid Fatty acids 6.1 g ↑ no change
Arachidonate Fatty acids 6.1 d ↑ ↓
cis-4,7,10,13,16,19-Docosahexaenoate Fatty acids 6.1 e ↑ =
Creatinine Misc 6.3 d ↑ no change
D-Ribose Misc 6.2 f ↑ ↓ (trend)
Glyceric acid Fatty acids 6.1 b ↑ no change
Glycerol Fatty acids 6.1 a ↑ no change
Glycerol-3-phosphate Mitochondria 6.2 a ↑ =
Linoleic acid Fatty acids 6.1 c ↑ = (trend)
Malate Mitochondria 6.2 d ↑ =
Unknown fatty acid (311) Fatty acids 6.1 h ↑ no change
5-Tetradecenoic acid Fatty acids 6.1 f ↑ (trend) ↑
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Table 6.1 continued from previous page
Name Type Figure Baseline effect of disease Effect of treatment regimen
L-Serine Amino acid 6.3 b ↓ (trend) ↑
L-Threonine Amino acid 6.3 c ↓ (trend) = (trend)
Unknown compound (350-1) Misc 6.3 g ↓ (trend) =
Cholesterol Misc 6.3 h no change ↑
Fumarate Mitochondria 6.2 c no change no change
Glutamate Amino acid 6.2 e no change ↑
L-Phenylalanine Amino acid 6.3 a no change ↑
Pyroglutamic acid Misc 6.3 f no change ↑
Unknown glycerodiphosphate (654) Misc 6.2 b no change ↑
Uracil Misc 6.3 e no change ↑
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Figure 6.1: Change in serum metabolite levels of 22-week old OPMD mice (faħy acids): Mice were administered a weekly regimen of either saline or the
RK35 anধbody (10mg/kg IP) for 10 weeks from the 12th week of age (n = 5 per group), fasted and sera extracted by cardiac puncture. GCMS analysis was
performed on sera, metabolite abundance was normalised to an internal standard and an ANOVA was performed on normalised metabolite abundance in-
order to detect significant differences between groups when comparing faħy acid molecules. Data presented as mean SEM, with Tukey’s HSD correcধon
applied for mulধple comparison.
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Figure 6.2: Change in serum metabolite levels of 22-week old OPMD mice (mitochondrial intermediates): Mice were administered a weekly regimen of either
saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 12th week of age (n = 5 per group), fasted and sera extracted by cardiac puncture. GCMS
analysis was performed on sera, metabolite abundance was normalised to an internal standard and an ANOVA was performed on normalised metabolite
abundance in-order to detect significant differences between groups when comparing metabolites involved in mitochondrial processes. Data presented as
mean SEM, with Tukey’s HSD correcধon applied for mulধple comparison.
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Figure 6.3: Change in serum metabolite levels of 22-week old OPMD mice (Amino acids and misc.): Mice were administered a weekly regimen of either saline
or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 12th week of age (n = 5 per group), fasted and sera extracted by cardiac puncture. GCMS analysis
was performed on sera, metabolite abundance was normalised to an internal standard and an ANOVA was performed on normalised metabolite abundance
in-order to detect significant differences between groups. Data presented as mean SEM, with Tukey’s HSD correcধon applied for mulধple comparison.
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Figure 6.4: PLS-DA of serum metabolite features from 22-week old OPMD mice: Mice were administered a weekly regimen of either saline or the RK35
anধbody (10mg/kg IP) for 10 weeks from the 12th week of age (n = 5 per group), fasted and sera extracted by cardiac puncture. GCMS data was subject to a
(a)Mulধvariate PLS-DA analysis (b) and associated VIP scores to idenধfy important features were conducted. Analyses were conducted using Metaboanalyst
v4.0 422.
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the A17 mice. The quality of the PLS-DAmodel evaluated by R2 (indicating model fit) and
Q2 parameters (indicating model prediction ability) over first 5 principle components, were
0.94 and 0.59 respectively. To investigate metabolites contributing most to observed differ-
ences between the untreated A17 mice, treated A17 mice and the FvB controls, metabolite
features ranked by variable importance in projection (VIP) scores based on the PLS-DA
statistical model were analysed. The VIP scores mathematically estimate the importance of
a variable (in this case expression of a metabolite feature per animal) and calculates the in-
fluence of said variable on group separation. They scores estimate the importance of each
variable (variables that contribute most to the separation of atleast 2 groups) in the pro-
jection used in a PLS model. A variable with a VIP Score close to or greater than 1 (one)
can be considered important in given model . Metabolite features with VIP > 1 (figure: 6.4
(b)), include Glycerol (VIP 5.2; figure: 6.1 (a)), Pyroglutamate (VIP 2.3; figure: 6.3 (f)), N-
Acetylgalactosamine (VIP 1.9), L-Serine (VIP 1.8; figure: 6.3 (f)) and Arachidonate (VIP 1.6;
figure: 6.1 (d)). Interestingly, the PLS-DA plots indicate that while the serummetabolome
is not reverted to a wild-type phenotype following an anti-myostatin regimen in the un-
treated A17 mice. The metabolic profile of the treated A17 mice while distinct from the
control FvB mice (in terms of group separation along the first two principle components),
the variable spread partially overlaps with the confidence bands of the untreated A17 mice
(figure: 6.4 (a)) suggesting variance in the expression levels of select metabolites than a
metabolome wide change.
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6.3 Functional analyses of serummetabolic profile
Whole metabolite sets between the untreated A17 and FvB groups were subject to metabolic
set enrichment analyses (MSEA). Metabolic enrichment determines likelihood of the en-
riched pathway being significantly altered by random chance, and hence MSEA assists in
detecting any biologically meaningful groups of metabolites that are significantly enriched
in the detected metabolite sets422. MSEA was conducted along the following two primary
axes: Quantitative enrichment analyses (QEA) combined with topological pathway anal-
ysis (PA) to determine impact of feature dysregulation on the overall pathway422, and cor-
relation of metabolite concentration with enzyme dysfunction predicted by a genome scale
network model of metabolism (enzyme enrichment) 355.
6.3.1 Quantitative enrichment analyses reveal a dysregulation of energy pro-
duction pathways between the untreated A17 and FvB mice
The metabolite features were initially profiled against a (curated) superset of 99 human
metabolite sets based on metabolic pathways (similar to a gene ontology analysis). The
MSEA-QEA reports Of the top 25 pathways enriched, 9 pathways were found to be signifi-
cantly affected with a cut off p value set to 0.05. Curated terms (matched against the human
small molecule pathway database with SMP ids provided 129,189) found significantly enriched
wereGlycerolipid Metabolism (SMP00039),Galactose Metabolism (SMP00043),Alpha
Linolenic Acid and Linoleic Acid Metabolism (SMP00018),Arachidonic Acid Metabolism
(SMP00075), Cardiolipin Biosynthesॾ (SMP20986),De Novo Triacylglycerol Biosynthesॾ
(SMP15896),Glycerol Phosphate Shuttle (SMP00124),Mitochondrial Electron Transport
Chain (SMP00355), and Phospholipid Biosynthesॾ (SMP00025) (figure 6.5 (a)).
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The metabolite features were then subject to topological analysis in the MSEA-PA against
a mouse reference metabolome, which mathematically determines the importance of said
metabolite by analysing the position of the metabolite (a metabolite which as a hub / bot-
tleneck gets assigned a higher impact score than a metabolite that is in a branch of the path-
way) in said pathway represented as a percentage score (the topological impact)422. It must
however be noted that the MSEA-PA analyses relies on a subset of curated KEGG pathways
implemented intoMetaboanalyst and thus does not represent all enriched pathways re-
ported inMSEA-QEA. Of the top 25 pathways enriched in the MSEA-PA, 6 pathways were
found to be significantly enriched with a cut off p value set to 0.05. Significantly enriched
curated terms (matched against the murine KEGG database with KEGGMMU pathway
ids provided) reported from theMSEA-PA include Linoleic acid metabolism (mmu00591;
topological impact 100%),Glycerolipid metabolism (mmu00561; topological impact 41%),
Glyoxylate and dicarboxylate metabolism ( mmu00630; topological impact 6%),Glyc-
erophospholipid metabolism (mmu00564; topological impact 6%),Galactose metabolism
mmu00052 (topological impact < 5%), and Biosynthesॾ of unsaturated fatty-acids mmu01040
(topological impact < 5%). Two non-significantly enriched high-impact curated terms ob-
served were Phenylalanine, tyrosine and tryptophan biosynthesॾ (mmu00360; topological
impact 50%) and Phenylalanine metabolism (mmu00360; topological impact 40%).
6.3.2 Enrichment in predicted databases suggest dysregulation of enzymes
between the untreated A17 and FvB mice
Differences in normalised metabolite levels were correlated next to predicted enzyme dys-
function 355,422. Of 153 enzymes and enzyme associated events discovered, 18 curated terms
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Figure 6.5: Metabolic set enrichment analysis of serum metabolites from 22-week old untreated A17 and FvB mice:
All idenধfied metabolites detected from sera of untreated A17 and FvB mice (n = 5 per group) were subject to (a) a
quanধtaধve enrichment analysis on a curated human pathways database highlighধng enriched cellular processes, or
(b) enrichment against a predicted database highlighধng enriched enzymaধc processes. Analysis was performed on
Metaboanalyst v4.0
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were found to be significantly different with a cut off p value set to 0.05. Two distinct
patterns of sub-cellular localisations of enriched enzymes emerged: enzymes localised to
the mitochondrion includingATP synthase (UniProt - Q06055), glutamine synthetase
(UniProt - P15104), and carnitine O-palmitoyltransferase (UniProt - Q92523) ; and enzymes
localised to the cytosol including glucosamine-6-phosphate deaminase (UniProt - P46926),
phosphoribosylpyrophosphate synthetase (UniProt - P60891), 1-acylglycerol-3-phosphate O-
acyltransferase 1 (UniProt - Q8WTS1), and glycerol-3-phosphate acyltransferase (UniProt -
Q53EU6; localised to the endoplasmic reticulum) (figure 6.5 (b)). 6 enzyme families were
also enriched: R group coenzyme a ligase, lipase, fatty-acid-CoA ligase fatty acyl-CoA desat-
urase , carnitine transferase, R group artificial flux along with the following enzyme associ-
ated events: Trehalose exchange, Linoleic acid transport in via diffusion, transport into the
mitochondria (carnitine), gamma-linolenic acid exchange, and Beta oxidation of fatty-acid
(figure 6.5 (b)) 355.
6.3.3 Effect of anti-myostatin regimen on A17 metabolome
Metabolites from the treated A17 mice were next compared to the untreated A17 mice
and control FvB mice; and were profiled against a curated superset of human metabo-
lite sets. Curiously, no enriched terms were detected when the untreated A17 mice were
compared to the treated A17 mice. However when the treated A17 mice were compared
against the control FvB mice, 2 of 48 terms detected were significantly enriched (matched
against the human small molecule pathway database with SMP ids provided 129,189), with a
cut off p value set to 0.05: Glycerolipid Metabolism (SMP00039) andGalactose Metabolism
(SMP00043) (figure: 6.6 (a)). Topological pathway analysis against a curated mouse ref-
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erence metabolome (matched against the murine KEGG database with KEGGMMU
pathway ids provided) of the treated A17 mice and the control FvB mice revealed the fol-
lowing enriched terms: Linoleic acid metabolism (mmu00591; topological impact 100%),
Glycerolipid metabolism (mmu00561; topological impact 41%),Glyoxylate and dicarboxy-
late metabolism (mmu00630; topological impact 6%),Galactose metabolism (mmu00052;
topological impact < 5%), Biosynthesॾ of unsaturated fatty acids (mmu01040; topological
impact < 5%).
In order to correlate and predict dysregulated enzymes arising from differences in nor-
malised metabolite levels, metabolite features from treated A17 mice with the untreated A17
and control FvB mice were enriched against the genome scale network model of metabolism 355.
Surprisingly, no significantly enriched terms were detected when the untreated A17 mice
were compared to the treated A17 mice. However, of 178 curated terms detected in enrich-
ment analysis of the treated A17 mice against the control FvB mice, the following terms are
reported to be enriched 355, with a cut off p value set to 0.05: glutamine synthetase (UniProt -
P15104),ATP synthase (UniProt - Q06055), phosphoribosylpyrophosphate synthetase (UniProt
- P60891), 1-acylglycerol-3-phosphate O-acyltransferase 1 (UniProt - Q8WTS1), glycerol-3-
phosphate acyltransferase (UniProt - Q53EU6) and glucosamine-6-phosphate deaminase
(UniProt - P46926). The following processes and enzyme families were also significantly
enriched:Trehalose exchange, R group coenzyme a ligase and lipase (figure: 6.6 (b)).
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Figure 6.6: Metabolic set enrichment analysis of serum metabolites from 22-week old treated A17 and FvB mice: All
idenধfied metabolites from sera of A17 mice treated with the anধ-myostaধn anধbody RK35 and control FvB mice (n
= 5 per group) were subject to (a) a quanধtaধve enrichment analysis on a curated human pathways database high-
lighধng enriched cellular processes, or (b) enrichment against a predicted database highlighধng enriched enzymaধc
processes. Analysis was performed on Metaboanalyst v4.0
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6.4 Change in metabolic profile is accompanied by alteration in expression
levels of select transcripts and proteins
To examine if the change in the mitochondria associated transcript is associated with a
change in protein expression of the mitochondrial complexes II (Succinate dehydroge-
nase), III (CoQH2-cytochrome c reductase), IV (cytochrome c oxidase) and V (ATP syn-
thase) were analysed by western blots. Complexes I had a large intra-gel variation and was
not analysed. While we observed no change in the expression of the complexes between
the untreated and treated A17 mice, there was a marked decrease of the expression of the
complexes (normalised to the levels of α-tubulin77,94) between the A17 and the FvB mice.
Specifically, we report a difference between the untreated A17 and FvB mice of 49% (p <
0.05 ), 98% (p < 0.01 ), 134% (p < 0.01 ) and 134% (p < 0.01) for the CII, CIII, CIV and CV
respectively.
The levels of Ckmt-1 transcript were measured next to determine the effect of the disease
and treatment on a marker of oxidative damage and mitochondrial homeostasis. Though
no difference was observed between the untreated A17 mice and the treated A17 mice across
all complexes, a 100% (p < 0.001 ; 3 fold log10 difference) relative difference in expression
of Ckmt-1 exists between the untreated A17 mice and the untreated FvB mice. To investi-
gate if this change in expression of mitochondria related transcript and proteins was accom-
panied by a shift in fibre type 276, we next examined theMyh-2 andMyh-4 transcripts. A
negligible relative difference of 53% (p > 0.05 ) and 49% (p > 0.05 ) exists for theMyh-2
andMyh-4 transcripts when comparing the untreated A17 mice and the control FvB mice.
Similarly a non-significant exists relative difference of 95% (p > 0.05 ) and 31% (p > 0.05 )
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Figure 6.7: Mitochondrial oxidaধve phosphorylaধon acধvity in TA of 22-week old OPMD mice: Idenধcal amounts of
total proteins from the TA of untreated A17 and FvB mice (n = 5 per group), and mice treated with an anধ-myostaধn
anধbody (10mg/kg IP weekly for 10 weeks) were bloħed and detected with fluorescent anধbodies directed against
individual subunits of all OXPHOS complexes. Protein abundance was quanধfied by the raধo of per-sample flores-
cence intensity normalised to the intensity of the loading control α-Tubulin. Band intensity for complexes 2-5 (a-d)
was quanধfied by the LI-COR Odyssey system. Mulধple t-tests were performed, and p values were corrected by
FDR. Means of normalised protein abundance were ploħed with bars represenধng SEM.
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for theMyh-2 andMyh-4 caused by the treatment with the antibody between the treated
and untreated A17 mice.
6.5 Discussion
OPMD is a late-onset under-diagnosed rare muscle wasting disease with a strong founder
effect, which reduces quality of life of patients 158. Therefore, strategies that allow the early
detection and expedition of diagnosis in patients will provide a clinically relevant method
to follow therapeutic progression and development of novel therapeutic strategies in pre-
clinical model 280. The primary objectives of this study involves the generation of hypothe-
ses from the analysis of the primary metabolic dataset to inform further studies, the iden-
tification and analysis of candidate metabolite biomarkers in the serum of A17 mice to
elucidate the state of disease progression when compared to the healthy FvB mice, and to
compare candidate metabolites to A17 mice subject to an anti-myostatin treatment regimen
in-order to analyse metabolic response to the therapeutic increase of muscle mass. The anal-
ysis of disease markers will also enable the development of alternative targets to ameliorate
disease symptoms.
Exploratory metabolic profiling of serum from A17 and FvB models demonstrated a dys-
regulation of key metabolites involved in pathways supporting energy metabolism. Uni-
variate statistical analyses identified a subset of metabolites that differ between the A17 and
FvB mice, and multivariate statistical models differentiated the metabolic signature of the
healthy FvB control mice and the A17 disease model mice. The metabolic signature ob-
served by GCMS in the OPMDmouse was further analysed as a function of mitochondrial
dysfunction.
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Figure 6.8: Expression of select transcripts in TA of 22-week old OPMD mice: qRT-PCR was performed on total RNA
extracts from the TA of untreated A17 and FvB mice (n = 5 per group), and A17 mice treated with an anধ-myostaধn
anধbody RK35 (10mg/kg IP weekly for 10 weeks) from 12 weeks of age. Expression of the (a) mitochondrial cre-
taine kinease, (b) the muscle ring finger nuclease as an atrogen, (c) and (d) the myosin heavy chains as a proxy for
muscle fibre type. Mulধple t-tests were performed, and p values were corrected by FDR. Means of cDNA expression
(normalised to RPLP0) were ploħed with bars represenধng SEM.
134
Mitochondria integrate complex cellular pathways such as apoptotic signals, calcium
homeostasis, energy production and have been implicated in various pathologies 25,49,80,290,342,346.
Mitochondrial dysregulation in OPMD has been proposed as a pathological aspect of the
disease as early as 1991, and electron microscopic analysis has revealed abnormal mitochon-
drial ultrastructure marked by ”large” mitochondria and dense, convoluted cristae or ring
like mitochondria with minimal cristae 305. Such morphologies observed inmdxmice are
usually correlated with myofibres undergoing degeneration and perturbance in calcium
homeostasis † . While the state of calcium homeostasis has not been examined in the A17
model mice or humans, a study in transfected myoblasts reveal an inhibition of rate of
calcium release due to reduced sarcoplasmic reticulum calcium content during excitation
contraction coupling (ECC) 133. However, no such change was observed in adult myofibres
transfected in-vivowith the expanded PABPN1 gene suggesting a defect in myogenesis 133.
Another study has linked splicing defects caused in the troponin complex by the OPMD
genotype to reduced calcium sensitivity in the soleus, suggesting an undescribed role of cal-
cium ion gradients in disease pathogenesis 210. The role of calcium homeostasis has however
been indirectly examined across two mechanisms: the mitochondrial apoptosis pathway is
effected by the BCL2 ‡ protein family. BCL2 over expression has been shown to reduce
steady state calcium levels within the endoplasmic reticulum and prevent apoptosis re-
lated mitochondrial calcium uptake 82, and this strategy has been explored in the OPMD
†Dysregulated calcium signalling sensitises the cell to apoptosis, and mitochondrial calcium overload leads
to the swelling and rupture of the mitochondrial outer membrane, which releases apoptotic factors from the
inter membrane space into the cytosol 139
‡In brief, the BH3 proteins act as sensors for cellular stress, and activate the executor proteins such as
Bax / Bak which alter the permeability of the mitochondrial outer membrane via interactions with the mito-
chondrial PTP complex, releasing components from the intermembrane space that finally activate effector
caspases and other apoptosis related cascades. The anti-apoptosis protein Bcl2 attenuates the overall process
by inhibiting the sensor and executor proteins 116.
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mouse90.
Mitochondria present unique organelles in the cell as they are under the influence of
two separate genomes: the nuclear encoded mitochondrial genome and the inherent (lo-
cal) mitochondrial genome (which primarily encodes complexes I, III, IV and V, along
with a few other genes responsible for RNA translation 319). Previous transcriptomic and
proteomic analysis in theDrosophilamodel of OPMD confirmed dysregulation in the nu-
clear encoded mitochondrial genes, and deletions in the mitochondrial genome in human
samples 230. In agreement to phenotypes previously observed in OPMD67,393, our results
indicate a decrease in protein levels of complexes II, II, IV, and V as measured by western
blotting, suggesting a dysregulation of OXPHOS complexes and consequently the electron
transport chain.
Dysregulation of the OXPHOS complexes have been previously shown to have a direct
impact on mitochondrial function primarily due to causing inefficient energy metabolism,
production of superoxide through ineffective transfer of electrons through the electron
transport chain and consequent production of reactive oxygen species (which has been re-
ported in theDrosophilamodel of OPMD67), induction of apoptosis and remain a com-
mon element of most mitochondrial diseases and DMD 319. We speculate the impact of
inefficient energy transfer in OPMD pathogenesis along two axes: the dysregulation of
mitochondrial substrate utilisation during cellular respiration and secondly the shuttle
mechanisms that link cytosolic respiration with mitochondrial respiration and the export
of generated mitochondrial ATP to the cytosol.
The metabolic stress induced by the high demand for ATP by skeletal muscle is met by
two distinct sources of fatty-acid substrates 377. The primary source of fatty-acids comes
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from storage locations around the body, wherein the fatty-acids are released into the blood,
absorbed into cells and eventually the mitochondria by the carnitine shuttle 309. Muscles
also maintain local reservoirs of intramyocellular triglycerides spatially located next to mi-
tochondria. Mitochondrial β-oxidation is the terminal process that converts stored fatty-
acids to acetyl CoA (which is fed into the tricarboxylic acid (TCA) cycle) 111,402. Interestingly,
GCMS analysis of the A17 mouse sera revealed a significant up-regulation of fatty-acid moi-
eties detected (Linoleic acid, Arachidonic acid, Docosahexanoic acid, 5-Tetradeconic acid,
3-Hydroxyadipic acid). We speculate that the inefficient energy transfer along the TCA and
electron transport chain (ETC) pathways results in an excess accumulation of unused en-
ergetic substrates which are subsequently converted to stored fatty-acids. Supporting this
hypothesis, intramyocellular lipid droplets are present in limited quantities in healthy tis-
sues, muscles of aged humans, DMD and OPMD patients have been shown to have an
increased muscle fat content 140,142,199,310, which we speculate diffuse into the serum due to
muscle dystrophy 377. which is observed as an abnormal lipid profile in the OPMDmouse
serum.
Another crucial step of ATP production in mitochondria involves the transfer of reduc-
ing equivalents generated during glycolysis in the cytoplasm across the selectively permeable
mitochondrial membrane by the mitochondrial shuttles. We speculate a reduction in pro-
tein expression of mitochondrial ETC complexes may also be accompanied by a dysfunc-
tion in the mitochondrial shuttle mechanisms and possibly the components of the TCA it-
self. The glycerophosphate shuttle functions at the crossroads of glycolysis, oxidative phos-
phorylation and fatty-acid metabolism, and has been suggested to be concentrated in fast
twitch muscles along with the malate-aspartate shuttle 311. The main metabolic role of this
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shuttle is the transport of reducing equivalents from cytosol into mitochondria where they
can be used for aerobic mitochondrial ATP production by entering the electron transport
chain at complex III as ubiquinol 37,75. The malate-aspartate shuttle fulfils a similar function
as a primary shuttle in slow twitch fibres 311, it translocates electrons produced during glycol-
ysis across the inner membrane of the mitochondrion for oxidative phosphorylation in the
mitochondrial complex I 341.
Serummetabolic analysis of OPMDmouse samples identified a key compound involved
in the glycerol phosphate shuttle: glycerol-3-phosphate (significantly up-regulated in A17
mice compared to FvB mice). Further analysis also identified two metabolites linked to
the malate-aspartate shuttle: malate (significantly up-regulated in A17 mice compared to
FvB mice) and glutamate (no significant change observed). It remains to be investigated if
the difference in metabolite concentrations correspond to a change in permeability of the
mitochondrial membrane and the effect of such a change on efficacy of the oxidative phos-
phorylation mechanism. Interestingly, fumarate and malate form crucial components of
the TCA itself, with fumarate generated form succinate by complex II of ETC, and malate
being converted from fumarate by the enzyme fumarase, further implicating the core en-
ergy production mechanisms in OPMDmitochondria (KEGG 00020). The pathway is
summarised in figure: 6.9 .
The second axis investigated involved the phoshogen energy systems which maintain
a spatio-temporal energy buffer in tissues with high energy demand such as skeletal mus-
cles. The phosphogen systems rely on the reversible phosporylation of creatine by the
mitochondrial and cytosolic creatine kinases to transport / regenerate ATP rapidly in the
cytosol 87. Mitochondrial creatine kinase (CKMT1) is ubiquitously expressed in human tis-
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sues. The primary function of CKMt1 remains the maintenence of the creatine/phosphocreatine
shuttle, which transports ATP produced in the mitochondria to the cytosol , maintaining
a spatio-temproal energy buffer. CKMT1 is localised to the mitochondrial cristae and inter-
membrane space near contact sites of the outer and inner mitochondrial membranes and
has been implicated to play an inhibitory role in mitochondrial permeability transition 87.
Overexpression of CKMT1 is also shown to confer resistance against mitochondrial depo-
larization and apoptosis421 § . The up-regulation of mitochondrial creatine kinases have
been observed in tissues with high energy turnover such as tumour tissues in lung cancer,
gastric cancer, prostate cancer, breast cancer, and has been explored as a therapeutic target
in DMD 179,346. A significant up-regulation of mitochondrial creatine kinase is also observed
from whole muscle total RNA extracts from the OPMDmice in this study. We speculate
that availability of the enzymatic substrate of mitochondrial creatine kinase (creatine) may
have a positive therapeutic effect (by enhancing the phosphocreatine shuttle 85, and main-
tenance of the PTP complex 105), and creatine supplementation been explored as a thera-
peutic target previously in muscular dystrophies ¶ . While serum creatine was not detected
in the study, there was a significant increase in the levels of serum creatinine (a by product
§There are two major pathways which facilitate the transfer of energy out of the mitochondria and into
the cell: The primary pathway involves the direct diffusion of ATP from the mitochondria and into the
cell via the voltage-dependent anion carriers (VDACs) 201,308, The secondary pathway involves the phospho-
rylation of creatine (Cr) with the use of a mitochondrial ATP to produce pCr via mitochondrial creatine
kinease. pCr then diffuses to the cytosol and is acted upon by cytosolic creatine kinease and ADP to locally
regenerate ATP. The creatine then shuttles back into the mitochondria completing the cycle. The creatine-
phosphocreatine shuttle is particularly efficient in tissues with a very variable energy demand like muscles
(skeletal and cardiac mucles), as well as in brain and neural tissues as it provides a spatio-temporal energy
buffer 105,201
¶Creatine supplementation has been examined in several studies 346 including Duchenne muscular dys-
trophy 120,368,404, mitochondrial cytopathies 369, glycogen phosphorylase deficiency 398, and in animal models
of amyotrophic lateral sclerosis 11,212,214, Huntington’s disease 10,96, Parkinsonism 213,254, as well as in brain is-
chemia 5,435.
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Figure 6.9: Dysregulaধon of metabolites linked to mitochondrial shuħles in OPMD: The glycerophosphate shuħles (yellow circles) and the malate aspartate
shuħles (blue squares) funcধon to transport reducing equivalents generated from glycolysis in the cytosol into the mitochondria for ATP producধon via the
electron transport chain (red irregular pentagon). Metabolites that are upregulated when compared to the FvB controls are marked as a green chevron, those
who have not changed as blue ”equals”, and those downregulated as a red inverted chevron.
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of phosphocreatine breakdown 148) observed. The secondary proposed (non-enzymatic)
function of mitochondrial creatine kinase involves conferring resistance against mitochon-
drial permeability transition pore (PTP) inducers, and subsequently to protect against mi-
tochondrial depolarization and induction of apoptosis 87. We speculate that the increased
expression of Ckmt-1 observed in the muscle total RNA extract may be a compensatory
(protective) response to the apoptotic signals generated by the cellular stress due to dystro-
phy, and further knockdown, transcriptomic and proteomic studies need to be undertaken
in-order to fully elucidate the role of Ckmt-1 in OPMDmuscles 87. Further interactions that
can be explored further include associations with cardiolipin and other phospholipids, mi-
tochondrial porin and calcium homeostasis 286,328,345,347,348,389.
Further investigation into the role of intracellular and intra-mitochondrial calcium gradi-
ents may present an opportunity to discover therapeutic target that regulates mitochondrial
apoptosis and may be a valid adjuvant therapy. Further experiments that can be conducted
include the examination of inherent defects in the assembly of mitochondrial complexes
due to dysregulation of poly adenylation signalling in OPMD, whether the mitochondrial
defects affect all involved cell types (satellite cells, myoblasts and myotubes) in a similar pat-
tern, whether a similar metabolic signature can be observed in human samples.
In order to assess the response of the possible candidate biomarkers to a therapeutic in-
crease of muscle mass, the metabolic profile of A17 mice treated with an anti-myostatin
antibody was compared to the untreated A17 and control FvB mice. In brief, select metabo-
lites involved in energy metabolism (which were elevated in the untreated A17 mice) were
found to be restored to wild type levels following an anti-myostatin regimen. However
another subset of metabolites (including amino acids) were found to be significantly ele-
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vated in the serum of mice treated with the RK35 antibody. While understanding that the
treatment regimen does not correct the genetic mutation of OPMD, this dichotomous ex-
pression pattern suggests that inhibition of myostatin may result in a unique metabolic
fingerprint distinct from the disease model and wild type mouse. The effect of inhibition
of myostatin on energy metabolism has been studied extensively, with various reports sug-
gesting an improved lipid profile and reduced adipogenesis in knockout animals 192,235,263,265,
though minimal reports exist on the effect of myostatin inhibition on circulating amino
acids. As amino acids are essential inorder to effect muscle growth420, we speculate the in-
crease in serum amino acids to be resultant from the increased muscle mass observed by
the inhibition of myostatin (see chapter 4). Furthermore, we speculate that the increased
muscle mass resulted in an increased basal metabolic rate thereby further reducing concen-
trations of select fatty acids and other energy related metabolites in the serum.
Curiously, no differences were observed in enrichment analyses between the untreated
and treated A17 mice. We speculate that due to the relatively limited amount of metabo-
lites detected (a subset of which have responded to an anti-myostatin regimen), a larger
dataset might be required in order to effect enrichment of myostatin associated metabo-
lites in curated databases. The metabolomic analysis of FvB mice treated with the antibody
RK35 may assist in further elucidating the effect of myostatin inhibition on a healthy ani-
mal model. Furthermore as muscles comprise roughly 40% of the average human body, we
hypothesised that a change in the metabolome of the muscle will be reflected as a change in
the serummetabolome. However, in order to fully correlate and link observed changes in
the serummetabolome with the disease state, the analysis of the muscle metabolome needs
to be conducted .
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Lastly, there exists a significant overlap of enriched terms between the untreated A17
- control FvB comparison and the treated A17 - control FvB comparison, suggesting the
metabolic profile of treated A17 mice remain distinct from the control FvB mice, similar
to the untreated A17 mice. We speculate that a genetic correction of the expanded gene 246,
might restore the metabolic signature of the A17 mice to those of the wild type. Though
no large scale differences were observed, broad metabolic signatures observed in the serum
metabolome of OPMDmodel mice highly correlate with what was observed previously in
other murine and canine models muscular dystrophies2,360. A more comprehensive study
will aid to tease out, characterise, and assay other significant subtle metabolites differences
in-order to identify unique metabolites to disease progression.
143
The syndrome of ocular ptosॾ and dysphagia appears to
deserve nosologic identification...a provocative biologic
problem ॾ [however] posed - how a genetic abnormality
may lead to a progressive degeneration of a limited group
of musclॽ - forty or more years after birth.
Victor et al. 394
Chapter 7
Discussion
The 9 general types of muscular dystrophies , each an unique genetic myodegenerative dis-
ease vary in their age of onset, disease progression and severity display a primary specificity
for skeletal muscles. Recent advances in molecular biology have assisted in elucidating the
mechanisms of the muscular dystrophies, and as such the downstreammolecular pathways
of the various myopathies resulting from cachexia, dystrophy and atrophy share a remark-
able similarity 27. More than 300 * clinical trials have been conducted in the field of muscu-
lar dystrophy to either elucidate a disease state or examine the effects of therapeutic agents,
both suggesting a strong clinical interest to develop therapeutic strategies to ameliorate
symptoms.
Oculopharyngeal muscular dystrophy (OPMD) presents a rare late-onset myopathy
*Data retrieved from www.clinicaltrials.gov with the search term of ”muscular dystrophies”
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with a strong founder effect in populations of Canada, Israel, China and South America,
who are reportedly affected 158. The underlying expansion of the PABPN1 gene in OPMD
causes tissue wide transcriptomic dysregulation which manifests as muscle atrophy of prox-
imal limbs, ptosis and dysphagia 158,246,384. Life expectancy is also believed to be reduced due
to complications arising from pneumonia or malnutrition (Butler-Browne, personal com-
munication), and there is a severe impairment in quality of life 158. Current methods rely on
surgery (blepharoplasty for ptosis and cricopharyngeal myotomy for dysphagia) to amelio-
rate disease symptoms. Surgical techniques often are non-repeatable and carry a high risk
of relapse 158. Two promising strategies are currently in clinical trials (the administration of
trehalose and a myoblast transplant based cell therapy) and show improvement in clinical
outcome measures such as the 80ml swallowing test 14,158,306.
In our study, we present an alternative therapeutic approach to ameliorate atrophic
symptoms in OPMD, by effecting myostatin blockade which targets the muscle atrophy
rather than the disease pathway itself. Myostatin acts as a negative regulator of muscle mass,
and its discovery in 1998 attracted great clinical interest 224,325. In brief, anti-myostatin ther-
apeutic regimens have been previously reported to increase muscle mass, increase muscle
strength, reduce the accumulation of fibrotic tissue and ameliorate atrophic symptoms in
myopathies41,221,287,288,431.
This report examined the efficacy of myostatin blockade in murine models of OPMD at
two stages of disease progression, by the use of a monoclonal antibody RK35. The antibody
RK35 forms a second generation anti-myostatin therapeutic agent, that has been / is being
tested in pre-clinical and clinical settings9,173,378, which provides additional data (including a
safety and tolerability phase I clinical study of other severe muscular dystrophies 32), which
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may expedite clinical testing in alternative use cases such as OPMD. Furthermore, mon-
oclonal antibodies are more palatable for regulatory authorities than gene therapy based
drugs, as evidenced by more than 100 antibody products in the market (after approval by
regulatory agencies), and represent the second largest class of therapeutic molecules (before
vaccines) in various stages of clinical trials 83.
The OPMD disease model mice observed in this study, consistently displayed muscle
atrophy and reduced muscle strength. Limitation of the model system used in this study in-
volves the fact that though the mouse model recapitulates the disease phenotype at a tissue
level, it does not represent an accurate genocopy of the disease92,384,393. This limitation can
be however addressed by the use of a recently reported model developed by a Cre-lox based
knock-in of expanded PABPN1 in-order to replicate the genotype present in patients 393, as
opposed to a transgenic overexpression of an alanine expanded bovine PABPN192. Another
limitation of murine models utilised in OPMD concern the fact that while the muscular
dystrophy is prevalent in all skeletal muscles in the mice, it is specific to particular muscle
subsets in humans: a crucial variable to be considered when translating any studies from
murine models. Histological analysis of the cricopharyngeal muscle in humans further
highlight hypotrophic fibres with increased endomysial fibrosis and lack of muscle spin-
dles44, a profile distinct from canonically examined skeletal muscles such as the TA 136.
Interestingly, a limited extent of disease progression was observed between the 22 week
old and 52 week old mice in terms of myofibre diameter, collagen deposition, and INI den-
sity. In brief, the mice displayed a general growth or no change in body mass or myofibre
diameter, no change in collagen deposition, no increase in INI density between the two age
groups. Though OPMDmice, while have demonstrable disease progression upto 26 weeks
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of age especially in terms of increase in INI density, the model has not been characterised
at 52 weeks of age. Hence, the series of results observed in our study thereby underline a
requirement to further characterise the model and elucidate disease progression at more
advanced timepoints .
The administration of the anti-myostatin antibody RK35 employed herein at a clini-
cally relevant dose ameliorates histopathological atrophic symptoms observed in the 12-
week-old OPMD disease model administered the reagent for 10 weeks. In brief, a signifi-
cant treatment associated increase in muscle mass, myofibre diameter and muscle strength
was observed. This result outcome is most promising as it indicates the efficacy of an anti-
myostatin regimen in OPMD. As OPMD is a late-onset disease and in-order to assess the
impact of an anti-myostatin treatment regimen on tissues subject to a dystrophic microen-
vironment for prolonged periods of time, 42-week old mice were administered with an
identical treatment regimen as outlined above. A decrease in efficacy of the antibody RK35
was however observed when the relatively older cohort was examined, with a partial amelio-
ration of atrophic symptoms reported. In brief, while small but significant treatment asso-
ciated increases were observed in muscle mass, no significant changes were observed in my-
ofibre diameter, or muscle strength. We speculate this loss of efficacy to result either from
a compromise in the muscle structure, or a compensatory decrease in myostatin levels251.
Follow-up dose escalation studies, along with the measurement of circulating myostatin
levels can be conducted in-order to fully elucidate this effect. This further suggests that in
addition to disease severity, the timing of myostatin inhibition presents a critical variable
in-order to maximally ameliorate atrophic symptoms. This hypothesis can be examined by
long-term administration of the antibody (6-8 months) from an early age (6 weeks) in the
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murine models.
A promising observation observed across both cohorts, is that fast twitch muscles like
the EDL displayed more sensitivity to the antibody RK35. As progression of OPMD is re-
ported to be more specific to fast twitch muscle fibres such as those found in the EDL 269,424,
the treatment associated response observed may complement the aetiological profile of the
disease. Furthermore, the collagen VI content of the TA was found to be significantly re-
duced in both cohorts, suggesting a decreased rate of fibrotic tissue formation, indicating
a possible use of this antibody for preventive intervention in OPMD, for patient clusters
known to be at risk. Interestingly, no changes in collagen VI content was observed in the
EDL in both cohorts, perhaps suggesting a fibre-type dependant progression of muscle fi-
brosis in OPMD (and by extension, disease progression) 384. The fibre type specificity of
OPMD disease aetiology has been observed before, and this can be investigated between
the EDL and soleus by performing histochemical stains using antibodies generated for the
myosin heavy chain proteins, to quantify the effect of atrophy on different fibre types, and
correlating with intensity of SDH staining across the muscle. Knowing the differences on
the effect of the therapeutic regimen on the disease progression between human skeletal
muscle fibre types will allow clinicians to understand the morphological and physiological
basis for the effectiveness of the anti-myostatin intervention . Further histochemical stains
can be conducted such as the pico-sirius red staining in-order to quantify deposition of col-
lagen I and III.
Myostatin inhibition can be achieved by direct and indirect means. Early clinical re-
ports demonstrate a distinct disjunction between efficacy of antibody based anti-myostatin
agents when translated over to clinical trials, as opposed to soluble receptor based strate-
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gies. The first generation antibodyMyo-029 (dosed up to 30mg/kg) was discontinued due
to lack of an efficacy at a clinically relevant dose 399. The second generation antibodies en-
compass the RK35 used in this report, a humanised variant of which (Domagrozumab;
PF-06252616 currently in phase II trials), generated a 4.5% increase in muscle mass on mul-
tiple doses (1x up-to 40mg/kg ascending dose administration followed by a 3x 10mg/kg
fortnightly dose administration) in clinical trials 32. While promising, this is in contrast
to the efficacy of the antibodies observed in mice9,173,288,378, which we speculate may result
from differences in human and mouse physiology, and perhaps a change in antibody struc-
ture during the humanisation process. Interestingly however, in another strategy where
an ACTRIIb soluble receptor ACE-031 was utilised in a clinical setting, a 5% gain in mus-
cle mass (with a whole body lean mass gain of about 1 kg) was observed with a significantly
minimal single dose (up to 3mg/kg) 18. Though the reagent was discontinued due to safety
concerns 56, the difference in mode of action between the specific antibodies and the broad
spectrum TGF-β antagonist suggest additional molecules involved in muscle mass regu-
lation. Recent reports have implicated activin A as a co-regulator of muscle mass along
with myostatin 219. Indeed, specific inhibition of activin A and myostatin was reported to
induce muscle hypertrophy and force production in mice and monkeys219. The efficacy
of this dual inhibition was similar to hypertrophy observed with a broad spectrum TGF-
β blockers such as the soluble receptor while minimising observed adverse effects †, and
suggest a possible strategy to be explored in OPMD 219. Other gene therapy strategies for
†The administration of a broad spectrum TGF-β blockers while inhibiting myostatin and activin A, how-
ever also inhibit other essential signalling pathways that occur via the activin and BMP receptors 219. Reports
have demonstrated attenuation of BMP9 signalling via endoglin-ALK1-BMPRII/ActRIIB pathway essential
for angiogenesis and vascular homeostasis in mice administered a soluble receptor 19,88,292. Administration
of the soluble receptor has also resulted in observed splenomegaly and extramedullary hematopoiesis in the
splenic red pulp 219,423.
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myostatin blockade include the use of recombinant propeptide genes42,125,253 and anti-sense
morpholino oligonucleotides 200,240,241, and as such these strategies are in various stages of
pre-clinical analysis. Indirect strategies to inhibit myostatin revolve around the use of gene
therapy based approaches that overexpress follistatin, which is a known natural antagonist
of myostatin (see chapter 1). Mendell et al. 268 reports promising results with a follistatin
based inhibition of myostatin in clinical trials for Becker’s muscular dystrophy and sporadic
inclusion body myositis267. In brief, patients enrolled in the trial displayed improved ambu-
lation as measured by the 6 minute walk test, an increase in myofibre diameter, reduction in
fibrotic tissue accumulation and reduction in the number of centrally nucleated fibres 267,268.
As hypothesised, no change was observed in the density of intranuclear inclusions (INI)
caused by treatment with the antibody in both cohorts in our study. The disease indepen-
dent mechanism of action of myostatin presents a disadvantage with respect to reducing
INI density as the strategy does not correct the disease genotype. There is hence a risk of
the tissue being susceptible to revert to an atrophic phenotype due to accumulation of
myostructural damage or accretion of satellite cells carrying the defective gene into the
treated muscle over the lifetime of the individual. This however, can be addressed by util-
isation of the anti-myostatin therapy as an adjuvant therapy, in addition to a strategy that
corrects the disease at the genotype. For instance, Malerba et al. 246 reported an improve-
ment in phenotypes associated with insoluble aggregates, muscle fibrosis, muscle strength
and normalisation of the muscle transcriptome (though no improvement in muscle mass
was observed). This was achieved by using a virus vector based therapy combining simulta-
neous knockdown of endogenous PABPN1 (expanded bovine and murine wild-type) and
replacement with wild-type PABPN1 (human). The combination of the increase in muscle
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mass and morphometry observed by myostatin inhibition, along with the correction of the
disease mutation by the gene therapy agent may significantly ameliorate symptoms, and
presents tempting avenues for further study. Other strategies to ameliorate disease symp-
toms include transplant of viable myoblasts from healthy (unaffected) muscles into affected
muscles, a strategy which has shown promise in clinical trials 306. We speculate that an adju-
vant anti-myostatin therapy prior to transplant (and perhaps continuing doses in-order to
maintain muscle mass) may assist in stabilising the affected muscle tissue and reduce accu-
mulation of fibrosis, which may result in enhanced muscle regeneration. On the same note,
concerns have been raised upon the effect of myostatin inhibition on the myogenicity of
satellite cells 138,255,257. Satellite cells in OPMD patients have been shown to display a hetero-
geneous profile, with increased PAX7-positive cells observed in both satellite and interstitial
positions in the cricopharyngeal muscle 136, an effect that needs to be further elucidated.
On the contrary, satellite cells on unaffected muscles remain quantitatively unchanged 136.
While the effect of myostatin inhibition on satellite cells was not examined in this study,
recent reports indicate a minimal effect of myostatin inhibition on satellite cell activation in
either pre-clinical 225,408 and clinical settings 268.
Current diagnostic criteria and outcome readouts for clinical trials involve measurement
of vertical separation of a palpebral fissure to characterise ptosis, quality of life question-
naires, videoendoscopic swallowing study (VESS), videofluoroscopic swallowing study
(VFSS), and a swallowing time greater than seven seconds when drinking 80 ml of ice-cold
water, followed by confirmatory testing of the GCN expansion at the PABPN1 gene 14,306.
The identification, development and characterisation of a robust, reproducible, and rela-
tively high throughput serummetabolomic method to diagnose disease and follow ther-
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apeutic progression will greatly aid clinical measures. This report encompasses the first
characterisation of the serummetabolome of OPMD. As muscle tissues are one of the key
regulators of metabolism 263, we speculate any disease state affecting the muscles will affect
the general metabolism state of the body, which will be reflected in a significant alteration
of metabolite levels in the blood serum. Gas chromatography based mass spectrometry
(GCMS) analysis of the sera from the murine model at 22-weeks of age revealed dysregula-
tion in energy production pathways, and mitochondrial energy generation. Further GCMS
analyses on 22-week old mice reveal that a subset of dysregulated metabolites observed in
the disease model were restored upon treatment with the antibody RK35, thereby demon-
strating response to a therapeutic increase in muscle mass and suggesting possible candi-
dates for biomarker characterisation. As this study forms the initial characterisation of the
OPMD serummetabolome, it is limited by the relatively low sample sizes used (n = 5 per
group), and due to platform limitations may not have detected subtle changes in the serum
metabolome.
A comprehensive targeted metabolomic analysis with larger sample sizes can be con-
ducted in-order to fully characterise the effect of metabolic dysregulation in the OPMD
model. Bioinformatic protocols allow the integration of metabolomic data with transcrip-
tomic data, allowing the researcher to examine and correlate changes in transcriptome with
that of the metabolome under specific conditions. Furthermore, GCMS analysis can be
conducted on the relatively older cohort at 52-weeks of age in-order to elucidate the effect
of disease progression and age on identified metabolites. Novel points of comparison can
also include identification of metabolites frommuscles, and the correlation of observed
muscle metabolites with other body fluids such as urine, serum and saliva, which will as-
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sist in characterising detected and related metabolites, mechanism of actions of existing
drugs, and suggest new therapeutic targets that can be explored to ameliorate symptoms
in OPMD. The metabolic profile of OPMD can be further complemented by liquid chro-
matography based mass spectrometric analysis of the serummetabolites in-order to identify
and characterise polar compounds such as amino acids, only a subset of which were de-
tected in this study. Finally, it is of utmost importance to correlate metabolites observed in
the mouse model to that of human samples at various stages of disease progression in-order
to elucidate the diagnostic potential of the biomarker panel.
In summary, we propose an anti-myostatin therapeutic strategy that relies on increasing
muscle mass in-order to attenuate the net loss of muscle mass experienced by an OPMD
patient. This report is encompasses the efficacy of myostatin blockade at two distinct stages
of disease progression in the OPMDmice. Though further analysis need to be performed
in-order to optimise the treatment regimen (particularly in mice at advanced stages of dis-
ease progression), we demonstrate the validity of this treatment strategy in murine models
of OPMD. Clinical testing of the reagent used herein can be expedited as it has already been
examined in a phase I (safety and tolerability) study for other severe muscular dystrophies
(with phase II trials ongoing). Furthermore, the proposed therapeutic strategy has the flex-
ibility to be employed independently, or as part of a combinatorial approach with an agent
that corrects the mutation / reduces nuclear aggregates. Further studies can be undertaken
in-order to optimise the dose and treatment efficacy in advanced stages of OPMD.We ad-
ditionally conducted the first serummetabolomic screen of a murine model of OPMD and
characterised a set of metabolites and metabolic pathways that were dysregulated in the
disease condition. A subset of identified dysregulated serummetabolites were found to be
153
restored to wild-type levels of expression by the administration of the anti-myostatin treat-
ment regimen. This set of results will inform future studies in-order to isolate and identify
a panel of biomarkers which will assist in pre-clinical and clinical environments.
154
References
[1] Aartsma-Rus, A., Ginjaar, I. B., & Bushby, K. (2016). The importance of genetic
diagnosis for Duchenne muscular dystrophy. J Med Genet, 53(3), 145–151.
[2] Abdullah, M., Kornegay, J. N., Honcoop, A., Parry, T. L., Balog-Alvarez, C. J.,
O’Neal, S. K., Bain, J. R., Muehlbauer, M. J., Newgard, C. B., Patterson, C., et al.
(2017). Non-targeted metabolomics analysis of golden retriever muscular dystrophy-
affected muscles reveals alterations in arginine and proline metabolism, and eleva-
tions in glutamic and oleic acid in vivo. Metabolitॽ, 7(3), 38.
[3] Abu-Baker, A., Messaed, C., Laganiere, J., Gaspar, C., Brais, B., & Rouleau, G. A.
(2003). Involvement of the ubiquitin–proteasome pathway and molecular chap-
erones in oculopharyngeal muscular dystrophy. Human molecular genetics, 12(20),
2609–2623.
[4] Abu-Baker, A. & Rouleau, G. A. (2007). Oculopharyngeal muscular dystrophy:
recent advances in the understanding of the molecular pathogenic mechanisms and
treatment strategies. Biochimica et Biophysica Acta (BBA)–Molecular Basॾ of Dis-
ease, 1772(2), 173–185.
[5] Adcock, K. H., Nedelcu, J., Loenneker, T., Martin, E., Wallimann, T., &Wagner,
B. P. (2002). Neuroprotection of creatine supplementation in neonatal rats with
transient cerebral hypoxia-ischemia. Developmental neuroscience, 24(5), 382–388.
[6] Allen, D. L. & Unterman, T. G. (2007). Regulation of myostatin expression and
myoblast differentiation by FoxO and SMAD transcription factors. American Jour-
nal of Physioloং-Cell Physioloং, 292(1), C188—-C199.
[7] Amirouche, A., Durieux, A.-C., Banzet, S., Koulmann, N., Bonnefoy, R., Mouret,
C., Bigard, X., Peinnequin, A., & Freyssenet, D. (2009). Down-regulation of
Akt/mammalian target of rapamycin signaling pathway in response to myostatin
overexpression in skeletal muscle. Endocrinoloং, 150(1), 286–294.
155
[8] Anderson, S. B., Goldberg, A. L., &Whitman, M. (2008). Identification of a novel
pool of extracellular pro-myostatin in skeletal muscle. Journal of Biological Chem-
istry, 283(11), 7027–7035.
[9] Andre, M. S., Johnson, M., Bansal, P. N., Wellen, J., Robertson, A., Opsahl, A.,
Burch, P. M., Bialek, P., Morris, C., & Owens, J. (2017). A mouse anti-myostatin an-
tibody increases muscle mass and improves muscle strength and contractility in the
mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent,
domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
Skeletal muscle, 7(1), 25.
[10] Andreassen, O. A., Dedeoglu, A., Ferrante, R. J., Jenkins, B. G., Ferrante, K. L.,
Thomas, M., Friedlich, A., Browne, S. E., Schilling, G., Borchelt, D. R., et al.
(2001a). Creatine increases survival and delays motor symptoms in a transgenic
animal model of huntington’s disease. Neurobioloং of disease, 8(3), 479–491.
[11] Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Ferrante, K. L., Bogdanov, M. B.,
Kaddurah-Daouk, R., & Beal, M. F. (2001b). Increases in cortical glutamate concen-
trations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine
supplementation. Journal of neurochemistry, 77(2), 383–390.
[12] Apponi, L. H., Corbett, A. H., & Pavlath, G. K. (2013). Control of mRNA stability
contributes to low levels of nuclear poly(A) binding protein 1 (PABPN1) in skeletal
muscle. Skeletal muscle, 3(1), 23.
[13] Apponi, L. H., Leung, S. W., Williams, K. R., Valentini, S. R., Corbett, A. H., &
Pavlath, G. K. (2010). Loss of nuclear poly(A)-binding protein 1 causes defects in
myogenesis and mRNA biogenesis. Human Molecular Genetics, 19(6), 1058–1065.
[14] Argov, Z., Gliko-Kabir, I., Brais, B., Caraco, Y., &Megiddo, D. (2016). Intravenous
trehalose improves dysphagia and muscle function in oculopharyngeal muscular
dystrophy (opmd): Preliminary results of 24 weeks open label phase 2 trial (s28.
004). Neuroloং, 86(16 Supplement), S28–004.
[15] Argov, Z., Vornovitsky, H., Blumen, S., & Caraco, Y. (2015). First human use of
high dose iv trehalose: Safety, tolerability and pharmacokinetic results from the ocu-
lopharyngeal muscular dystrophy (opmd) therapy trial (p7. 068). Neuroloং, 84(14
Supplement), P7–068.
[16] Arounleut, P., Bialek, P., Liang, L. F., Upadhyay, S., Fulzele, S., Johnson, M.,
Elsalanty, M., Isales, C. M., &Hamrick, M.W. (2013). A myostatin inhibitor
156
(propeptide-Fc) increases muscle mass and muscle fiber size in aged mice but does
not increase bone density or bone strength. Exp Gerontol, 48(9), 898–904.
[17] Aryani, O., Akbari, M., Aghsaei-Fard, M., Mirmohammad-Sadeghi, A., & Yadegari,
S. (2017). Oculopharyngeal muscular dystrophy misdiagnosed as myasthenia gravis:
Case report and review of literature. Iranian journal of neuroloং, 16(2), 98.
[18] Attie, K. M., Borgstein, N. G., Yang, Y., Condon, C. H., Wilson, D. M., Pearsall,
A. E., Kumar, R., Willins, D. A., Seehra, J. S., & Sherman, M. L. (2013). A single
ascending dose study of muscle regulator ACE 031 in healthy volunteers. Muscle &
nerve, 47(3), 416–423.
[19] Aykul, S. &Martinez-Hackert, E. (2016). Transforming growth factor-β family lig-
ands can function as antagonists by competing for type ii receptor binding. Journal
of Biological Chemistry, 291(20), 10792–10804.
[20] Bakkar, N., Wackerhage, H., & Guttridge, D. C. (2005). Myostatin and NF‐κB Reg-
ulate Skeletal Myogenesis Through Distinct Signaling Pathways. Signal transduction,
5(4), 202–210.
[21] Bao, Y. P., Cook, L. J., O’Donovan, D., Uyama, E., & Rubinsztein, D. C. (2002).
Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation
and death in a cell model of oculopharyngeal muscular dystrophy. Journal of Biolog-
ical Chemistry, 277(14), 12263–12269.
[22] Bao, Y. P., Sarkar, S., Uyama, E., & Rubinsztein, D. C. (2004). Congo red, doxycy-
cline, and HSP70 overexpression reduce aggregate formation and cell death in cell
models of oculopharyngeal muscular dystrophy. J Med Genet, 41(1), 47–51.
[23] Barbezier, N., Chartier, A., Bidet, Y., Buttstedt, A., Voisset, C., Galons, H., Blondel,
M., Schwarz, E., & Simonelig, M. (2011). Antiprion drugs 6-aminophenanthridine
and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscu-
lar dystrophy. EMBO Molecular Medicine, 3(1), 35–49.
[24] Bawa, P. N. S., Jones, K. E., & Stein, R. B. (2014). Assessment of size ordered recruit-
ment. Frontiers in human neuroscience, 8.
[25] Beal, M. F. (2000). Energetics in the pathogenesis of neurodegenerative diseases.
Trends in neurosciencॽ, 23(7), 298–304.
157
[26] Becher, M. W., Morrison, L., Davis, L. E., Maki, W. C., King, M. K., Bicknell, J. M.,
Reinert, B. L., Bartolo, C., & Bear, D. G. (2001). Oculopharyngeal muscular dystro-
phy in hispanic newmexicans. Jama, 286(19), 2437–2440.
[27] Berardi, E. (2017). Muscular dystrophies and cancer cachexia: Similarities in chronic
skeletal muscle degeneration. Journal of Functional Morpholoং and Kinesioloং,
2(4), 39.
[28] Berciano, M. T., Villagra, N. T., Ojeda, J. L., Navascues, J., Gomes, A., Lafarga, M.,
& Carmo-Fonseca, M. (2004). Oculopharyngeal muscular dystrophy-like nuclear
inclusions are present in normal magnocellular neurosecretory neurons of the hy-
pothalamus. Hum Mol Genet, 13(8), 829–838.
[29] Berger, M. J. & Doherty, T. J. (2010). Sarcopenia: prevalence, mechanisms, and
functional consequences. In Body Composition and Aging, volume 37 (pp. 94–114).
Karger Publishers.
[30] Bernardi, H., Gay, S., Fedon, Y., Vernus, B., Bonnieu, A., & Bacou, F. (2011). Wnt4
activates the canonical β-catenin pathway and regulates negatively myostatin: func-
tional implication in myogenesis. American Journal of Physioloং-Cell Physioloং,
300(5), C1122—-C1138.
[31] Bestas, B., McClorey, G., Tedebark, U., Moreno, P. M., Roberts, T. C., Hammond,
S. M., Smith, C. I., Wood, M. J., & Andaloussi, S. E. (2014). Design and application
of bispecific splice-switching oligonucleotides. Nucleic Acid Ther, 24(1), 13–24.
[32] Bhattacharya, I., Pawlak, S., Marraffino, S., Christensen, J., Sherlock, S. P., Alvey, C.,
Morris, C., Arkin, S., & Binks, M. (2017). Safety, Tolerability, Pharmacokinetics,
and Pharmacodynamics of Domagrozumab (PF-06252616), an Antimyostatin Mon-
oclonal Antibody, in Healthy Subjects. Clinical pharmacoloং in drug development.
[33] Bialek, P., Parkington, J., Li, X., Gavin, D., Wallace, C., Zhang, J., Root, A., Yan,
G., Warner, L., Seeherman, H. J., & Yaworsky, P. J. (2014). A myostatin and activin
decoy receptor enhances bone formation in mice. Bone, 60, 162–171.
[34] Biesemann, N., Mendler, L., Kostin, S., Wietelmann, A., Borchardt, T., & Braun, T.
(2015). Myostatin induces interstitial fibrosis in the heart via TAK1 and p38. Cell and
tissue research, 361(3), 779–787.
[35] Biesemann, N., Mendler, L., Wietelmann, A., Hermann, S., Schäfers, M., Krüger,
M., Boettger, T., Borchardt, T., & Braun, T. (2014). Myostatin regulates energy
158
homeostasis in the heart and prevents heart failure. Circulation research, 115(2), 296–
310.
[36] Bilsen, P. v., Jaspers, L., Lombardi, M., Odekerken, J., Burright, E., & Kaemmerer,
W. (2008). Identification and allele-specific silencing of the mutant huntingtin allele
in huntington’s disease patient-derived fibroblasts. Human gene therapy, 19(7), 710–
718.
[37] Blanchaer, M. (1964). Respiration of mitochondria of red and white skeletal muscle.
American Journal of Physioloং–Legacy Content, 206(5), 1015–1020.
[38] Blumen, S. C., Korczyn, a. D., Lavoie, H., Medynski, S., Chapman, J., Asherov, a.,
Nisipeanu, P., Inzelberg, R., Carasso, R. L., Bouchard, J. P., Tomé, F. M., Rouleau,
G. a., & Brais, B. (2000). Oculopharyngeal MD among Bukhara Jews is due to a
founder (GCG)9 mutation in the PABP2 gene. Neuroloং, 55(9), 1267–1270.
[39] Boca, S. M., Nishida, M., Harris, M., Rao, S., Cheema, A. K., Gill, K., Seol, H.,
Morgenroth, L. P., Henricson, E., McDonald, C., et al. (2016). Discovery of
metabolic biomarkers for duchenne muscular dystrophy within a natural history
study. PloS one, 11(4), e0153461.
[40] Bogdanov, M., Matson, W. R., Wang, L., Matson, T., Saunders-Pullman, R., Bress-
man, S. S., & Beal, M. F. (2008). Metabolomic profiling to develop blood biomark-
ers for parkinson’s disease. Brain, 131(2), 389–396.
[41] Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A.,
Ahima, R. S., & Khurana, T. S. (2002). Functional improvement of dystrophic
muscle by myostatin blockade. Nature, 420(6914), 418–421.
[42] Bogdanovich, S., Perkins, K. J., Krag, T. O. B., Whittemore, L.-A., & Khurana, T. S.
(2005). Myostatin propeptide-mediated amelioration of dystrophic pathophysiol-
ogy. The FASEB Journal, 19(6), 543–549.
[43] Bonetto, A., Andersson, D. C., &Waning, D. L. (2015). Assessment of muscle mass
and strength in mice. BoneKEy reports, 4.
[44] Bonington, A., Mahon, M., &Whitmore, I. (1988). A histological and histochemical
study of the cricopharyngeus muscle in man. Journal of anatomy, 156, 27.
[45] Bourne, G. H. (1972). The structure and function of muscle. Academic Press New
York.
159
[46] Braga, M., Pervin, S., Norris, K., Bhasin, S., & Singh, R. (2013). Inhibition of in
vitro and in vivo brown fat differentiation program by myostatin. Obesity, 21(6),
1180–1188.
[47] Brais, B., Bouchard, J. P., Xie, Y. G., Rochefort, D. L., Chrétien, N., Tomé, F. M.,
Lafrenière, R. G., Rommens, J. M., Uyama, E., Nohira, O., Blumen, S., Korczyn,
a. D., Heutink, P., Mathieu, J., Duranceau, a., Codère, F., Fardeau, M., & Rouleau,
G. a. (1998). Short GCG expansions in the PABP2 gene cause oculopharyngeal mus-
cular dystrophy. Nature genetics, 18(2), 164–167.
[48] Breitbart, A., Auger-Messier, M., Molkentin, J. D., &Heineke, J. (2011). Myostatin
from the heart: local and systemic actions in cardiac failure and muscle wasting.
American Journal of Physioloং-Heart and Circulatory Physioloং, 300(6), H1973—-
H1982.
[49] Brenner, C. & Kroemer, G. (2000). Mitochondria–the death signal integrators.
Science, 289(5482), 1150–1151.
[50] Brindle, J. T., Antti, H., Holmes, E., Tranter, G., Nicholson, J. K., Bethell, H. W.,
Clarke, S., Schofield, P. M., McKilligin, E., Mosedale, D. E., et al. (2002). Rapid and
noninvasive diagnosis of the presence and severity of coronary heart disease using 1
h-nmr-based metabonomics. Nature medicine, 8(12), 1439.
[51] Bullough, W. S. (1965). Mitotic and functional homeostasis: a speculative review.
Cancer Research, 25(10), 1683–1727.
[52] C Clark, B. & L Taylor, J. (2011). Age-related changes in motor cortical properties
and voluntary activation of skeletal muscle. Current aging science, 4(3), 192–199.
[53] C Kostek, M. & J Delmonico, M. (2011). Age-related changes in adult muscle mor-
phology. Current aging science, 4(3), 221–233.
[54] Cai, D., Frantz, J. D., Tawa, N. E., Melendez, P. A., Oh, B.-C., Lidov, H. G. W., Has-
selgren, P.-O., Frontera, W. R., Lee, J., & Glass, D. J. (2004). IKKβ/NF-κB activa-
tion causes severe muscle wasting in mice. Cell, 119(2), 285–298.
[55] Calado, A., Tome, F. M., Brais, B., Rouleau, G. A., Kuhn, U., Wahle, E., & Carmo-
Fonseca, M. (2000). Nuclear inclusions in oculopharyngeal muscular dystrophy
consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA.
Hum Mol Genet, 9(15), 2321–2328.
160
[56] Campbell, C., McMillan, H. J., Mah, J. K., Tarnopolsky, M., Selby, K., McClure, T.,
Wilson, D. M., Sherman, M. L., Escolar, D., & Attie, K. M. (2017). Myostatin in-
hibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy:
Results of a randomized, placebo-controlled clinical trial. Muscle & nerve, 55(4),
458–464.
[57] Camporez, J.-P. G., Petersen, M. C., Abudukadier, A., Moreira, G. V., Jurczak,
M. J., Friedman, G., Haqq, C. M., Petersen, K. F., & Shulman, G. I. (2016). Anti-
myostatin antibody increases muscle mass and strength and improves insulin sensi-
tivity in old mice. Proceedings of the National Academy of Sciencॽ, 113(8), 2212–2217.
[58] Cardinale, A. & Biocca, S. (2008). The potential of intracellular antibodies for thera-
peutic targeting of protein-misfolding diseases. Trends in molecular medicine, 14(9),
373–380.
[59] Carlson, J. R. (1988). A newmeans of inducibly inactivating a cellular protein.
Molecular and cellular bioloং, 8(6), 2638–2646.
[60] Carpentier, I., Declercq, W., Malinin, N. L., Wallach, D., Fiers, W., & Beyaert, R.
(1998). TRAF2 plays a dual role in NF‐κB‐dependent gene activation by mediating
the TNF‐induced activation of p38MAPK and IκB kinase pathways. FEBS letters,
425(2), 195–198.
[61] Carrarelli, P., Yen, C.-F., Arcuri, F., Funghi, L., Tosti, C., Wang, T.-H., Huang, J. S.,
& Petraglia, F. (2015). Myostatin, follistatin and activin type ii receptors are highly
expressed in adenomyosis. Fertility and sterility, 104(3), 744–752.
[62] Casarejos, M., Solano, R., Gomez, A., Perucho, J., De Yébenes, J., &Mena, M.
(2011). The accumulation of neurotoxic proteins, induced by proteasome inhibi-
tion, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma
cells. Neurochemistry international, 58(4), 512–520.
[63] Cash, J. N., Angerman, E. B., Kattamuri, C., Nolan, K., Zhao, H., Sidis, Y., Keut-
mann, H. T., & Thompson, T. B. (2012). Structure of myostatin follistatin-like 3
n-terminal domains of follistatin-type molecules exhibit alternate modes of binding.
Journal of Biological Chemistry, 287(2), 1043–1053.
[64] Cash, J. N., Rejon, C. A., McPherron, A. C., Bernard, D. J., & Thompson, T. B.
(2009). The structure of myostatin: follistatin 288: insights into receptor utilization
and heparin binding. The EMBO journal, 28(17), 2662–2676.
161
[65] Catoire, H., Pasco, M. Y., Abu-Baker, A., Holbert, S., Tourette, C., Brais, B.,
Rouleau, G. a., Parker, J. A., & Néri, C. (2008). Sirtuin inhibition protects from
the polyalanine muscular dystrophy protein PABPN1. Human Molecular Genetics,
17(14), 2108–2117.
[66] Chartier, A., Benoit, B., & Simonelig, M. (2006). A Drosophila model of oculopha-
ryngeal muscular dystrophy reveals intrinsic toxicity of PABPN1. The EMBO jour-
nal, 25(10), 2253–2262.
[67] Chartier, A., Klein, P., Pierson, S., Barbezier, N., Gidaro, T., Casas, F., Carberry, S.,
Dowling, P., Maynadier, L., Bellec, M., et al. (2015). Mitochondrial dysfunction
reveals the role of mrna poly (a) tail regulation in oculopharyngeal muscular dystro-
phy pathogenesis. PLoS genetics, 11(3), e1005092.
[68] Chartier, A., Raz, V., Sterrenburg, E., Verrips, C. T., van der Maarel, S. M., & Si-
monelig, M. (2009). Prevention of oculopharyngeal muscular dystrophy by muscu-
lar expression of llama single-chain intrabodies in vivo. Human molecular genetics,
18(10), 1849–1859.
[69] Chartier, A. & Simonelig, M. (2013). Animal models in therapeutic drug discovery
for oculopharyngeal muscular dystrophy. Drug Discovery Today: Technologiॽ, 10(1),
e103——–e108.
[70] Chawla, J. (2011). Stepwise approach to myopathy in systemic disease. Frontiers in
neuroloং, 2, 49.
[71] Chien, Y.-Y. (2012). Oculopharyngeal muscular dystrophy–An under-diagnosed
disease in China? Report a China-born Chinese with PABPN1 mutation and epi-
demiology review of the literature. Journal of the Formosan Medical Association,
111(7), 397–402.
[72] Chiu, C. S., Peekhaus, N., Weber, H., Adamski, S., Murray, E. M., Zhang, H. Z.,
Zhao, J. Z., Ernst, R., Lineberger, J., Huang, L., Hampton, R., Arnold, B. A.,
Vitelli, S., Hamuro, L., Wang, W. R., Wei, N., Dillon, G. M., Miao, J., Alves, S. E.,
Glantschnig, H., Wang, F., &Wilkinson, H. A. (2013). Increased muscle force pro-
duction and bone mineral density in ActRIIB-Fc-treated mature rodents. J Gerontol
A Biol Sci Med Sci, 68(10), 1181–1192.
[73] Cho, T. J., Gerstenfeld, L. C., & Einhorn, T. A. (2002). Differential temporal ex-
pression of members of the transforming growth factor beta superfamily during
murine fracture healing. J Bone Miner Rॽ, 17(3), 513–520.
162
[74] Choi, S. J., Yablonka-Reuveni, Z., Kaiyala, K. J., Ogimoto, K., Schwartz, M. W.,
&Wisse, B. E. (2011). Increased energy expenditure and leptin sensitivity account
for low fat mass in myostatin-deficient mice. American Journal of Physioloং-
Endocrinoloং and Metabolism, 300(6), E1031–E1037.
[75] Chowdhury, S. K., Gemin, A., & Singh, G. (2005). High activity of mitochondrial
glycerophosphate dehydrogenase and glycerophosphate-dependent ros production
in prostate cancer cell lines. Biochemical and biophysical research communications,
333(4), 1139–1145.
[76] Cleasby, M. E., Jarmin, S., Eilers, W., Elashry, M., Andersen, D. K., Dickson, G., &
Foster, K. (2014). Local overexpression of the myostatin propeptide increases glucose
transporter expression and enhances skeletal muscle glucose disposal. American
Journal of Physioloং-Endocrinoloং and Metabolism, 306(7), E814——–E823.
[77] Coen, P. M., Menshikova, E. V., Distefano, G., Zheng, D., Tanner, C. J., Standley,
R. A., Helbling, N. L., Dubis, G. S., Ritov, V. B., Xie, H., et al. (2015). Exercise and
weight loss improve muscle mitochondrial respiration, lipid partitioning and insulin
sensitivity following gastric bypass surgery. Diabetॽ, (pp. db150809).
[78] Corbeil-Girard, L. P., Klein, A. F., Sasseville, A. M., Lavoie, H., Dicaire, M. J.,
Saint-Denis, A., Page, M., Duranceau, A., Codere, F., Bouchard, J. P., Karpati, G.,
Rouleau, G. A., Massie, B., Langelier, Y., & Brais, B. (2005). PABPN1 overexpres-
sion leads to upregulation of genes encoding nuclear proteins that are sequestered
in oculopharyngeal muscular dystrophy nuclear inclusions. Neurobiol Dॾ, 18(3),
551–567.
[79] Craig, R. & Padrón, R. (2004). Molecular structure of the sarcomere. Myoloং. 3rd
ed. Myoloং. 3rd ed. New York: McGrawHill.
[80] Crompton, M. (2000). Mitochondrial intermembrane junctional complexes and
their role in cell death. The Journal of physioloং, 529(1), 11–21.
[81] Cruz-Aguilar, M., Guerrero-de Ferran, C., Tovilla-Canales, J. L., Nava-Castañeda,
A., & Zenteno, J. C. (2016). Characterization of pabpn1 expansion mutations in a
large cohort of mexican patients with oculopharyngeal muscular dystrophy (opmd).
Journal of Investigative Medicine, (pp. jim–2016).
[82] Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014). Control of apop-
tosis by the bcl-2 protein family: implications for physiology and therapy. Nature
reviews Molecular cell bioloং, 15(1), 49.
163
[83] da Silva, F. A., Corte-Real, S., & Goncalves, J. (2008). Recombinant antibodies as
therapeutic agents. BioDrugs, 22(5), 301–314.
[84] da Silva, F. A., Santa-Marta, M., Freitas-Vieira, A., Mascarenhas, P., Barahona, I.,
Moniz-Pereira, J., Gabuzda, D., & Goncalves, J. (2004). Camelized rabbit-derived vh
single-domain intrabodies against vif strongly neutralize hiv-1 infectivity. Journal of
molecular bioloং, 340(3), 525–542.
[85] Dalbo, V. J., Roberts, M. D., Lockwood, C. M., Tucker, P. S., Kreider, R. B., &
Kerksick, C. M. (2009). The effects of age on skeletal muscle and the phospho-
creatine energy system: can creatine supplementation help older adults. Dynamic
Medicine, 8(1), 6.
[86] D’Antona, G., Pellegrino, M. A., Adami, R., Rossi, R., Carlizzi, C. N., Canepari,
M., Saltin, B., & Bottinelli, R. (2003). The effect of ageing and immobilization on
structure and function of human skeletal muscle fibres. The Journal of physioloং,
552(2), 499–511.
[87] Datler, C., Pazarentzos, E., Mahul-Mellier, A.-L., Chaisaklert, W., Hwang, M.-S.,
Osborne, F., & Grimm, S. (2014). Ckmt1 regulates the mitochondrial permeability
transition pore in a process that provides evidence for alternative forms of the com-
plex. J Cell Sci, 127(8), 1816–1828.
[88] David, L., Mallet, C., Mazerbourg, S., Feige, J.-J., & Bailly, S. (2007). Identification
of bmp9 and bmp10 as functional activators of the orphan activin receptor-like ki-
nase 1 (alk1) in endothelial cells. Blood, 109(5), 1953–1961.
[89] Davies, J. E., Rose, C., Sarkar, S., & Rubinsztein, D. C. (2010). Cystamine suppresses
polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy. Sci-
ence translational medicine, 2(34), 34ra40.
[90] Davies, J. E. & Rubinsztein, D. C. (2011). Over-expression of bcl2 rescues muscle
weakness in a mouse model of oculopharyngeal muscular dystrophy. Human molec-
ular genetics, 20(6), 1154–1163.
[91] Davies, J. E., Sarkar, S., & Rubinsztein, D. C. (2006). Trehalose reduces aggregate
formation and delays pathology in a transgenic mouse model of oculopharyngeal
muscular dystrophy. Human molecular genetics, 15(1), 23–31.
164
[92] Davies, J. E., Wang, L., Garcia-Oroz, L., Cook, L. J., Vacher, C., O’Donovan, D. G.,
& Rubinsztein, D. C. (2005). Doxycycline attenuates and delays toxicity of the ocu-
lopharyngeal muscular dystrophy mutation in transgenic mice. Nature medicine,
11(6), 672–677.
[93] De Braekeleer, M. (1991). Hereditary disorders in Saguenay-Lac-St-Jean (Quebec,
Canada). Human heredity, 41(3), 141–146.
[94] De Rosa, V., Iommelli, F., Monti, M., Fonti, R., Votta, G., Stoppelli, M. P., &
Del Vecchio, S. (2015). Reversal of warburg effect and reactivation of oxidative phos-
phorylation by differential inhibition of egfr signaling pathways in non–small cell
lung cancer. Clinical Cancer Research, 21(22), 5110–5120.
[95] De Santis, C., Wade, N. M., Jerry, D. R., Preston, N. P., Glencross, B. D., & Sellars,
M. J. (2011). Growing backwards: an inverted role for the shrimp ortholog of verte-
brate myostatin and GDF11. J Exp Biol, 214(Pt 16), 2671–2677.
[96] Dedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F.,
et al. (2003). Creatine therapy provides neuroprotection after onset of clinical symp-
toms in huntington’s disease transgenic mice. Journal of neurochemistry, 85(6), 1359–
1367.
[97] Delbono, O. (2011). Expression and regulation of excitation-contraction coupling
proteins in aging skeletal muscle. Current aging science, 4(3), 248–259.
[98] Deng, B., Zhang, F., Wen, J., Ye, S., Wang, L., Yang, Y., Gong, P., & Jiang, S. (2017).
The function of myostatin in the regulation of fat mass in mammals. Nutrition &
metabolism, 14(1), 29.
[99] Denkert, C., Budczies, J., Kind, T., Weichert, W., Tablack, P., Sehouli, J., Nies-
porek, S., Könsgen, D., Dietel, M., & Fiehn, O. (2006). Mass spectrometry–based
metabolic profiling reveals different metabolite patterns in invasive ovarian carcino-
mas and ovarian borderline tumors. Cancer research, 66(22), 10795–10804.
[100] Derynck, R., Zhang, Y., & Feng, X.-H. (1998). Transcriptional activators of TGF-β
responses: Smads. Cell, 95(6), 737–740.
[101] Dettmer, K., Aronov, P. A., &Hammock, B. D. (2007). Mass spectrometry-based
metabolomics. Mass spectrometry reviews, 26(1), 51–78.
[102] Di Prospero, N. a. & Fischbeck, K. H. (2005). Therapeutics development for triplet
repeat expansion diseases. Nature reviews. Genetics, 6(10), 756–765.
165
[103] DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J.,
Reeves, P., Pandey, R. K., Rajeev, K. G., et al. (2007). Therapeutic silencing of
mutant huntingtin with sirna attenuates striatal and cortical neuropathology and
behavioral deficits. Proceedings of the National Academy of Sciencॽ, 104(43), 17204–
17209.
[104] Dogra, C., Changotra, H., Wedhas, N., Qin, X., Wergedal, J. E., & Kumar, A.
(2007). TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal
muscle-wasting cytokine. The FASEB Journal, 21(8), 1857–1869.
[105] Dolder, M., Walzel, B., Speer, O., Schlattner, U., &Wallimann, T. (2003). Inhi-
bition of the mitochondrial permeability transition by creatine kinase substrates
requirement for microcompartmentation. Journal of Biological Chemistry, 278(20),
17760–17766.
[106] Doorbar, J. & Griffin, H. (2007). Intrabody strategies for the treatment of human
papillomavirus-associated disease. Expert opinion on biological therapy, 7(5), 677–
689.
[107] Drummond, M. J., Glynn, E. L., Fry, C. S., Dhanani, S., Volpi, E., & Rasmussen,
B. B. (2009). Essential amino acids increase microrna-499,-208b, and-23a and down-
regulate myostatin and myocyte enhancer factor 2c mrna expression in human skele-
tal muscle. The Journal of nutrition, 139(12), 2279–2284.
[Dubach-Powell] Dubach-Powell, J. Quantitative determination of muscle fiber diameter
(minimal Feret’s diameter) and percentage of centralized nuclei. Treat NMD EU,
(2nd).
[109] Dubowitz, V., Sewry, C. A., Oldfors, A., & Lane, R. J. (2013). Muscle biopsy: a
practical approach, expert consult; online and print, 4: muscle biopsy: a practical ap-
proach. Elsevier Health Sciences.
[110] Durieux, A.-C., Amirouche, A., Banzet, S., Koulmann, N., Bonnefoy, R., Pasde-
loup, M., Mouret, C., Bigard, X., Peinnequin, A., & Freyssenet, D. (2007). Ectopic
Expression of Myostatin Induces Atrophy of Adult Skeletal Muscle by Decreasing
Muscle Gene Expression. Endocrinoloং, 148(7), 3140–3147.
[111] Eaton, S., Bartlett, K., & Pourfarzam, M. (1996). Mammalian mitochondrial beta-
oxidation. Biochemical Journal, 320(Pt 2), 345.
[112] Eliasson, P., Andersson, T., Kulas, J., Seemann, P., & Aspenberg, P. (2009). Myo-
statin in tendon maintenance and repair. Growth Factors, 27(4), 247–254.
166
[113] Elkasrawy, M. N. &Hamrick, M.W. (2010). Myostatin (GDF-8) as a key factor
linking muscle mass and bone structure. J Musculoskelet Neuronal Interact, 10(1),
56–63.
[114] Elkina, Y., von Haehling, S., Anker, S. D., & Springer, J. (2011). The role of myo-
statin in muscle wasting: An overview. Journal of Cachexia, Sarcopenia and Muscle,
2(3), 143–151.
[115] Emanuele, E. (2014). Can trehalose prevent neurodegeneration? insights from exper-
imental studies. Current drug targets, 15(5), 551–557.
[116] Emily, H.-Y. C., Wei, M. C., Weiler, S., Flavell, R. A., Mak, T. W., Lindsten, T., &
Korsmeyer, S. J. (2001). Bcl-2, bcl-xl sequester bh3 domain-only molecules prevent-
ing bax-and bak-mediated mitochondrial apoptosis. Molecular cell, 8(3), 705–711.
[117] Evans, W. J. & Lexell, J. (1995). Human aging, muscle mass, and fiber type composi-
tion. The Journals of Gerontoloং Seriॽ A: Biological Sciencॽ and Medical Sciencॽ,
50(Special_Issue), 11–16.
[118] Fakhfakh, R., Lee, S. J., & Tremblay, J. P. (2012). Administration of a soluble activin
type IIB receptor promotes the transplantation of human myoblasts in dystrophic
mice. Cell Transplant, 21(7), 1419–1430.
[119] Fan, X., Messaed, C., Dion, P., Laganiere, J., Brais, B., Karpati, G., & Rouleau, G. A.
(2003). HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscu-
lar dystrophy. Can J Neurol Sci, 30(3), 244–251.
[120] Felber, S., Skladal, D., Wyss, M., Kremser, C., Koller, A., & Sperl, W. (2000). Oral
creatine supplementation in duchenne muscular dystrophy: a clinical and 31 p mag-
netic resonance spectroscopy study. Neurological research, 22(2), 145–150.
[121] Feldman, B. J., Streeper, R. S., Farese, R. V., & Yamamoto, K. R. (2006). Myostatin
modulates adipogenesis to generate adipocytes with favorable metabolic effects. Pro-
ceedings of the National Academy of Sciencॽ, 103(42), 15675–15680.
[122] Flück, M. &Hoppeler, H. (2003). Molecular basis of skeletal muscle plasticity-from
gene to form and function. In Reviews of physioloং, biochemistry and pharmacoloং
(pp. 159–216). Springer.
[123] Foley, J. W., Bercury, S. D., Finn, P., Cheng, S. H., Scheule, R. K., & Ziegler, R. J.
(2010). Evaluation of systemic follistatin as an adjuvant to stimulate muscle repair
and improve motor function in Pompe mice. Molecular Therapy, 18(9), 1584–1591.
167
[124] Forbes, D., Jackman, M., Bishop, A., Thomas, M., Kambadur, R., & Sharma, M.
(2006). Myostatin auto‐regulates its expression by feedback loop through Smad7
dependent mechanism. Journal of cellular physioloং, 206(1), 264–272.
[125] Foster, K., Graham, I. R., Otto, A., Foster, H., Trollet, C., Yaworsky, P. J., Walsh,
F. S., Bickham, D., Curtin, N. A., Kawar, S. L., & Others (2009). Adeno-associated
virus-8-mediated intravenous transfer of myostatin propeptide leads to systemic
functional improvements of slow but not fast muscle. Rejuvenation research, 12(2),
85–94.
[126] Fournier, B., Murray, B., Gutzwiller, S., Marcaletti, S., Marcellin, D., Bergling, S.,
Brachat, S., Persohn, E., Pierrel, E., Bombard, F., et al. (2012). Blockade of the activin
receptor iib activates functional brown adipogenesis and thermogenesis by inducing
mitochondrial oxidative metabolism. Molecular and cellular bioloং, 32(14), 2871–
2879.
[127] Frank, R. &Hargreaves, R. (2003). Clinical biomarkers in drug discovery and devel-
opment. Nature Reviews Drug Discovery, 2(7), 566.
[128] Freise, C., Erben, U., Muche, M., Farndale, R., Zeitz, M., Somasundaram, R., &
Ruehl, M. (2009). The alpha 2 chain of collagen type vi sequesters latent proforms
of matrix-metalloproteinases and modulates their activation and activity. Matrix
Bioloং, 28(8), 480–489.
[129] Frolkis, A., Knox, C., Lim, E., Jewison, T., Law, V., Hau, D. D., Liu, P., Gautam,
B., Ly, S., Guo, A. C., et al. (2009). Smpdb: the small molecule pathway database.
Nucleic acids research, 38(suppl_1), D480–D487.
[130] Fulzele, S., Arounleut, P., Cain, M., Herberg, S., Hunter, M., Wenger, K., &Ham-
rick, M.W. (2010). Role of myostatin (GDF-8) signaling in the human anterior
cruciate ligament. J Orthop Rॽ, 28(8), 1113–1118.
[131] Gabillard, J. C., Biga, P. R., Rescan, P. Y., & Seiliez, I. (2013). Revisiting the paradigm
of myostatin in vertebrates: insights from fishes. Gen Comp Endocrinol, 194, 45–54.
[132] Gagnon, K. T., Pendergraff, H. M., Deleavey, G. F., Swayze, E. E., Potier, P., Ran-
dolph, J., Roesch, E. B., Chattopadhyaya, J., Damha, M. J., Bennett, C. F., et al.
(2010). Allele-selective inhibition of mutant huntingtin expression with antisense
oligonucleotides targeting the expanded cag repeat. Biochemistry, 49(47), 10166–
10178.
168
[133] García-Castañeda, M., Vega, A. V., Rodríguez, R., Montiel-Jaen, M. G., Cisneros, B.,
Zarain-Herzberg, A., & Avila, G. (2017). Functional impact of an oculopharyngeal
muscular dystrophy mutation in pabpn1. The Journal of physioloং, 595(13), 4167–
4187.
[134] Garcin, C. L. &Habib, S. J. (2017). A comparative perspective on wnt/β-catenin
signalling in cell fate determination. InAsymmetric Cell Division in Development,
Differentiation and Cancer (pp. 323–350). Springer.
[135] Garikipati, D. K., Gahr, S. A., Roalson, E. H., & Rodgers, B. D. (2007). Charac-
terization of Rainbow Trout Myostatin-2 Genes (rtMSTN-2a and -2b): Genomic
Organization Differential Expression, and Pseudogenization. Endocrinoloং, 148(5),
2106–2115.
[136] Gidaro, T., Negroni, E., Perié, S., Mirabella, M., Lainé, J., St Guily, J. L., Butler-
Browne, G., Mouly, V., & Trollet, C. (2013). Atrophy, fibrosis, and increased
pax7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy
patients. Journal of Neuropatholoং & Experimental Neuroloং, 72(3), 234–243.
[137] Gilson, H., Schakman, O., Combaret, L., Lause, P., Grobet, L., Attaix, D., Ke-
telslegers, J. M., & Thissen, J. P. (2007). Myostatin gene deletion prevents
glucocorticoid-induced muscle atrophy. Endocrinoloং, 148(1), 452–460.
[138] Gilson, H., Schakman, O., Kalista, S., Lause, P., Tsuchida, K., & Thissen, J.-P.
(2009). Follistatin induces muscle hypertrophy through satellite cell proliferation
and inhibition of both myostatin and activin. American Journal of Physioloং-
Endocrinoloং and Metabolism, 297(1), E157–E164.
[139] Giorgi, C., Baldassari, F., Bononi, A., Bonora, M., DeMarchi, E., Marchi, S., Mis-
siroli, S., Patergnani, S., Rimessi, A., Suski, J. M., et al. (2012). Mitochondrial ca2+
and apoptosis. Cell calcium, 52(1), 36–43.
[140] Gloor, M., Fasler, S., Fischmann, A., Haas, T., Bieri, O., Heinimann, K., Wetzel,
S. G., Scheffler, K., & Fischer, D. (2011). Quantification of fat infiltration in ocu-
lopharyngeal muscular dystrophy: comparison of three mr imaging methods. Jour-
nal of magnetic resonance imaging, 33(1), 203–210.
[141] Gonzalez-Cadavid, N. F., Taylor, W. E., Yarasheski, K., Sinha-Hikim, I., Ma, K., Ez-
zat, S., Shen, R., Lalani, R., Asa, S., Mamita, M., Gonzalez-Cadavid, N. F., Taylor,
W. E., Yarasheski, K., Sinha-Hikim, I., Ma, K., Ezzat, S., Shen, R., Lalani, R., Asa, S.,
Mamita, M., Nair, G., Arver, S., & Bhasin, S. (1998). Organization of the human
169
myostatin gene and expression in healthy men and HIV-infected men with muscle
wasting. Proceedings of the National Academy of Sciencॽ of the United Statॽ of
America, 95(25), 14938–14943.
[142] Gorgey, A. & Dudley, G. (2007). Skeletal muscle atrophy and increased intramuscu-
lar fat after incomplete spinal cord injury. Spinal cord, 45(4), 304.
[143] Graham, Z. A., Collier, L., Peng, Y., Saez, J. C., Bauman, W. A., Qin, W., & Cardozo,
C. P. (2016). A Soluble Activin Receptor IIB Fails to Prevent Muscle Atrophy in a
Mouse Model of Spinal Cord Injury. J Neurotrauma, 33(12), 1128–1135.
[144] Griffin, C. A., Kafadar, K. A., & Pavlath, G. K. (2009). MOR23 Promotes Muscle
Regeneration and Regulates Cell Adhesion andMigration. Developmental Cell,
17(5), 649–661.
[145] Griffin, J. L. (2006). Understanding mouse models of disease through
metabolomics. Current opinion in chemical bioloং, 10(4), 309–315.
[146] Groot, A. J., Gort, E. H., van der Wall, E., van Diest, P. J., & Vooijs, M. (2008). Con-
ditional inactivation of hif-1 using intrabodies. Analytical Cellular Patholoং, 30(5),
397–409.
[147] Groppe, J., Hinck, C. S., Samavarchi-Tehrani, P., Zubieta, C., Schuermann, J. P.,
Taylor, A. B., Schwarz, P. M., Wrana, J. L., &Hinck, A. P. (2008). Cooperative
assembly of TGF-β superfamily signaling complexes is mediated by two disparate
mechanisms and distinct modes of receptor binding. Molecular cell, 29(2), 157–168.
[148] Guimarães-Ferreira, L. (2014). Role of the phosphocreatine system on energetic
homeostasis in skeletal and cardiac muscles. Einstein (Sao Paulo), 12(1), 126–131.
[149] Guo, T., Jou, W., Chanturiya, T., Portas, J., Gavrilova, O., &McPherron, A. C.
(2009). Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass
and improves insulin sensitivity. PloS one, 4(3), e4937.
[150] Guo, W., Miller, A. D., Pencina, K., Wong, S., Lee, A., Yee, M., Toraldo, G., Jasuja,
R., & Bhasin, S. (2016). Joint dysfunction and functional decline in middle age
myostatin null mice. Bone, 83, 141–148.
[151] Guttridge, D. C., Mayo, M.W., Madrid, L. V., Wang, C.-Y., & Baldwin Jr, A. S.
(2000). NF-κB-induced loss of MyoDmessenger RNA: possible role in muscle
decay and cachexia. Science, 289(5488), 2363–2366.
170
[152] Halket, J. M., Waterman, D., Przyborowska, A. M., Patel, R. K., Fraser, P. D., &
Bramley, P. M. (2004). Chemical derivatization and mass spectral libraries in
metabolic profiling by gc/ms and lc/ms/ms. Journal of experimental botany, 56(410),
219–243.
[153] Hamrick, M.W., McPherron, A. C., & Lovejoy, C. O. (2002). Bone mineral content
and density in the humerus of adult myostatin-deficient mice. Calcif Tissue Int,
71(1), 63–68.
[154] Hamrick, M.W., Pennington, C., & Byron, C. D. (2003). Bone architecture and disc
degeneration in the lumbar spine of mice lacking GDF-8 (myostatin). J Orthop Rॽ,
21(6), 1025–1032.
[155] Hamrick, M.W., Samaddar, T., Pennington, C., &McCormick, J. (2006). Increased
muscle mass with myostatin deficiency improves gains in bone strength with exer-
cise. J Bone Miner Rॽ, 21(3), 477–483.
[156] Hamrick, M.W., Shi, X., Zhang, W., Pennington, C., Thakore, H., Haque, M.,
Kang, B., Isales, C. M., Fulzele, S., &Wenger, K. H. (2007). Loss of myostatin
(GDF8) function increases osteogenic differentiation of bone marrow-derived mes-
enchymal stem cells but the osteogenic effect is ablated with unloading. Bone, 40(6),
1544–1553.
[157] Hanaoka, B. Y., Peterson, C. A., Horbinski, C., & Crofford, L. J. (2012). Implications
of glucocorticoid therapy in idiopathic inflammatory myopathies. Nature Reviews
Rheumatoloং, 8(8), 448.
[158] Harish, P., Malerba, A., Dickson, G., & Bachtarzi, H. (2015). Progress on Gene
Therapy, Cell Therapy, and Pharmacological Strategies Toward the Treatment of
Oculopharyngeal Muscular Dystrophy. Human gene therapy, 26(5), 286–292.
[159] Harmsen, M. &DeHaard, H. (2007). Properties, production, and applications of
camelid single-domain antibody fragments. Applied microbioloং and biotechnoloং,
77(1), 13–22.
[160] Hasan, N. A. K. A. K., Kamal, H. M., &Hussein, Z. A. (2016). Relation between
body mass index percentile and muscle strength and endurance. Eংptian Journal of
Medical Human Genetics, 17(4), 367–372.
[161] Hathout, Y., Seol, H., Han, M. H. J., Zhang, A., Brown, K. J., & Hoffman, E. P.
(2016). Clinical utility of serum biomarkers in duchenne muscular dystrophy. Clini-
cal proteomics, 13(1), 9.
171
[162] Hayashi, H., Abdollah, S., Qiu, Y., Cai, J., Xu, Y.-Y., Grinnell, B. W., Richardson,
M. A., Topper, J. N., Gimbrone, M. A., &Wrana, J. L. (1997). TheMAD-related
protein Smad7 associates with the TGFβ receptor and functions as an antagonist of
TGFβ signaling. Cell, 89(7), 1165–1173.
[163] Heineke, J., Auger-Messier, M., Xu, J., Sargent, M., York, A., Welle, S., &
Molkentin, J. D. (2010). Genetic deletion of myostatin from the heart prevents
skeletal muscle atrophy in heart failure. Circulation, 121(3), 419–425.
[164] Hepple, R. T. (2012). Muscle atrophy is not always sarcopenia. Journal of Applied
Physioloং, 113(4), 677–679.
[165] Hilber, K., Galler, S., Gohlsch, B., & Pette, D. (1999). Kinetic properties of myosin
heavy chain isoforms in single fibers from human skeletal muscle. FEBS letters,
455(3), 267–270.
[166] Hill, J. J., Davies, M. V., Pearson, A. A., Wang, J. H., Hewick, R. M., Wolfman,
N. M., &Qiu, Y. (2002). The myostatin propeptide and the follistatin-related gene
are inhibitory binding proteins of myostatin in normal serum. Journal of Biological
Chemistry, 277(43), 40735–40741.
[167] Hill, J. J., Qiu, Y., Hewick, R. M., &Wolfman, N. M. (2003). Regulation of myo-
statin in vivo by growth and differentiation factor-associated serum protein-1: a
novel protein with protease inhibitor and follistatin domains. Molecular endocrinol-
oং, 17(6), 1144–1154.
[168] Hino, H., Araki, K., Uyana, E., Takeya, M., Araki, M., Yoshinobu, K., Miike, K.,
Kawazoe, Y., Maeda, Y., Uchino, M., & Yamamura, K. I. (2004). Myopathy pheno-
type in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal
muscular dystrophy. Human Molecular Genetics, 13(2), 181–190.
[169] Hittel, D. S., Axelson, M., Sarna, N., Shearer, J., Huffman, K. M., & Kraus, W. E.
(2010). Myostatin decreases with aerobic exercise and associates with insulin resis-
tance. Medicine and science in sports and exercise, 42(11), 2023.
[170] Hittel, D. S., Berggren, J. R., Shearer, J., Boyle, K., &Houmard, J. A. (2009). In-
creased secretion and expression of myostatin in skeletal muscle from extremely
obese women. Diabetॽ, 58(1), 30–38.
172
[171] Hjorth, M., Pourteymour, S., Görgens, S., Langleite, T., Lee, S., Holen, T., Gulseth,
H., Birkeland, K., Jensen, J., Drevon, C., et al. (2016). Myostatin in relation to phys-
ical activity and dysglycaemia and its effect on energy metabolism in human skeletal
muscle cells. Acta Physiologica, 217(1), 45–60.
[172] Holmes, E., Tsang, T. M., Huang, J. T.-J., Leweke, F. M., Koethe, D., Gerth, C. W.,
Nolden, B. M., Gross, S., Schreiber, D., Nicholson, J. K., et al. (2006). Metabolic
profiling of csf: evidence that early intervention may impact on disease progression
and outcome in schizophrenia. PLoS medicine, 3(8), e327.
[173] Holzbaur, E. L. F., Howland, D. S., Weber, N., Wallace, K., She, Y., Kwak, S., Tchis-
tiakova, L. a., Murphy, E., Hinson, J., Karim, R., Tan, X. Y., Kelley, P., McGill,
K. C., Williams, G., Hobbs, C., Doherty, P., Zaleska, M. M., Pangalos, M. N., &
Walsh, F. S. (2006). Myostatin inhibition slows muscle atrophy in rodent models of
amyotrophic lateral sclerosis. Neurobioloং of Disease, 23(3), 697–707.
[174] Hoogaars, W. M., Mouisel, E., Pasternack, A., Hulmi, J. J., Relizani, K., Schuelke,
M., Schirwis, E., Garcia, L., Ritvos, O., Ferry, A., t Hoen, P. A., & Amthor, H.
(2012). Combined effect of AAV-U7-induced dystrophin exon skipping and solu-
ble activin Type IIB receptor in mdx mice. Hum Gene Ther, 23(12), 1269–1279.
[175] Hsu, H., Xiong, J., & Goeddel, D. V. (1995). The TNF receptor 1-associated protein
TRADD signals cell death and NF-κB activation. Cell, 81(4), 495–504.
[176] Hu, J., Matsui, M., Gagnon, K. T., Schwartz, J. C., Gabillet, S., Arar, K., Wu, J.,
Bezprozvanny, I., & Corey, D. R. (2009). Allele-specific silencing of mutant hunt-
ingtin and ataxin-3 genes by targeting expanded cag repeats in mrnas. Nature
biotechnoloং, 27(5), 478.
[177] Huang, Z., Chen, X., & Chen, D. (2011). Myostatin: A novel insight into its role in
metabolism signal pathways, and expression regulation. Cellular signalling, 23(9),
1441–1446.
[178] Huang, Z., Chen, X., Yu, B., He, J., & Chen, D. (2012). Microrna-27a promotes
myoblast proliferation by targeting myostatin. Biochemical and biophysical research
communications, 423(2), 265–269.
[179] Hughes, M. C., Ramos, S. V., Polidovitch, N., Backx, P., & Perry, C. G. (2017).
Mitochondrial-targeted peptide sbt-20 improves mitochondrial bioenergetics in
duchenne muscular dystrophy in a mitochondrial creatine kinase dependent man-
ner. The FASEB Journal, 31(1 Supplement), 696–7.
173
[180] Hunter, R. B. & Kandarian, S. C. (2004). Disruption of either the Nfkb1 or the Bcl3
gene inhibits skeletal muscle atrophy. The Journal of clinical investigation, 114(10),
1504–1511.
[181] Huxley, A. F. C. . (1974). Muscular contraction. J Physiol, 243, 1–43.
[182] Huxley, H. &Hanson, J. (1954). Changes in the cross-striations of muscle during
contraction and stretch and their structural interpretation. Nature, 173(4412), 973–
976.
[183] Ichijo, H., Nishida, E., Irie, K., ten Dijke, P., Saitoh, M., Moriguchi, T., Takagi, M.,
Matsumoto, K., Miyazono, K., & Gotoh, Y. (1997). Induction of apoptosis by
ASK1, a mammalianMAPKKK that activates SAPK/JNK and p38 signaling path-
ways. Science, 275(5296), 90–94.
[184] Jain, N. K. & Roy, I. (2010). Trehalose and protein stability. Current protocols in
protein science, (pp. 4–9).
[185] Janssen, I., Heymsfield, S. B., Wang, Z., & Ross, R. (2000). Skeletal muscle mass and
distribution in 468 men and women aged 18–88 yr. Journal of applied physioloং,
89(1), 81–88.
[186] Jason, S., Ramasamy, T. S., Murphy, N., Holt, M. K., Czapiewski, R., Wei, S.-K.,
& Cui, W. (2015). Pi3k/mtorc2 regulates tgf-β/activin signalling by modulating
smad2/3 activity via linker phosphorylation. Nature communications, 6, 7212.
[187] Jenal, M., Elkon, R., Loayza-Puch, F., Van Haaften, G., Kühn, U., Menzies, F. M.,
Vrielink, J. a. F. O., Bos, A. J., Drost, J., Rooijers, K., Rubinsztein, D. C., & Agami,
R. (2012). The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and
polyadenylation sites. Cell, 149(3), 538–553.
[188] Jeong, J., Conboy, M. J., & Conboy, I. M. (2013). Pharmacological inhibition of
myostatin/TGF-beta receptor/pSmad3 signaling rescues muscle regenerative re-
sponses in mouse model of type 1 diabetes. Acta Pharmacol Sin, 34(8), 1052–1060.
[189] Jewison, T., Su, Y., Disfany, F. M., Liang, Y., Knox, C., Maciejewski, A., Poelzer, J.,
Huynh, J., Zhou, Y., Arndt, D., et al. (2013). Smpdb 2.0: big improvements to the
small molecule pathway database. Nucleic acids research, 42(D1), D478–D484.
[190] Ji, S., Losinski, R. L., Cornelius, S. G., Frank, G. R., Willis, G. M., Gerrard, D. E.,
Depreux, F. F., & Spurlock, M. E. (1998). Myostatin expression in porcine tissues:
174
tissue specificity and developmental and postnatal regulation. Am J Physiol, 275,
R1265—-73.
[191] Jiang, Y., Woronicz, J. D., Liu, W., & Goeddel, D. V. (1999). Prevention of consti-
tutive TNF receptor 1 signaling by silencer of death domains. Science, 283(5401),
543–546.
[192] Jianxiang, X., Dengke, P., Jie, Z., Jianwu, W., Xiaohong, H., Yuehui, M., & Ning, L.
(2015). Metabonomic study of the biochemical profiles of heterozygous myostatin
knockout swine. Frontiers of Agricultural Science and Engineering, 2(1), 90–99.
[193] Johnston, I. A. & Abercromby, M. (2004). Rapid evolution of muscle fibre num-
ber in post-glacial populations of Arctic charr Salvelinus alpinus. The Journal of
experimental bioloং, (pp. 4343–4360).
[194] Johnston, I. a., Abercromby, M., & Andersen, Ø. (2005). Loss of muscle fibres in a
landlocked dwarf Atlantic salmon population. Bioloং letters, 1(4), 419–422.
[195] Johnston, I. A., Bower, N. I., &Macqueen, D. J. (2011). Growth and the regulation
of myotomal muscle mass in teleost fish. The Journal of Experimental Bioloং, 214,
1617–1628.
[196] Joseloff, E., Sha, W., Bell, S. C., Wetmore, D. R., Lawton, K. A., Milburn, M. V.,
Ryals, J. A., Guo, L., &Muhlebach, M. S. (2014). Serummetabolomics indicate
altered cellular energy metabolism in children with cystic fibrosis. Pediatric pul-
monoloং, 49(5), 463–472.
[197] Kalyani, R. R., Corriere, M., & Ferrucci, L. (2014). Age-related and disease-related
muscle loss: the effect of diabetes, obesity, and other diseases. The lancet Diabetॽ &
endocrinoloং, 2(10), 819–829.
[198] Kambadur, R., Sharma, M., Smith, T. P., & Bass, J. J. (1997). Mutations in myo-
statin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Rॽ,
7, 910–916.
[199] Kan, H., Klomp, D., Wohlgemuth, M., van Loosbroek-Wagemans, I., van Engelen,
B., Padberg, G., &Heerschap, A. (2010). Only fat infiltrated muscles in resting lower
leg of fshd patients show disturbed energy metabolism. NMR in biomedicine, 23(6),
563–568.
175
[200] Kang, J. K., Malerba, A., Popplewell, L., Foster, K., & Dickson, G. (2011). Antisense-
induced myostatin exon skipping leads to muscle hypertrophy in mice following
octa-guanidine morpholino oligomer treatment. Mol Ther, 19(1), 159–164.
[201] Karo, J., Peterson, P., & Vendelin, M. (2012). Molecular dynamics simulations of cre-
atine kinase and adenine nucleotide translocase in mitochondrial membrane patch.
Journal of Biological Chemistry, 287(10), 7467–7476.
[202] Kawada, S., Tachi, C., & Ishii, N. (2001). Content and localization of myostatin in
mouse skeletal muscles during aging, mechanical unloading and reloading. Journal
of Muscle Research & Cell Motility, 22(8), 627–633.
[203] Kellum, E., Starr, H., Arounleut, P., Immel, D., Fulzele, S., Wenger, K., &Hamrick,
M.W. (2009). Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5
expression, and callus bone volume. Bone, 44(1), 17–23.
[204] Kemaladewi, D. U., Hoogaars, W. M., van Heiningen, S. H., Terlouw, S., de Gorter,
D. J., den Dunnen, J. T., van Ommen, G. J., Aartsma-Rus, A., ten Dijke, P., &
t Hoen, P. A. (2011). Dual exon skipping in myostatin and dystrophin for Duchenne
muscular dystrophy. BMC Med Genomics, 4, 36.
[205] Kemp, P., Paul, R., Lee, J., Donaldson, A., Connolly, M., Sharif, M., Natanek, S.,
Rosendahl, U., Polkey, M., & Griffiths, M. (2017). mir-422a suppresses smad4 pro-
tein expression and promotes resistance to muscle loss.
[206] Kharraz, Y., Guerra, J., Pessina, P., Serrano, A. L., &Muñoz-Cánoves, P. (2014).
Understanding the process of fibrosis in Duchenne muscular dystrophy. BioMed
research international, 2014.
[207] Kim, K. M., Jang, H. C., & Lim, S. (2016). Differences among skeletal muscle mass
indices derived from height-, weight-, and body mass index-adjusted models in as-
sessing sarcopenia. The Korean journal of internal medicine, 31(4), 643.
[208] Kim, Y. J., Noguchi, S., Hayashi, Y. K., Tsukahara, T., Shimizu, T., & Arahata, K.
(2001). The product of an oculopharyngeal muscular dystrophy gene, poly(A)-
binding protein 2, interacts with SKIP and stimulates muscle-specific gene expres-
sion. Human molecular genetics, 10(11), 1129–1139.
[209] Kind, T., Tolstikov, V., Fiehn, O., &Weiss, R. H. (2007). A comprehensive uri-
nary metabolomic approach for identifying kidney cancer. Analytical biochemistry,
363(2), 185–195.
176
[210] Klein, P., Oloko, M., Roth, F., Montel, V., Malerba, A., Jarmin, S., Gidaro, T.,
Popplewell, L., Perie, S., Lacau St Guily, J., et al. (2016). Nuclear poly (a)-binding
protein aggregates misplace a pre-mrna outside of sc35 speckle causing its abnormal
splicing. Nucleic acids research, 44(22), 10929–10945.
[211] Klimek, M. E. B., Aydogdu, T., Link, M. J., Pons, M., Koniaris, L. G., Zimmers,
T. A., Benny Klimek, M. E., Aydogdu, T., Link, M. J., Pons, M., Koniaris, L. G., &
Zimmers, T. A. (2010). Acute inhibition of myostatin-family proteins preserves
skeletal muscle in mouse models of cancer cachexia. Biochemical and biophysical
research communications, 391(3), 1548–1554.
[212] Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., An-
dreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F.
(1999). Neuroprotective effects of creatine in a transgenic animal model of amy-
otrophic lateral sclerosis. Nature medicine, 5(3), 347.
[213] Klivenyi, P., Gardian, G., Calingasan, N. Y., Yang, L., & Beal, M. F. (2003). Ad-
ditive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against
dopamine depletion in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (mptp)
mouse model of parkinson’s disease. Journal of Molecular Neuroscience, 21(3), 191–
198.
[214] Klivenyi, P., Kiaei, M., Gardian, G., Calingasan, N. Y., & Beal, M. F. (2004). Ad-
ditive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a trans-
genic mouse model of amyotrophic lateral sclerosis. Journal of neurochemistry, 88(3),
576–582.
[215] Kornegay, J. N., Childers, M. K., Bogan, D. J., Bogan, J. R., Nghiem, P., Wang, J.,
Fan, Z., Howard, J. F., Schatzberg, S. J., Dow, J. L., & Others (2012). The paradox
of muscle hypertrophy in muscular dystrophy. Physical medicine and rehabilitation
clinics of North America, 23(1), 149–172.
[216] Krüger, U., Wang, Y., Kumar, S., &Mandelkow, E.-M. (2012). Autophagic degra-
dation of tau in primary neurons and its enhancement by trehalose. Neurobioloং of
aging, 33(10), 2291–2305.
[217] Larsson, L. (1978). Morphological and functional characteristics of the aging skeletal
muscle in man. Acta Physiol Scan (Sappl).
[218] Larsson, L., Li, X., & Frontera, W. R. (1997). Effects of aging on shortening velocity
and myosin isoform composition in single human skeletal muscle cells. American
Journal of Physioloং-Cell Physioloং, 272(2), C638——–C649.
177
[219] Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H.,
Cavino, K., Na, E., Papatheodorou, A., et al. (2017). Activin a more prominently
regulates muscle mass in primates than does gdf8. Nature Communications, 8, 15153.
[220] Latres, E., Pangilinan, J., Miloscio, L., Bauerlein, R., Na, E., Potocky, T. B., Huang,
Y., Eckersdorff, M., Rafique, A., Mastaitis, J., & Others (2015). Myostatin blockade
with a fully human monoclonal antibody induces muscle hypertrophy and reverses
muscle atrophy in young and aged mice. Skeletal muscle, 5(1), 34.
[221] LeBrasseur, N. K., Schelhorn, T. M., Bernardo, B. L., Cosgrove, P. G., Loria, P. M.,
& Brown, T. A. (2009). Myostatin inhibition enhances the effects of exercise on
performance and metabolic outcomes in aged mice. Journals of Gerontoloং Seriॽ
A: Biomedical Sciencॽ and Medical Sciencॽ, 64(9), 940–948.
[222] Lee, E. K., Lee, Y. S., Han, I.-O., & Park, S. H. (2007). Expression of caveolin-1
reduces cellular responses to TGF-β1 through down-regulating the expression of
TGF-β type II receptor gene in NIH3T3 fibroblast cells. Biochemical and biophysical
research communications, 359(2), 385–390.
[223] Lee, J. J. & Yokota, T. (2013). Antisense therapy in neurology. Journal of personalized
medicine, 3(3), 144–176.
[224] Lee, S.-J. (2004). Regulation of muscle mass by myostatin. Annual review of cell
and developmental bioloং, 20, 61–86.
[225] Lee, S.-J., Huynh, T. V., Lee, Y.-S., Sebald, S. M., Wilcox-Adelman, S. A., Iwamori,
N., Lepper, C., Matzuk, M. M., & Fan, C.-M. (2012). Role of satellite cells versus
myofibers in muscle hypertrophy induced by inhibition of the myostatin/activin
signaling pathway. Proceedings of the National Academy of Sciencॽ, 109(35), E2353–
E2360.
[226] Lee, S.-J., Lee, Y.-S., Zimmers, T. A., Soleimani, A., Matzuk, M. M., Tsuchida, K.,
Cohn, R. D., & Barton, E. R. (2010). Regulation of muscle mass by follistatin and
activins. Molecular endocrinoloং, 24(10), 1998–2008.
[227] Lee, S. J. &McPherron, a. C. (2001). Regulation of myostatin activity and muscle
growth. Proceedings of the National Academy of Sciencॽ of the United Statॽ of
America, 98(16), 9306–9311.
178
[228] Lee, S.-J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E. P., Tomkinson,
K. N., Wright, J. F., Barker, C., Ehrmantraut, G., &Holmstrom, J. (2005). Reg-
ulation of muscle growth by multiple ligands signaling through activin type II re-
ceptors. Proceedings of the National Academy of Sciencॽ of the United Statॽ of
America, 102(50), 18117–18122.
[229] Lenk, K., Schur, R., Linke, A., Erbs, S., Matsumoto, Y., Adams, V., & Schuler, G.
(2009). Impact of exercise training on myostatin expression in the myocardium and
skeletal muscle in a chronic heart failure model. European journal of heart failure,
11(4), 342–348.
[230] Lezza, A., Cormio, A., Gerardi, P., Silvestri, G., Servidei, S., Serlenga, L., Cantatore,
P., & Gadaleta, M. N. (1997). Mitochondrial dna deletions in oculopharyngeal mus-
cular dystrophy. FEBS letters, 418(1-2), 167–170.
[231] Li, F., Yang, H., Duan, Y., & Yin, Y. (2011). Myostatin regulates preadipocyte differ-
entiation and lipid metabolism of adipocyte via erk1/2. Cell bioloং international,
35(11), 1141–1146.
[232] Li, Y.-p., Schwartz, R. J., Waddell, I. D., Holloway, B. R., & Reid, M. B. (1998).
Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-
κB activation in response to tumor necrosis factor α. The FASEB Journal, 12(10),
871–880.
[233] Li, Z. B., Kollias, H. D., &Wagner, K. R. (2008). Myostatin directly regulates skele-
tal muscle fibrosis. Journal of Biological Chemistry, 283(28), 19371–19378.
[234] Li, Z. B., Zhang, J., &Wagner, K. R. (2012). Inhibition of myostatin reverses muscle
fibrosis through apoptosis. J Cell Sci, 125(17), 3957–3965.
[235] Lin, J., Arnold, H. B., Della-Fera, M. A., Azain, M. J., Hartzell, D. L., & Baile, C. A.
(2002). Myostatin knockout in mice increases myogenesis and decreases adipogene-
sis. Biochemical and biophysical research communications, 291(3), 701–706.
[236] Lipina, C., Kendall, H., McPherron, A. C., Taylor, P. M., &Hundal, H. S. (2010).
Mechanisms involved in the enhancement of mammalian target of rapamycin sig-
nalling and hypertrophy in skeletal muscle of myostatin-deficient mice. FEBS Let-
ters, 584(11), 2403–2408.
[237] Lisanti, M. P. (2001). Caveolins in Signaling, Oncogenic Transformation, andMus-
cular Dystrophy. Biochemical Society Transactions, 29(3), A64—-A64.
179
[238] Lo, P. C. H. & Frasch, M. (1999). Sequence and expression of myoglianin a novel
Drosophila gene of the TGF-β superfamily. Mechanisms of Development, 86(1-2),
171–175.
[239] Lodderstedt, G., Hess, S., Hause, G., Scheuermann, T., Scheibel, T., & Schwarz, E.
(2007). Effect of oculopharyngeal muscular dystrophy-associated extension of seven
alanines on the fibrillation properties of the N-terminal domain of PABPN1. FEBS
J, 274(2), 346–355.
[240] Lu-Nguyen, N., Malerba, A., Popplewell, L., Schnell, F., Hanson, G., & Dickson, G.
(2017). Systemic Antisense Therapeutics for Dystrophin andMyostatin Exon Splice
Modulation Improve Muscle Pathology of Adult mdxMice. Molecular Therapy-
Nucleic Acids, 6, 15–28.
[241] Lu-Nguyen, N. B., Jarmin, S. A., Saleh, A. F., Popplewell, L., Gait, M. J., & Dickson,
G. (2015). Combination Antisense Treatment for Destructive Exon Skipping of
Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdxMice.
Mol Ther, 23(8), 1341–1348.
[242] Luk, H., Lo, I., Fu, K., Lui, C. H., Tong, T. M., Chan, D. H., & Lam, S. T. (2013).
Oculopharyngeal muscular dystrophy: underdiagnosed disease in hong kong. Hong
Kong Med J, 19(6), 556–9.
[243] Lyons, J.-A., Haring, J. S., & Biga, P. R. (2010). Myostatin expression, lympho-
cyte population, and potential cytokine production correlate with predisposition to
high-fat diet induced obesity in mice. PloS one, 5(9), e12928.
[244] MacLea, K. S., Covi, J. A., Kim, H.-W., Chao, E., Medler, S., Chang, E. S., &Mykles,
D. L. (2010). Myostatin from the American lobster, Homarus americanus: cloning
and effects of molting on expression in skeletal muscles. Comparative Biochemistry
and Physioloং Part A: Molecular & Integrative Physioloং, 157(4), 328–337.
[245] Malerba, A., Kang, J. K., McClorey, G., Saleh, A. F., Popplewell, L., Gait, M. J.,
Wood, M. J., & Dickson, G. (2012). Dual Myostatin and Dystrophin Exon Skipping
byMorpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is
a Promising Therapeutic Strategy for the Treatment of DuchenneMuscular Dystro-
phy. Mol Ther Nucleic Acids, 1, e62.
[246] Malerba, A., Klein, P., Bachtarzi, H., Jarmin, S. A., Cordova, G., Ferry, A., Strings,
V., Espinoza, M. P., Mamchaoui, K., Blumen, S. C., & Others (2017). PABPN1 gene
therapy for oculopharyngeal muscular dystrophy. Nature Communications, 8.
180
[247] Manjaly, J. G., Vaughan-Shaw, P. G., Dale, O. T., Tyler, S., Corlett, J. C., & Frost,
R. A. (2012). Cricopharyngeal dilatation for the long-term treatment of dysphagia in
oculopharyngeal muscular dystrophy. Dysphagia, 27(2), 216–220.
[248] Mankodi, A., Wheeler, T. M., Shetty, R., Salceies, K. M., Becher, M. W., & Thorn-
ton, C. a. (2012). Progressive myopathy in an inducible mouse model of oculopha-
ryngeal muscular dystrophy. Neurobioloং of Disease, 45(1), 539–546.
[249] Mann, C. J., Perdiguero, E., Kharraz, Y., Aguilar, S., Pessina, P., Serrano, A. L., &
Muñoz-Cánoves, P. (2011). Aberrant repair and fibrosis development in skeletal
muscle. Skeletal muscle, 1(1), 21.
[250] Marasco, W. A., Chen, S., Richardson, J. H., Ramstedt, U., & Jones, S. D. (1998).
Intracellular antibodies against hiv-1 envelope protein for aids gene therapy. dana
farber cancer institute, boston, massachusetts. Human gene therapy, 9(11), 1627–
1642.
[251] Mariot, V., Joubert, R., Hourdé, C., Féasson, L., Hanna, M., Muntoni, F.,
Maisonobe, T., Servais, L., Bogni, C., Panse, R., & Others (2017). Downregula-
tion of myostatin pathway in neuromuscular diseases may explain challenges of anti-
myostatin therapeutic approaches. Nature communications, 8(1), 1859.
[252] Marsh, E. A. & Robinson, D. O. (2008). A case of rare recessive oculopharyngeal
muscular dystrophy (opmd) coexisting with hereditary neuropathy with liability to
pressure palsies (hnpp). Clinical neuroloং and neurosurgery, 110(5), 525–528.
[253] Matsakas, A., Macharia, R., Otto, A., Elashry, M. I., Mouisel, E., Romanello, V.,
Sartori, R., Amthor, H., Sandri, M., Narkar, V., & Others (2012). Exercise training
attenuates the hypermuscular phenotype and restores skeletal muscle function in the
myostatin null mouse. Experimental physioloং, 97(1), 125–140.
[254] Matthews, R. T., Ferrante, R. J., Klivenyi, P., Yang, L., Klein, A. M., Mueller, G.,
Kaddurah-Daouk, R., & Beal, M. F. (1999). Creatine and cyclocreatine attenuate
mptp neurotoxicity. Experimental neuroloং, 157(1), 142–149.
[255] McCroskery, S., Thomas, M., Maxwell, L., Sharma, M., & Kambadur, R. (2003).
Myostatin negatively regulates satellite cell activation and self-renewal. Journal of
Cell Bioloং, 162(6), 1135–1147.
[256] McElhinny, A. S., Kazmierski, S. T., Labeit, S., & Gregorio, C. C. (2003). Nebulin:
The nebulous, multifunctional giant of striated muscle. Trends in Cardiovascular
Medicine, 13(5), 195–201.
181
[257] McFarlane, C., Hennebry, A., Thomas, M., Plummer, E., Ling, N., Sharma, M., &
Kambadur, R. (2008). Myostatin signals through pax7 to regulate satellite cell self-
renewal. Experimental cell research, 314(2), 317–329.
[258] McFarlane, C., Langley, B., Thomas, M., Hennebry, A., Plummer, E., Nicholas, G.,
McMahon, C., Sharma, M., & Kambadur, R. (2005). Proteolytic processing of
myostatin is auto-regulated during myogenesis. Developmental bioloং, 283(1), 58–
69.
[259] McFarlane, C., Plummer, E., Thomas, M., Hennebry, A., Ashby, M., Ling, N.,
Smith, H., Sharma, M., & Kambadur, R. (2006). Myostatin induces cachexia by
activating the ubiquitin proteolytic system through an NF-??B-independent, FoxO1-
dependent mechanism. Journal of Cellular Physioloং, 209(2), 501–514.
[260] McFarlane, C., Vajjala, A., Arigela, H., Lokireddy, S., Ge, X., Bonala, S., Manickam,
R., Kambadur, R., & Sharma, M. (2014). Negative auto-regulation of myostatin
expression is mediated by smad3 and microrna-27. PloS one, 9(1), e87687.
[261] McKoy, G., Bicknell, K. A., Patel, K., & Brooks, G. (2007). Developmental expres-
sion of myostatin in cardiomyocytes and its effect on foetal and neonatal rat car-
diomyocyte proliferation. Cardiovascular research, 74(2), 304–312.
[262] McPherron, A. (2016). The ups and downs of exercise and insulin sensitivity: a role
for the myokine myostatin in glucose metabolism? Acta Physiologica, 217(1), 6–10.
[263] McPherron, A. C. (2010). Metabolic Functions of Myostatin and GDF11. Immunol-
oং Endocrine & Metabolic Agents in Medicinal Chemistry, 10(4), 217–231.
[264] McPherron, a. C., Lawler, a. M., & Lee, S. J. (1997). Regulation of skeletal muscle
mass in mice by a new TGF-beta superfamily member. Nature, 387(6628), 83–90.
[265] McPherron, A. C. & Lee, S.-J. (2002). Suppression of body fat accumulation in
myostatin-deficient mice. Journal of clinical Investigation, 109(5), 595–601.
[266] Megeney, L. A., Kablar, B., Garrett, K., Anderson, J. E., & Rudnicki, M. A. (1996).
MyoD is required for myogenic stem cell function in adult skeletal muscle. Genॽ &
development, 10(10), 1173–1183.
[267] Mendell, J. R., Sahenk, Z., Al-Zaidy, S., Rodino-Klapac, L. R., Lowes, L. P., Alfano,
L. N., Berry, K., Miller, N., Yalvac, M., Dvorchik, I., et al. (2017). Follistatin gene
therapy for sporadic inclusion body myositis improves functional outcomes. Molec-
ular Therapy, 25(4), 870–879.
182
[268] Mendell, J. R., Sahenk, Z., Malik, V., Gomez, A. M., Flanigan, K. M., Lowes, L. P.,
Alfano, L. N., Berry, K., Meadows, E., Lewis, S., Braun, L., Shontz, K., Rouhana,
M., Clark, K. R., Rosales, X. Q., Al-Zaidy, S., Govoni, A., Rodino-Klapac, L. R.,
Hogan, M. J., & Kaspar, B. K. (2015). A phase 1/2a follistatin gene therapy trial for
becker muscular dystrophy. Mol Ther, 23(1), 192–201.
[269] Mendias, C. L. (2006). Contractile properties of EDL and soleus muscles of
myostatin-deficient mice. Journal of Applied Physioloং, 101(3), 898–905.
[270] Mendias, C. L., Bakhurin, K. I., & Faulkner, J. a. (2008). Tendons of myostatin-
deficient mice are small, brittle, and hypocellular. Proceedings of the National
Academy of Sciencॽ of the United Statॽ of America, 105(1), 388–393.
[271] Mendias, C. L., Kayupov, E., Bradley, J. R., Brooks, S. V., & Claflin, D. R. (2011).
Decreased specific force and power production of muscle fibers frommyostatin-
deficient mice are associated with a suppression of protein degradation. Journal of
applied physioloং, 111(1), 185–191.
[272] Messer, A., Lynch, S. M., & Butler, D. C. (2009). Developing intrabodies for the
therapeutic suppression of neurodegenerative pathology. Expert opinion on biologi-
cal therapy, 9(9), 1189–1197.
[273] Messer, A. &McLear, J. (2006). The therapeutic potential of intrabodies in neuro-
logic disorders. BioDrugs, 20(6), 327–333.
[274] Miller, T. W., Shirley, T. L., Wolfgang, W. J., Kang, X., &Messer, A. (2003). Dna
vaccination against mutant huntingtin ameliorates the hdr6/2 diabetic phenotype.
Molecular Therapy, 7(5), 572–579.
[275] Minetti, C., Sotgia, F., Bruno, C., Scartezzini, P., Broda, P., Bado, M., Masetti, E.,
Mazzocco, M., Egeo, A., Donati, M. A., et al. (1998). Mutations in the caveolin-3
gene cause autosomal dominant limb-girdle muscular dystrophy. Nature genetics,
18(4), 365.
[276] Mishra, P., Varuzhanyan, G., Pham, A. H., & Chan, D. C. (2015). Mitochondrial
dynamics is a distinguishing feature of skeletal muscle fiber types and regulates or-
ganellar compartmentalization. Cell metabolism, 22(6), 1033–1044.
[277] Mitchell, M. D., Osepchook, C. C., Leung, K.-C., McMahon, C. D., & Bass, J. J.
(2006). Myostatin is a human placental product that regulates glucose uptake. The
Journal of Clinical Endocrinoloং & Metabolism, 91(4), 1434–1437.
183
[278] Monestier, O., Brun, C., Cocquempot, O., Petit, D., & Blanquet, V. (2012).
GASP/WFIKKN proteins: evolutionary aspects of their functions. PloS one, 7(8),
e43710.
[279] Montarras, D., Lindon, C., Pinset, C., & Domeyne, P. (2000). Cultured myf5 null
and myoD null muscle precursor cells display distinct growth defects. Bioloং of the
Cell, 92(8‐9), 565–572.
[280] Monteiro, M., Carvalho, M., Bastos, M., & Guedes de Pinho, P. (2013).
Metabolomics analysis for biomarker discovery: advances and challenges. Current
medicinal chemistry, 20(2), 257–271.
[281] Morine, K. J., Bish, L. T., Pendrak, K., Sleeper, M. M., Barton, E. R., & Sweeney,
H. L. (2010). Systemic myostatin inhibition via liver-targeted gene transfer in normal
and dystrophic mice. PLoS ONE, 5(2), e9176.
[282] Morissette, M. R., Cook, S. A., Foo, S., McKoy, G., Ashida, N., Novikov, M.,
Scherrer-Crosbie, M., Li, L., Matsui, T., Brooks, G., et al. (2006). Myostatin reg-
ulates cardiomyocyte growth through modulation of akt signaling. Circulation
research, 99(1), 15–24.
[283] Morissette, M. R., Stricker, J. C., Rosenberg, M. A., Buranasombati, C., Levitan,
E. B., Mittleman, M. A., & Rosenzweig, A. (2009). Effects of myostatin deletion in
aging mice. Aging cell, 8(5), 573–583.
[284] Mouisel, E., Relizani, K., Mille-Hamard, L., Denis, R., Hourdé, C., Agbulut, O.,
Patel, K., Arandel, L., Morales-Gonzalez, S., Vignaud, A., et al. (2014). Myostatin is a
key mediator between energy metabolism and endurance capacity of skeletal muscle.
American Journal of Physioloং-Regulatory, Integrative and Comparative Physioloং,
307(4), R444–R454.
[285] Mourkioti, F., Kratsios, P., Luedde, T., Song, Y.-H., Delafontaine, P., Adami, R.,
Parente, V., Bottinelli, R., Pasparakis, M., & Rosenthal, N. (2006). Targeted ab-
lation of IKK2 improves skeletal muscle strength, maintains mass, and promotes
regeneration. The Journal of clinical investigation, 116(11), 2945–2954.
[286] Müller, M., Moser, R., Cheneval, D., & Carafoli, E. (1985). Cardiolipin is the mem-
brane receptor for mitochondrial creatine phosphokinase. Journal of Biological
Chemistry, 260(6), 3839–3843.
184
[287] Murphy, K. T., Chee, A., Gleeson, B. G., Naim, T., Swiderski, K., Koopman, R., &
Lynch, G. S. (2011). Antibody-directed myostatin inhibition enhances muscle mass
and function in tumor-bearing mice. American journal of physioloং. Regulatory,
integrative and comparative physioloং, 301(3), R716—-R726.
[288] Murphy, K. T., Koopman, R., Naim, T., Léger, B., Trieu, J., Ibebunjo, C., & Lynch,
G. S. (2010). Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel
roles for myostatin signaling in skeletal muscle structure and function. The FASEB
journal : official publication of the Federation of American Societiॽ for Experimental
Bioloং, 24(11), 4433–4442.
[289] Nakao, A., Imamura, T., Souchelnytskyi, S., Kawabata, M., Ishisaki, A., Oeda, E.,
Tamaki, K., Hanai, J., Heldin, C., &Miyazono, K. (1997). TGF‐β receptor‐mediated
signalling through Smad2, Smad3 and Smad4. The EMBO journal, 16(17), 5353–
5362.
[290] Newmeyer, D. D. & Ferguson-Miller, S. (2003). Mitochondria: releasing power for
life and unleashing the machineries of death. Cell, 112(4), 481–490.
[291] Nishiumi, S., Kobayashi, T., Ikeda, A., Yoshie, T., Kibi, M., Izumi, Y., Okuno, T.,
Hayashi, N., Kawano, S., Takenawa, T., et al. (2012). A novel serummetabolomics-
based diagnostic approach for colorectal cancer. PloS one, 7(7), e40459.
[292] Nolan-Stevaux, O., Zhong, W., Culp, S., Shaffer, K., Hoover, J., Wickramasinghe,
D., & Ruefli-Brasse, A. (2012). Endoglin requirement for bmp9 signaling in en-
dothelial cells reveals new mechanism of action for selective anti-endoglin antibod-
ies. PloS one, 7(12), e50920.
[293] Nunez-Acuna, G. & Gallardo-Escarate, C. (2014). The myostatin gene of Mytilus
chilensis evidences a high level of polymorphism and ubiquitous transcript expres-
sion. Gene, 536(1), 207–212.
[294] Ohsawa, Y., Hagiwara, H., Nakatani, M., Yasue, A., Moriyama, K., Murakami,
T., Tsuchida, K., Noji, S., & Sunada, Y. (2006). Muscular atrophy of caveolin-3–
deficient mice is rescued by myostatin inhibition. The Journal of clinical investiga-
tion, 116(11), 2924–2934.
[295] Østbye, T.-K. K., Wetten, O. F., Tooming-Klunderud, A., Jakobsen, K. S., Yafe, A.,
Etzioni, S., Moen, T., & Andersen, Ø. (2007). Myostatin (MSTN) gene duplications
in Atlantic salmon (Salmo salar): Evidence for different selective pressure on teleost
MSTN-1 and -2. Gene, 403(1-2), 159–169.
185
[296] O’Connell, T. M., Ardeshirpour, F., Asher, S. A., Winnike, J. H., Yin, X., George, J.,
Guttridge, D. C., He, W., Wysong, A., Willis, M. S., et al. (2008). Metabolomic anal-
ysis of cancer cachexia reveals distinct lipid and glucose alterations. Metabolomics,
4(3), 216.
[297] Padhi, D., Higano, C. S., Shore, N. D., Sieber, P., Rasmussen, E., & Smith, M. R.
(2014). Pharmacological inhibition of myostatin and changes in lean body mass and
lower extremity muscle size in patients receiving androgen deprivation therapy for
prostate cancer. J Clin Endocrinol Metab, 99(10), E1967—-75.
[298] Palermo, G., Piraino, P., & Zucht, H.-D. (2009). Performance of pls regression
coefficients in selecting variables for each response of a multivariate pls for omics-
type data. Advancॽ and applications in bioinformatics and chemistry: AABC, 2,
57.
[299] Parsons, S. A., Millay, D. P., Sargent, M. A., McNally, E. M., &Molkentin, J. D.
(2006). Age-dependent effect of myostatin blockade on disease severity in a murine
model of limb-girdle muscular dystrophy. The American journal of patholoং,
168(6), 1975–1985.
[300] Parton, R. G. (2003). Caveolae—from ultrastructure to molecular mechanisms.
Nature reviews Molecular cell bioloং, 4(2), 162–167.
[301] Parton, R. G. & Simons, K. (2007). The multiple faces of caveolae. Nature reviews
Molecular cell bioloং, 8(3), 185–194.
[302] Pasco, M. Y., Catoire, H., Parker, J. A., Brais, B., Rouleau, G. a., & Néri, C. (2010a).
Cross-talk between canonical Wnt signaling and the sirtuin-FoxO longevity pathway
to protect against muscular pathology induced by mutant PABPN1 expression in C.
elegans. Neurobioloং of Disease, 38(3), 425–433.
[303] Pasco, M. Y., Rotili, D., Altucci, L., Farina, F., Rouleau, G. A., Mai, A., & Neri, C.
(2010b). Characterization of sirtuin inhibitors in nematodes expressing a muscular
dystrophy protein reveals muscle cell and behavioral protection by specific sirtinol
analogues. J Med Chem, 53(3), 1407–1411.
[304] Patti, G. J., Yanes, O., & Siuzdak, G. (2012). Innovation: Metabolomics: the apogee
of the omics trilogy. Nature reviews Molecular cell bioloং, 13(4), 263.
[305] Pauzner, R., Blatt, I., Mouallem, M., Ben-David, E., Farfel, Z., & Sadeh, M. (1991).
Mitochondrial abnormalities in oculopharyngeal muscular dystrophy. Muscle &
nerve, 14(10), 947–952.
186
[306] Perie, S., Trollet, C., Mouly, V., Vanneaux, V., Mamchaoui, K., Bouazza, B., Marol-
leau, J. P., Laforet, P., Chapon, F., Eymard, B., Butler-Browne, G., Larghero, J., &
St Guily, J. L. (2014). Autologous myoblast transplantation for oculopharyngeal
muscular dystrophy: a phase I/IIa clinical study. Mol Ther, 22(1), 219–225.
[307] Perkins, N. D. (2000). The Rel/NF-κB family: friend and foe. Trends in biochemical
sciencॽ, 25(9), 434–440.
[308] Perry, C. G., Kane, D. A., Herbst, E. A., Mukai, K., Lark, D. S., Wright, D. C.,
Heigenhauser, G. J., Neufer, P. D., Spriet, L. L., &Holloway, G. P. (2012). Mito-
chondrial creatine kinase activity and phosphate shuttling are acutely regulated by
exercise in human skeletal muscle. The Journal of physioloং, 590(21), 5475–5486.
[309] Perseghin, G. (2005). Muscle lipid metabolism in the metabolic syndrome. Current
opinion in lipidoloং, 16(4), 416–420.
[310] Phoenix, J., Betal, D., Roberts, N., Helliwell, T. R., & Edwards, R. H. (1996). Ob-
jective quantification of muscle and fat in human dystrophic muscle by magnetic
resonance image analysis. Muscle & nerve, 19(3), 302–310.
[311] Picard, M., Hepple, R. T., & Burelle, Y. (2011). Mitochondrial functional special-
ization in glycolytic and oxidative muscle fibers: tailoring the organelle for optimal
function. American Journal of Physioloং-Cell Physioloং, 302(4), C629–C641.
[312] Ploquin, C., Chabi, B., Fouret, G., Vernus, B., Feillet-Coudray, C., Coudray, C.,
Bonnieu, A., & Ramonatxo, C. (2012). Lack of myostatin alters intermyofibrillar
mitochondria activity, unbalances redox status, and impairs tolerance to chronic
repetitive contractions in muscle. American Journal of Physioloং-Endocrinoloং
And Metabolism, 302(8), E1000—-E1008.
[313] Psychogios, N., Hau, D. D., Peng, J., Guo, A. C., Mandal, R., Bouatra, S., Sinel-
nikov, I., Krishnamurthy, R., Eisner, R., Gautam, B., et al. (2011). The human serum
metabolome. PloS one, 6(2), e16957.
[314] Ratkevicius, A., Joyson, A., Selmer, I., Dhanani, T., Grierson, C., Tommasi, A. M.,
DeVries, A., Rauchhaus, P., Crowther, D., Alesci, S., & Others (2011). Serum con-
centrations of myostatin and myostatin-interacting proteins do not differ between
young and sarcopenic elderly men. Journals of Gerontoloং Seriॽ A: Biomedical
Sciencॽ and Medical Sciencॽ, 66(6), 620–626.
[315] Raz, V., Dickson, G., & AC’t Hoen, P. (2017). Dysfunctional transcripts are formed
by alternative polyadenylation in opmd. Oncotarget, 8(43), 73516.
187
[316] Raz, V., Routledge, S., Venema, A., Buijze, H., van der Wal, E., Anvar, S.,
Straasheijm, K. R., Klooster, R., Antoniou, M., & van der Maarel, S. M. (2011).
Modeling oculopharyngeal muscular dystrophy in myotube cultures reveals reduced
accumulation of soluble mutant PABPN1 protein. Am J Pathol, 179(4), 1988–2000.
[317] Raz, Y. & Raz, V. (2014). Oculopharyngeal muscular dystrophy as a paradigm for
muscle aging. Frontiers in aging neuroscience, 6, 317.
[318] Rebbapragada, a., Benchabane, H., Wrana, J. L., Celeste, a. J., & Attisano, L. (2003).
Myostatin signals through a transforming growth factor beta-like signaling pathway
to block adipogenesis. Molecular and cellular bioloং, 23(20), 7230–7242.
[319] Reinecke, F., Smeitink, J. A., & Van DerWesthuizen, F. H. (2009). Oxphos gene
expression and control in mitochondrial disorders. Biochimica et Biophysica Acta
(BBA)-Molecular Basॾ of Disease, 1792(12), 1113–1121.
[320] Reisz-Porszasz, S., Bhasin, S., Artaza, J. N., Shen, R., Sinha-Hikim, I., Hogue, A.,
Fielder, T. J., & Gonzalez-Cadavid, N. F. (2003a). Lower skeletal muscle mass in
male transgenic mice with muscle-specific overexpression of myostatin. American
Journal of Physioloং - Endocrinoloং And Metabolism, 285(4), E876—-E888.
[321] Reisz-Porszasz, S., Bhasin, S., Artaza, J. N., Shen, R., Sinha-Hikim, I., Hogue, A.,
Fielder, T. J., & Gonzalez-Cadavid, N. F. (2003b). Lower skeletal muscle mass in
male transgenic mice with muscle-specific overexpression of myostatin. American
Journal of Physioloং-Endocrinoloং and Metabolism, 285(4), E876–E888.
[322] Riaz, M., Raz, Y., van Putten, M., Paniagua-Soriano, G., Krom, Y. D., Florea, B. I.,
& Raz, V. (2016). Pabpn1-dependent mrna processing induces muscle wasting. PLoS
genetics, 12(5), e1006031.
[323] Rivas, E., Avila, R., Marquez, C., Paradas, C., & Castellanos, F. (2016). Pathology
of criocopharyngeal muscles in oculopharyngeal muscular dystrophy (OPMD): A
quantitative histological and histochemical study. Neuromuscular Disorders, 26,
S140.
[324] Robertson, I. B., Horiguchi, M., Zilberberg, L., Dabovic, B., Hadjiolova, K., &
Rifkin, D. B. (2015). Latent TGF-β-binding proteins. Matrix Bioloং, 47, 44–53.
[325] Rodgers, B. D. & Garikipati, D. K. (2008). Clinical, agricultural, and evolutionary
biology of myostatin: A comparative review. Endocrine Reviews, 29(5), 513–534.
188
[326] Rodino-Klapac, L. R., Janssen, P. M., Shontz, K. M., Canan, B., Montgomery, C. L.,
Griffin, D., Heller, K., Schmelzer, L., Handy, C., Clark, K. R., Sahenk, Z., Mendell,
J. R., & Kaspar, B. K. (2013). Micro-dystrophin and follistatin co-delivery restores
muscle function in aged DMDmodel. Hum Mol Genet, 22(24), 4929–4937.
[327] Roessner, U. & Bowne, J. (2009). What is metabolomics all about? Biotechniquॽ,
46(5), 363.
[328] Rojo, M., Hovius, R., Demel, R., Wallimann, T., Eppenberger, H. M., & Nicolay,
K. (1991). Interaction of mitochondrial creatine kinase with model membranes a
monolayer study. FEBS letters, 281(1-2), 123–129.
[329] Roovers, R. C. et al. (2007). Nanobodies in therapeutic applications. Current opin-
ion in molecular therapeutics, 9(4), 327–335.
[330] Ruegg, S., Hagen, M. L., Hohl, U., Kappos, L., Fuhr, P., Plasilov, M., Muller, H., &
Heinimann, K. (2005). Oculopharyngeal muscular dystrophy-an under-diagnosed
disorder? Swiss medical weekly, 135(39-40), 574–586.
[331] Ryall, J. G., Schertzer, J. D., & Lynch, G. S. (2008). Cellular and molecular mecha-
nisms underlying age-related skeletal muscle wasting and weakness. Biogerontoloং,
9(4), 213–228.
[332] Ryan, A., Li, G., Blumenthal, J., & Ortmeyer, H. (2013). Aerobic exercise+ weight
loss decreases skeletal muscle myostatin expression and improves insulin sensitivity
in older adults. Obesity, 21(7), 1350–1356.
[333] Rı́os, R., Carneiro, I., Arce, V. M., & Devesa, J. (2002). Myostatin is an inhibitor of
myogenic differentiation. American Journal of Physioloং-Cell Physioloং, 282(5),
C993—-C999.
[334] Sabatine, M. S., Liu, E., Morrow, D. A., Heller, E., McCarroll, R., Wiegand, R.,
Berriz, G. F., Roth, F. P., & Gerszten, R. E. (2005). Metabolomic identification of
novel biomarkers of myocardial ischemia. Circulation, 112(25), 3868–3875.
[335] Sakuma, K., Aoi, W., & Yamaguchi, A. (2014). The intriguing regulators of muscle
mass in sarcopenia and muscular dystrophy. Frontiers in aging neuroscience, 6, 230.
[336] Sakuma, K., Nakao, R., Inashima, S., Hirata, M., Kubo, T., & Yasuhara, M. (2004).
Marked reduction of focal adhesion kinase, serum response factor and myocyte en-
hancer factor 2C, but increase in RhoA and myostatin in the hindlimb dy mouse
muscles. Acta neuropathologica, 108(3), 241–249.
189
[337] Sandri, M., Barberi, L., Bijlsma, A. Y., Blaauw, B., Dyar, K. A., Milan, G., Mammu-
cari, C., Meskers, C. G. M., Pallafacchina, G., & Paoli, A. (2013). Signalling pathways
regulating muscle mass in ageing skeletal muscle. The role of the IGF1-Akt-mTOR-
FoxO pathway. Biogerontoloং, 14(3), 303–323.
[338] Sarkar, S., Davies, J. E., Huang, Z., Tunnacliffe, A., & Rubinsztein, D. C. (2007).
Trehalose, a novel mtor-independent autophagy enhancer, accelerates the clearance
of mutant huntingtin and α-synuclein. Journal of Biological Chemistry, 282(8),
5641–5652.
[339] Sartori, R., Milan, G., Patron, M., Mammucari, C., Blaauw, B., Abraham, R., &
Sandri, M. (2009). Smad2 and 3 transcription factors control muscle mass in adult-
hood. American Journal of Physioloং-Cell Physioloং, 296(6), C1248—-C1257.
[340] Sartori, R., Schirwis, E., Blaauw, B., Bortolanza, S., Zhao, J., Enzo, E., Stantzou, A.,
Mouisel, E., Toniolo, L., Ferry, A., Stricker, S., Goldberg, A. L., Dupont, S., Piccolo,
S., Amthor, H., & Sandri, M. (2013). BMP signaling controls muscle mass. Nature
genetics, 45(11), 1309–1318.
[341] Schantz, P., Sjöberg, B., & Svedenhag, J. (1986). Malate-aspartate and alpha-
glycerophosphate shuttle enzyme levels in human skeletal muscle: methodological
considerations and effect of endurance training. Acta Physiologica, 128(3), 397–407.
[342] Scheffler, I. E. (2001). Mitochondria make a come back. Advanced drug delivery
reviews, 49(1-2), 3–26.
[343] Schiaffino, S. & Reggiani, C. (2011). Fiber types in mammalian skeletal muscles.
Physiological reviews, 91(4), 1447–1531.
[344] Schirwis, E., Agbulut, O., Vadrot, N., Mouisel, E., Hourde, C., Bonnieu, A., Butler-
Browne, G., Amthor, H., & Ferry, A. (2013). The beneficial effect of myostatin
deficiency on maximal muscle force and power is attenuated with age. Experimental
gerontoloং, 48(2), 183–190.
[345] Schlattner, U., Dolder, M., Wallimann, T., & Tokarska-Schlattner, M. (2001). Mi-
tochondrial creatine kinase and mitochondrial outer membrane porin show a direct
interaction that is modulated by calcium. Journal of Biological Chemistry, 276(51),
48027–48030.
[346] Schlattner, U., Tokarska-Schlattner, M., &Wallimann, T. (2006). Mitochondrial
creatine kinase in human health and disease. Biochimica et Biophysica Acta (BBA)-
Molecular Basॾ of Disease, 1762(2), 164–180.
190
[347] Schlattner, U. &Wallimann, T. (2000a). Octamers of mitochondrial creatine kinase
isoenzymes differ in stability and membrane binding. Journal of Biological Chem-
istry, 275(23), 17314–17320.
[348] Schlattner, U. &Wallimann, T. (2000b). A quantitative approach to membrane
binding of human ubiquitous mitochondrial creatine kinase using surface plasmon
resonance. Journal of bioenergetics and biomembranॽ, 32(1), 123–131.
[349] Schwartz, E. A., Reaven, E., Topper, J. N., & Tsao, P. S. (2005). Transforming
growth factor-β receptors localize to caveolae and regulate endothelial nitric oxide
synthase in normal human endothelial cells. Biochemical Journal, 390(1), 199–206.
[350] Shan, J., Chen, B., Lin, P., Li, D., Luo, Y., Ji, K., Zheng, J., Yuan, Y., & Yan, C.
(2014). Oculopharyngeal muscular dystrophy: phenotypic and genotypic studies
in a chinese population. Neuromolecular medicine, 16(4), 782–786.
[351] Sharma, M., Kambadur, R., Matthews, K. G., Somers, W. G., Devlin, G. P., Cona-
glen, J. V., Fowke, P. J., & Bass, J. J. (1999). Myostatin, a transforming growth
factor‐β superfamily member, is expressed in heart muscle and is upregulated in car-
diomyocytes after infarct. Journal of cellular physioloং, 180(1), 1–9.
[352] Sharp, P. S., Bye-a Jee, H., &Wells, D. J. (2011). Physiological characterization of
muscle strength with variable levels of dystrophin restoration in mdx mice following
local antisense therapy. Molecular Therapy, 19(1), 165–171.
[353] Shi, L., Zhou, B., Li, P., Schinckel, A. P., Liang, T., Wang, H., Li, H., Fu, L., Chu,
Q., &Huang, R. (2015). Microrna-128 targets myostatin at coding domain sequence
to regulate myoblasts in skeletal muscle development. Cellular signalling, 27(9),
1895–1904.
[354] Shimamoto, G., Gegg, C., Boone, T., &Quéva, C. (2012). Peptibodies: A flexible al-
ternative format to antibodies. InMAbs, volume 4 (pp. 586–591).: Taylor & Francis.
[355] Shlomi, T., Cabili, M. N., & Ruppin, E. (2009). Predicting metabolic biomarkers of
human inborn errors of metabolism. Molecular systems bioloং, 5(1), 263.
[356] Shyu, K.-G., Lu, M., Wang, B., Sun, H., & Chang, H. (2006). Myostatin expression
in ventricular myocardium in a rat model of volume-overload heart failure. Euro-
pean journal of clinical investigation, 36(10), 713–719.
[357] Silverthorn, D. U., Johnson, B. R., & Ober, W. C. (2007). Human physioloং. Pear-
son/Benjamin Cummings.
191
[358] Siriett, V., Salerno, M. S., Berry, C., Nicholas, G., Bower, R., Kambadur, R., &
Sharma, M. (2007). Antagonism of myostatin enhances muscle regeneration dur-
ing sarcopenia. Molecular Therapy, 15(8), 1463–1470.
[359] Spiller, M. P., Kambadur, R., Jeanplong, F., Thomas, M., Martyn, J. K., Bass, J. J.,
& Sharma, M. (2002). The myostatin gene is a downstream target gene of basic
helix-loop-helix transcription factor MyoD. Molecular and Cellular Bioloং, 22(20),
7066–7082.
[360] Spitali, P., Hettne, K., Tsonaka, R., Sabir, E., Seyer, A., Hemerik, J., Goeman, J. J.,
Picillo, E., Ergoli, M., Politano, L., et al. (2018). Cross-sectional serummetabolomic
study of multiple forms of muscular dystrophy. Journal of cellular and molecular
medicine.
[361] Spriggs, B. & Ilse, W. (2004). Autosomal recessive oculopharyngeal muscular
dystrophy-an underrecognized syndrome. InASHG Annual Meeting, Program,
number 790.
[362] Sriram, S., Subramanian, S., Sathiakumar, D., Venkatesh, R., Salerno, M. S., McFar-
lane, C. D., Kambadur, R., & Sharma, M. (2011). Modulation of reactive oxygen
species in skeletal muscle by myostatin is mediated through NF‐κB. Aging cell, 10(6),
931–948.
[363] Steelman, C. A., Recknor, J. C., Nettleton, D., & Reecy, J. M. (2006). Transcrip-
tional profiling of myostatin-knockout mice implicates Wnt signaling in postnatal
skeletal muscle growth and hypertrophy. FASEB JOURNAL, 20(3), 580.
[364] Stolz, L., Li, D., Qadri, A., Jalenak, M., Klaman, L., & Tobin, J. (2008). Admin-
istration of myostatin does not alter fat mass in adult mice. Diabetॽ, Obesity and
Metabolism, 10(2), 135–142.
[365] Takata, H., Terada, K., Oka, H., Sunada, Y., Moriguchi, T., & Nohno, T. (2007).
Involvement of Wnt4 signaling during myogenic proliferation and differentiation of
skeletal muscle. Developmental Dynamics, 236(10), 2800–2807.
[366] Tamayo, T., Eno, E., Madrigal, C., Heydemann, A., Garcia, K., & Garcia, J. (2016).
Functional in situ assessment of muscle contraction in wild-type and mdx mice.
Muscle & nerve, 53(2), 260–268.
[367] Tanaka, T., Williams, R. L., & Rabbitts, T. H. (2007). Tumour prevention by a
single antibody domain targeting the interaction of signal transduction proteins
with ras. The EMBO journal, 26(13), 3250–3259.
192
[368] Tarnopolsky, M., Mahoney, D., Vajsar, J., Rodriguez, C., Doherty, T., Roy, B., &
Biggar, D. (2004). Creatine monohydrate enhances strength and body composition
in duchenne muscular dystrophy. Neuroloং, 62(10), 1771–1777.
[369] Tarnopolsky, M., Roy, B., &MacDonald, J. (1997). A randomized, controlled trial
of creatine monohydrate in patients with mitochondrial cytopathies. Muscle &
nerve, 20(12), 1502–1509.
[370] Tatem, K. S., Quinn, J. L., Phadke, A., Yu, Q., Gordish-Dressman, H., & Nagaraju,
K. (2014). Behavioral and locomotor measurements using an open field activity
monitoring system for skeletal muscle diseases. Journal of visualized experiments:
JoVE, (91).
[371] Tautenhahn, R., Patti, G. J., Rinehart, D., & Siuzdak, G. (2012). Xcms online: a
web-based platform to process untargeted metabolomic data. Analytical chemistry,
84(11), 5035–5039.
[372] Tavanez, J. P., Bengoechea, R., Berciano, M. T., Lafarga, M., Carmo-Fonseca, M.,
& Enguita, F. J. (2009). Hsp70 chaperones and type I PRMTs are sequestered at
intranuclear inclusions caused by polyalanine expansions in PABPN1. PLoS ONE,
4(7), e6418.
[373] Taylor, E. W. (1915). Progressive vagus-glossopharyngeal paralysis with ptosis: a
contribution to the group of family diseases. In Transactions of the American Neu-
rological Association: Annual Meeting, volume 1914 (pp. 192).: Springer Publishing
Company.
[374] Taylor, W. E., Bhasin, S., Artaza, J., Byhower, F., Azam, M., Willard, D. H., Kull,
F. C., & Gonzalez-Cadavid, N. (2001). Myostatin inhibits cell proliferation and pro-
tein synthesis in C2C12 muscle cells. American Journal of Physioloং-Endocrinoloং
And Metabolism, 280(2), E221—-E228.
[375] Thomas, M., Langley, B., Berry, C., Sharma, M., Kirk, S., Bass, J., & Kambadur, R.
(2000). Myostatin, a negative regulator of muscle growth, functions by inhibiting
myoblast proliferation. Journal of Biological Chemistry, 275(51), 40235–40243.
[376] Thompson, T. B., Woodruff, T. K., & Jardetzky, T. S. (2003). Structures of an Ac-
tRIIB: activin A complex reveal a novel binding mode for TGF‐β ligand: receptor
interactions. The EMBO journal, 22(7), 1555–1566.
193
[377] Timpani, C. A., Hayes, A., & Rybalka, E. (2015). Revisiting the dystrophin-atp con-
nection: how half a century of research still implicates mitochondrial dysfunction in
duchenne muscular dystrophy aetiology. Medical hypothesॽ, 85(6), 1021–1033.
[378] Tinklenberg, J. A., Siebers, E. M., Beatka, M. J., Meng, H., Yang, L., Zhang, Z.,
Ross, J. A., Ochala, J., Morris, C., Owens, J., & Others (2017). Myostatin inhibi-
tion using mRK35 produces skeletal muscle growth and tubular aggregate formation
in wild type and TgACTA1D286G nemaline myopathy mice. Human molecular
genetics.
[379] Todorovic, V. & Rifkin, D. B. (2012). LTBPs, more than just an escort service. Jour-
nal of cellular biochemistry, 113(2), 410–418.
[380] Tome, F. M., Chateau, D., Helbling-Leclerc, A., Fardeau, M., Tomé, F. M. S.,
Chateau, D., Helbling-Leclerc, A., & Fardeau, M. (1997). Morphological changes
in muscle fibers in oculopharyngeal muscular dystrophy. Neuromuscul Disord, 7
Suppl 1, S63—-S69.
[381] Torrado, M., Iglesias, R., Nespereira, B., &Mikhailov, A. T. (2010). Identification
of candidate genes potentially relevant to chamber-specific remodeling in postnatal
ventricular myocardium. BioMed Research International, 2010.
[382] Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., & Glass,
D. J. (2009). Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast
differentiation and myotube size. American journal of physioloং. Cell physioloং,
296(6), C1258—-C1270.
[383] Trinick, J. (1992). Understanding the functions of titin and nebulin. FEBS Letters,
307(1), 44–48.
[384] Trollet, C., Anvar, S. Y., Venema, A., Hargreaves, I. P., Foster, K., Vignaud, A.,
Ferry, A., Negroni, E., Hourde, C., Baraibar, M. a., ’t Hoen, P. a. C., Davies, J. E.,
Rubinsztein, D. C., Heales, S. J., Mouly, V., van der Maarel, S. M., Butler-Browne,
G., Raz, V., & Dickson, G. (2010). Molecular and phenotypic characterization of a
mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atro-
phy restricted to fast glycolytic fibres. Human Molecular Genetics, 19(11), 2191–2207.
[385] Tsang, T. M., Huang, J. T.-J., Holmes, E., & Bahn, S. (2006). Metabolic profiling of
plasma from discordant schizophrenia twins: correlation between lipid signals and
global functioning in female schizophrenia patients. Journal of proteome research,
5(4), 756–760.
194
[386] Underwood, B. R., Broadhurst, D., Dunn, W. B., Ellis, D. I., Michell, A. W.,
Vacher, C., Mosedale, D. E., Kell, D. B., Barker, R. A., Grainger, D. J., et al. (2006).
Huntington disease patients and transgenic mice have similar pro-catabolic serum
metabolite profiles. Brain, 129(4), 877–886.
[387] Urtizberea, J. A. (2004). Oculopharyngeal muscular dystrophy. Update.
[388] Uyama, E., Tsukahara, T., Goto, K., Kurano, Y., Ogawa, M., Kim, Y. J., Uchino, M.,
& Arahata, K. (2000). Nuclear accumulation of expanded PABP2 gene product in
oculopharyngeal muscular dystrophy. Muscle Nerve, 23(10), 1549–1554.
[389] Vacheron, M.-J., Clottes, E., Chautard, C., & Vial, C. (1997). Mitochondrial cre-
atine kinase interaction with phospholipid vesicles. Archivॽ of biochemistry and
biophysics, 344(2), 316–324.
[390] Vainzof, M., Ayub-Guerrieri, D., Onofre, P. C. G., Martins, P. C. M., Lopes, V. F.,
Zilberztajn, D., Maia, L. S., Sell, K., & Yamamoto, L. U. (2008). Animal models for
genetic neuromuscular diseases. Journal of Molecular Neuroscience, 34(3), 241–248.
[391] Verdijk, L. B., Koopman, R., Schaart, G., Meijer, K., Savelberg, H. H. C. M., & van
Loon, L. J. C. (2007). Satellite cell content is specifically reduced in type II skeletal
muscle fibers in the elderly. American Journal of Physioloং-Endocrinoloং and
Metabolism, 292(1), E151——–E157.
[392] Verheesen, P., de Kluijver, A., van Koningsbruggen, S., de Brij, M., de Haard, H. J.,
van Ommen, G.-J. B., van der Maarel, S. M., & Verrips, C. T. (2005). Prevention
of oculopharyngeal muscular dystrophy-associated aggregation of nuclear poly (a)-
binding protein with a single-domain intracellular antibody. Human molecular
genetics, 15(1), 105–111.
[393] Vest, K. E., Phillips, B. L., Banerjee, A., Apponi, L. H., Dammer, E. B., Xu, W.,
Zheng, D., Yu, J., Tian, B., Pavlath, G. K., & Corbett, A. H. (2017). Novel mouse
models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mito-
chondrial defects and suggest loss of PABPN1 may contribute to pathology. Human
molecular genetics, 26(17), 3235–3252.
[394] Victor, M., Hayes, R., & Adams, R. D. (1962). Oculopharyngeal muscular dystro-
phy: a familial disease of late life characterized by dysphagia and progressive ptosis of
the eyelids. New England Journal of Medicine, 267(25), 1267–1272.
195
[395] Villagra, N. T., Bengoechea, R., Vaque, J. P., Llorca, J., Berciano, M. T., & Lafarga,
M. (2008). Nuclear compartmentalization and dynamics of the poly(A)-binding
protein nuclear 1 (PABPN1) inclusions in supraoptic neurons under physiological
and osmotic stress conditions. Mol Cell Neurosci, 37(3), 622–633.
[396] Villas-Bôas, S. G., Rasmussen, S., & Lane, G. A. (2005). Metabolomics or metabo-
lite profiles? TRENDS in Biotechnoloং, 23(8), 385–386.
[397] Voermans, N. C., van Alfen, N., Pillen, S., Lammens, M., Schalkwijk, J., Zwarts,
M. J., van Rooij, I. A., Hamel, B. C., & van Engelen, B. G. (2009). Neuromuscular
involvement in various types of ehlers–danlos syndrome. Annals of Neuroloং:
Official Journal of the American Neurological Association and the Child Neuroloং
Society, 65(6), 687–697.
[398] Vorgerd, M., Zange, J., Kley, R., Grehl, T., Hüsing, A., Jäger, M., Müller, K.,
Schröder, R., Mortier, W., Fabian, K., et al. (2002). Effect of high-dose creatine ther-
apy on symptoms of exercise intolerance in mcardle disease: double-blind, placebo-
controlled crossover study. Archivॽ of neuroloং, 59(1), 97–101.
[399] Wagner, K. R., Fleckenstein, J. L., Amato, A. a., Barohn, R. J., Bushby, K., Escolar,
D. M., Flanigan, K. M., Pestronk, A., Tawil, R., Wolfe, G. I., Eagle, M., Florence,
J. M., King, W.M., Pandya, S., Straub, V., Juneau, P., Meyers, K., Csimma, C.,
Araujo, T., Allen, R., Parsons, S. A., Wozney, J. M., Lavallie, E. R., &Mendell, J. R.
(2008). A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy.
Annals of neuroloং, 63(5), 561–571.
[400] Wagner, K. R., Liu, X., Chang, X., & Allen, R. E. (2005). Muscle regeneration in
the prolonged absence of myostatin. Proceedings of the National Academy of Sci-
encॽ of the United Statॽ of America, 102(7), 2519–2524.
[401] Wagner, K. R., McPherron, A. C., Winik, N., & Lee, S. J. (2002). Loss of myostatin
attenuates severity of muscular dystrophy in mdx mice. Annals of Neuroloং, 52(6),
832–836.
[402] Wallace, D. C. (2005). A mitochondrial paradigm of metabolic and degenerative
diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet.,
39, 359–407.
[403] Wallace, G. Q. &McNally, E. M. (2009). Mechanisms of muscle degeneration,
regeneration, and repair in the muscular dystrophies. Annual review of physioloং,
71, 37–57.
196
[404] Walter, M., Lochmüller, H., Reilich, P., Klopstock, T., Huber, R., Hartard, M.,
Hennig, M., Pongratz, D., &Müller-Felber, W. (2000). Creatine monohydrate in
muscular dystrophies: A double-blind, placebo-controlled clinical study. Neuroloং,
54(9), 1848–1850.
[405] Wang, C., Kong, H., Guan, Y., Yang, J., Gu, J., Yang, S., & Xu, G. (2005a). Plasma
phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based
on high-performance liquid chromatography/electrospray mass spectrometry and
multivariate statistical analysis. Analytical chemistry, 77(13), 4108–4116.
[406] Wang, Q. & Bag, J. (2006). Ectopic expression of a polyalanine expansion mutant of
poly(A)-binding protein N1 in muscle cells in culture inhibits myogenesis. Biochem
Biophys Rॽ Commun, 340(3), 815–822.
[407] Wang, Q., Guo, T., Portas, J., &McPherron, A. C. (2015). A soluble activin receptor
type IIB does not improve blood glucose in streptozotocin-treated mice. Int J Biol
Sci, 11(2), 199–208.
[408] Wang, Q. &McPherron, A. C. (2012). Myostatin inhibition induces muscle fibre
hypertrophy prior to satellite cell activation. The Journal of physioloং, 590(9), 2151–
2165.
[409] Wang, Q., Mosser, D. D., & Bag, J. (2005b). Induction of HSP70 expression and re-
cruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine
expansion mutant of PABPN1 in HeLa cells. Human Molecular Genetics, 14(23),
3673–3684.
[410] Wang, Y. & Pessin, J. E. (2013). Mechanisms for fiber-type specificity of skeletal mus-
cle atrophy. Current opinion in clinical nutrition and metabolic care, 16(3), 243.
[411] Watkins, S. C. & Cullen, M. J. (1982). Muscle fibre size and shape in Duchenne
muscular dystrophy. Neuropatholoং and applied neurobioloং, 8(1), 11–17.
[412] Wei, C., Ren, H., Xu, L., Li, L., Liu, R., Zhang, L., Zhao, F., Lu, J., Zhang, X., &
Du, L. (2015). Signals of Ezh2 Src, and Akt Involve in Myostatin-Pax7 Pathways Reg-
ulating the Myogenic Fate Determination during the SheepMyoblast Proliferation
and Differentiation. PloS one, 10(3), e0120956.
[413] Welch, W. J. & Brown, C. R. (1996). Influence of molecular and chemical chaperones
on protein folding. Cell stress & chaperonॽ, 1(2), 109.
197
[414] Welle, S., Bhatt, K., Shah, B., & Thornton, C. A. (2002). Insulin-like growth factor-1
and myostatin mRNA expression in muscle: comparison between 62–77 and 21–31
yr old men. Experimental gerontoloং, 37(6), 833–839.
[415] West, R. L. (1974). Red to white fiber ratios as an index of double muscling in beef
cattle. Journal of Animal science, 38(5), 1165–1175.
[416] White, T. A. & LeBrasseur, N. K. (2014). Myostatin and sarcopenia: opportunities
and challenges-a mini-review. Gerontoloং, 60(4), 289–293.
[417] Whittemore, L.-A., Song, K., Li, X., Aghajanian, J., Davies, M., Girgenrath, S., Hill,
J. J., Jalenak, M., Kelley, P., & Knight, A. (2003). Inhibition of myostatin in adult
mice increases skeletal muscle mass and strength. Biochemical and biophysical re-
search communications, 300(4), 965–971.
[418] Wilkes, J. J., Lloyd, D. J., & Gekakis, N. (2009). Loss-of-function mutation in myo-
statin reduces tumor necrosis factor α production and protects liver against obesity-
induced insulin resistance. Diabetॽ, 58(5), 1133–1143.
[419] Winbanks, C. E., Chen, J. L., Qian, H., Liu, Y., Bernardo, B. C., Beyer, C., Watt,
K. I., Thomson, R. E., Connor, T., Turner, B. J., et al. (2013). The bone morpho-
genetic protein axis is a positive regulator of skeletal muscle mass. J Cell Biol, 203(2),
345–357.
[420] Wu, G. (2009). Amino acids: metabolism, functions, and nutrition. Amino acids,
37(1), 1–17.
[421] Wyss, M., Smeitink, J., Wevers, R. A., &Wallimann, T. (1992). Mitochondrial cre-
atine kinase: a key enzyme of aerobic energy metabolism. Biochimica et Biophysica
Acta (BBA)-Bioenergetics, 1102(2), 119–166.
[422] Xia, J., Sinelnikov, I. V., Han, B., &Wishart, D. S. (2015). Metaboanalyst 3.0—
making metabolomics more meaningful. Nucleic acids research, 43(W1), W251–
W257.
[423] Yamawaki, K., Ueda, S., Okada, T., Oshima, T., Kakitani, M., Kato, T., &
Tomizuka, K. (2013). Adult-specific systemic over-expression reveals novel in vivo
effects of the soluble forms of actriia, actriib and bmprii. PloS one, 8(10), e78076.
[424] Yamazaki, Y., Kamei, Y., Sugita, S., Akaike, F., Kanai, S., Miura, S., Hirata, Y., Troen,
B. R., Kitamura, T., Nishino, I., Suganami, T., Ezaki, O., & Ogawa, Y. (2010). The
198
cathepsin L gene is a direct target of FOXO1 in skeletal muscle. The Biochemical
journal, 427(1), 171–178.
[425] Yan, X., Liao, H., Cheng, M., Shi, X., Lin, X., Feng, X.-H., & Chen, Y.-G. (2016).
Smad7 protein interacts with receptor-regulated smads (r-smads) to inhibit trans-
forming growth factor-β (tgf-β)/smad signaling. Journal of Biological Chemistry,
291(1), 382–392.
[426] Yang, W., Zhang, Y., Li, Y., Wu, Z., & Zhu, D. (2007). Myostatin induces cy-
clin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-
kinase/AKT/GSK-3β pathway and is antagonized by insulin-like growth factor 1.
Journal of Biological Chemistry, 282(6), 3799–3808.
[427] Yarasheski, K. E., Bhasin, S., Sinha-Hikim, I., Pak-Loduca, J., & Gonzalez-Cadavid,
N. F. (2002). Serummyostatin-immunoreactive protein is increased in 60-92 year
old women and men with muscle wasting. Journal of Nutrition Health and Aging,
6(5), 343–348.
[428] Yuasa, T., Ohno, S., Kehrl, J. H., & Kyriakis, J. M. (1998). Tumor necrosis factor
signaling to stress-activated protein kinase (sapk)/jun nh2-terminal kinase (jnk) and
p38 germinal center kinase couples traf2 to mitogen-activated protein kinase/erk
kinase kinase 1 and sapk while receptor interacting protein associates with a mitogen-
activated protein kinase kinase kinase upstream of mkk6 and p38. Journal of Biologi-
cal Chemistry, 273(35), 22681–22692.
[429] Zanotti, S., Saredi, S., Ruggieri, A., Fabbri, M., Blasevich, F., Romaggi, S., Morandi,
L., &Mora, M. (2007). Altered extracellular matrix transcript expression and pro-
tein modulation in primary duchenne muscular dystrophy myotubes. Matrix Biol-
oং, 26(8), 615–624.
[430] Zhang, C., McFarlane, C., Lokireddy, S., Masuda, S., Ge, X., Gluckman, P. D.,
Sharma, M., & Kambadur, R. (2012). Inhibition of myostatin protects against diet-
induced obesity by enhancing fatty acid oxidation and promoting a brown adipose
phenotype in mice. Diabetologia, 55(1), 183–193.
[431] Zhang, L., Rajan, V., Lin, E., Hu, Z., Han, H. Q., Zhou, X., Song, Y., Min, H.,
Wang, X., Du, J., & Others (2011). Pharmacological inhibition of myostatin sup-
presses systemic inflammation and muscle atrophy in mice with chronic kidney dis-
ease. The FASEB Journal, 25(5), 1653–1663.
199
[432] Zhang, X. L., Topley, N., Ito, T., & Phillips, A. (2005). Interleukin-6 regulation of
transforming growth factor (TGF)-β receptor compartmentalization and turnover
enhances TGF-β1 signaling. Journal of Biological Chemistry, 280(13), 12239–12245.
[433] Zhao, C., Qiao, C., Tang, R. H., Jiang, J., Li, J., Martin, C. B., Bulaklak, K., Li, J.,
Wang, D. W., & Xiao, X. (2015). Overcoming Insulin Insufficiency by Forced Follis-
tatin Expression in beta-cells of db/dbMice. Mol Ther, 23(5), 866–874.
[434] Zhu, H. J., Pan, H., Zhang, X. Z., Li, N. S., Wang, L. J., Yang, H. B., & Gong, F. Y.
(2015). The effect of myostatin on proliferation and lipid accumulation in 3t3-l1
preadipocytes. Journal of molecular endocrinoloং, 54(3), 217–226.
[435] Zhu, S., Li, M., Figueroa, B. E., Liu, A., Stavrovskaya, I. G., Pasinelli, P., Beal, M. F.,
Brown, R. H., Kristal, B. S., Ferrante, R. J., et al. (2004). Prophylactic creatine ad-
ministration mediates neuroprotection in cerebral ischemia in mice. Journal of Neu-
roscience, 24(26), 5909–5912.
[436] Zimmers, T. A., Davies, M. V., Koniaris, L. G., Haynes, P., Esquela, A. F., Tomkin-
son, K. N., McPherron, A. C., Wolfman, N. M., & Lee, S.-J. (2002). Induction of
cachexia in mice by systemically administered myostatin. Science (New York, N.Y.),
296(5572), 1486–1488.
200
Appendix A
Additional data
Table A.1: Change in body mass of 22wk old OPMD mice: 8-10 A17 and FvB Mice were weighed and treated weekly
for 10 weeks from the 12th week of age, with an anধ-myostaধn anধbody or saline, with staধsধcal summaries of the
final body mass presented below:
Change in Statistic A17 + Saline A17 + RK35 FvB + Saline FvB + RK35
Final body mass (gms) Mean 27.21 30.16 29.31 30.98
Std. Error of Mean 0.5654 0.6527 0.6107 0.7544
Lower 95% CI 25.93 28.72 27.93 29.24
Upper 95% CI 28.49 31.59 30.69 32.72
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Table A.2: Change in muscle mass of 22wk old OPMD mice: 8-10 A17 and FvB Mice were treated weekly for 10
weeks from the 12th week of age, with an anধ-myostaধn anধbody or saline. The mean mass of all muscles were
normalized to the iniধal body mass of the respecধve animal of per group, and the normalised muscle masses are
presented below:
Muscle Mass (gms)
Of Statistic A17 + Saline A17 + RK35 FvB + Saline FvB + RK35
TA Mean 1.419 1.683 1.83 2.216
Std. Error of Mean 0.02036 0.07461 0.04477 0.0797
Lower 95% CI 1.373 1.521 1.729 2.028
Upper 95% CI 1.465 1.846 1.931 2.405
EDL Mean 0.2781 0.3908 0.3348 0.4184
Std. Error of Mean 0.01377 0.01004 0.02211 0.017
Lower 95% CI 0.247 0.3689 0.2847 0.3783
Upper 95% CI 0.3092 0.4126 0.3848 0.4586
Sol Mean 0.2251 0.2527 0.2277 0.2447
Std. Error of Mean 0.0145 0.01292 0.012 0.0141
Lower 95% CI 0.1923 0.2245 0.2005 0.2113
Upper 95% CI 0.2579 0.2808 0.2549 0.2781
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Table A.3: Change in minimum feret diameter of 22wk old OPMD mice: A17 and FvB mice were subject to a weekly
regimen of either saline or the anধ-myostaধn RK35 anধbody IP for ten weeks from the 12th week of age. Muscle
samples from 5 randomly selected mice were secধoned and stained for laminin. Either 1000 or 400 fibres randomly
selected from the TA or EDL, and the median minimum feret diameter of each sample was computed.
Change in Statistic A17 + Saline A17 + RK35 FvB + Saline FvB + RK35
Min. Feret
diameter of
the TA (μm) Mean 32.68 38.36 41.76 46.8
Std. Error of Mean 0.6373 1.536 1.338 0.6298
Lower 95% CI 30.91 34.09 38.05 45.05
Upper 95% CI 34.45 42.62 45.48 48.55
Min. Feret
diameter of
the EDL (μm) Mean 23.85 34.37 29.13 33.68
Std. Error of Mean 1.089 2.014 1.666 1.028
Lower 95% CI 21.06 27.96 24.5 30.41
Upper 95% CI 26.65 40.78 33.76 36.95
Table A.4: Change in collagen VI expression of 22wk old OPMD mice: Mice were subject to a weekly regimen of
either saline or the anধ-myostaধn RK35 anধbody IP for ten weeks from the 12th week of age. 5 whole muscle sam-
ples from all groups were stained for collagen VI, and random fields were imaged and analysed for the percentage
area of collagen VI staining.
Change in Statistic A17 + Saline A17 + RK35 FvB + Saline FvB + RK35
% expression of
collagen VI in
the TA Mean 10.16 6.117 4.471 3.346
Std. Error of Mean 0.7759 0.3576 0.22 0.7706
Lower 95% CI 8.008 4.979 3.905 0.0301
Upper 95% CI 12.32 7.255 5.036 6.662
% expression of
collagen VI in
the EDL Mean 10.27 9.413 4.943 5.759
Std. Error of Mean 0.5767 0.649 0.3978 0.6223
Lower 95% CI 8.788 6.621 3.231 3.081
Upper 95% CI 11.75 12.21 6.655 8.436
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Figure A.1: Effect of RK35 anধbody on minimum feret diameter of 22-week old OPMD mice: A17 and FvB mice
were administered a weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 12th
week of age. Muscle samples from 5 randomly selected mice were secধoned and stained for laminin. Either 1000
or 400 fibres randomly selected from the TA or EDL, and the probability density funcধon was computed by kernel
methods. The shaded region represents the 95% confidence interval.
Table A.5: Change in INI density in TA of 22-week old OPMD mice administered with RK35: Mice were subject to
a weekly regimen of either saline or the anধ-myostaধn RK35 anধbody IP for ten weeks from the 12th week of age.
5 whole muscle samples from all groups were stained for PABPN1 ađer a KCl wash, and random fields were imaged
and analysed for the percentage area of PABPN1 (+) nuclei to all nuclei.
Change in Statistic A17 + Saline A17 + RK35 FvB + Saline FvB + RK35
% INI density of
TA Mean 35.98 34.39 0 0
Std. Error of Mean 0.4591 1.616 0 0
Lower 95% CI 34 27.43 0 0
Upper 95% CI 37.96 41.34 0 0
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Table A.6: Change in forelimb grip strength in 22-week old OPMD mice administered with RK35: 8-10 mice were
treated weekly for 10 weeks from the 12th week of age, either with an anধ-myostaধn anধbody or saline. Median
measurement of 15 observaধons per mouse of forelimb grip strength was analysed. The grip strength was either
normalised to the iniধal body mass (normalised grip strength) or presented as is (raw grip strength).
Change in Statistic A17 + Saline A17 + RK35 FvB + Saline FvB + RK35
Normalised Mean 2.306 2.836 2.614 2.67
fore limb grip Std. Error of Mean 0.04181 0.06681 0.09154 0.1071
strength (KgF/Kg) Lower 95% CI 2.207 2.684 2.407 2.428
Upper 95% CI 2.405 2.987 2.821 2.912
Table A.7: Change in maximal force generated in TA of 22-week old OPMD mice administered with RK35: 8-10 mice
were treated weekly for 10 weeks from the 12th week of age ধll the 22nd either with an anধ-myostaধn anধbody
or saline. The leđ TA from all groups were mounted on a mechanotransducer and the sciaধc nerve was excited at
180Hz, and the maximal force was recorded.
Change in Statistic A17 + Saline A17 + RK35 FvB + Saline FvB + RK35
Maximal Force (KgF) Mean 1006 1222 1561 1648
Std. Error of Mean 64.72 60.33 69.22 105.6
Lower 95% CI 847.2 1083 1401 1399
Upper 95% CI 1164 1361 1720 1898
Table A.8: Change in body mass of 52wk old OPMD mice: 8-10 A17 and FvB Mice were weighed and treated weekly
for 10 weeks from the 42nd week of age, with an anধ-myostaধn anধbody or saline, with staধsধcal summaries of the
final body mass presented below:
Change in Statistic A17 + Saline A17 + RK35 FvB + Saline FvB + RK35
BodyMass Mean 29.74 31.47 34.29 35.68
Std. Error of Mean 0.438 0.825 0.5857 0.841
Lower 95% CI 28.67 29.56 32.9 33.81
Upper 95% CI 30.81 33.37 35.67 37.56
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Table A.9: Change in muscle mass of 52wk old OPMD mice: 8-10 A17 and FvB Mice were treated weekly for 10
weeks from the 42nd week of age, with an anধ-myostaধn anধbody or saline. The mean mass of all muscles were
normalized to the iniধal body mass of the respecধve animal of per group, and the normalised muscle masses are
presented below:
Change in Statistic A17 + Saline A17 + RK35 FvB + Saline FvB + RK35
Muscle mass of
TA Mean 1.247 1.423 1.531 1.764
Std. Error of Mean 0.0463 0.039 0.0705 0.0559
Lower 95% CI 1.133 1.334 1.364 1.64
Upper 95% CI 1.36 1.513 1.698 1.889
Muscle mass of
EDL Mean 0.2497 0.3292 0.2903 0.3664
Std. Error of Mean 0.0379 0.0072 0.0169 0.0163
Lower 95% CI 0.1601 0.3126 0.2503 0.3301
Upper 95% CI 0.3393 0.3459 0.3303 0.4027
Muscle mass of
Soleus Mean 1.86 2.374 1.777 1.846
Std. Error of Mean 0.1638 0.1049 0.1155 0.0869
Lower 95% CI 1.459 2.132 1.504 1.653
Upper 95% CI 2.261 2.616 2.05 2.04
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Table A.10: Change in raw muscle mass of 52wk old OPMD mice: 8-10 A17 and FvB Mice were treated weekly for
10 weeks from the 42nd week of age, with an anধ-myostaধn anধbody or saline. The mean mass of all muscles are
presented below:
Change in Statistic A17 + Saline A17 + RK35 FvB + Saline FvB + RK35
Muscle mass of
TA Mean 0.0349 0.0392 0.0489 0.0563
Std. Error of Mean 0.0016 0.0009 0.0015 0.0012
Lower 95% CI 0.0311 0.037 0.0453 0.0536
Upper 95% CI 0.0387 0.0413 0.0526 0.0589
Muscle mass of
EDL Mean 0.008 0.0091 0.0093 0.0117
Std. Error of Mean 0.0004 0.0002 0.0005 0.0003
Lower 95% CI 0.007 0.0086 0.0082 0.0109
Upper 95% CI 0.0089 0.0096 0.0104 0.0124
Muscle mass of
soleus Mean 0.0052 0.0066 0.0057 0.0059
Std. Error of Mean 0.0004 0.0003 0.0002 0.0003
Lower 95% CI 0.0041 0.0058 0.0051 0.0053
Upper 95% CI 0.0063 0.0073 0.0062 0.0065
207
Figure A.2: Effect of RK35 anধbody on minimum feret diameter 52-week old OPMD mice: A17 and FvB mice were
administered a weekly regimen of either saline or the RK35 anধbody (10mg/kg IP) for 10 weeks from the 42nd week
of age. Muscle samples from 5 randomly selected mice were secধoned and stained for laminin. Either 1000 or 400
fibres randomly selected from the TA or EDL, and the probability density funcধon was computed by kernel methods.
The shaded region represents the 95% confidence interval.
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Table A.11: Change in minimum feret diameter of 52wk old OPMD mice: A17 and FvB mice were subject to a weekly
regimen of either saline or the anধ-myostaধn RK35 anধbody IP for ten weeks from the 42nd week of age. Muscle
samples from 5 randomly selected mice were secধoned and stained for laminin. Either 1000 or 400 fibres randomly
selected from the TA or EDL, and the median minimum feret diameter of each sample was computed.
Change in Statistic A17 + Saline A17 + RK35 FvB + Saline FvB + RK35
Min. feret
diameter of TA Mean 33.36 34.81 39.47 44.65
Std. Error of Mean 0.6948 1.75 1.338 1.861
Lower 95% CI 31.43 29.95 35.76 39.49
Upper 95% CI 35.29 39.67 43.18 49.82
Min. feret
diameter of EDL Mean 30.67 30.14 32.65 37.18
Std. Error of Mean 0.9598 1.293 1.099 0.927
Lower 95% CI 27.61 26.03 29.15 34.23
Upper 95% CI 33.72 34.26 36.14 40.13
Table A.12: Change in collagen VI expression of 52wk old OPMD mice: Whole muscle samples from all groups were
stained for collagen VI, and random fields were imaged and analysed for the percentage area of collagen VI stain-
ing. The mean collagen VI area per muscle was measured and the areas were then staধsধcally tested ađer a FDR
correcধon for mulধple comparison between groups
Change in Statistic A17 + Saline A17 + RK35 FvB + Saline FvB + RK35
Expression of
collagen VI in
the TA
Mean 12.01 7.161 4.543 5.195
Std. Error of Mean 1.057 0.5838 0.352 0.2756
Lower 95% CI 9.077 5.66 3.638 4.521
Upper 95% CI 14.95 8.662 5.448 5.87
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Table A.13: Change in INI density in TA of 52-week old OPMD mice administered with RK35: Mice were subject to
a weekly regimen of either saline or the anধ-myostaধn RK35 anধbody IP for ten weeks from the 42nd week of age.
5 whole muscle samples from all groups were stained for PABPN1 ađer a KCl wash, and random fields were imaged
and analysed for the percentage area of PABPN1 (+) nuclei to all nuclei.
Change in Statistic A17 + Saline A17 + RK35 FvB + Saline FvB + RK35
INI Density Mean 36.52 37.34 0 0
Std. Error of Mean 1.019 0.6182 0 0
Lower 95% CI 32.13 34.68 0 0
Upper 95% CI 40.9 40 0 0
Table A.14: Change in forelimb grip strength in 52-week old OPMD mice administered with RK35: 8-10 mice were
treated weekly for 10 weeks from the 42nd week of age, either with an anধ-myostaধn anধbody or saline. Median
measurement of 15 observaধons per mouse of forelimb grip strength was analysed. The grip strength was either
normalised to the iniধal body mass (normalised grip strength) or presented as is (raw grip strength).
Change in Statistic A17 + Saline A17 + RK35 FvB + Saline FvB + RK35
Normalised
Grip Strength Mean 3.755 4.143 4.935 4.483
Std. Error of Mean 0.4267 0.1662 0.2597 0.4419
Lower 95% CI 2.397 3.681 3.818 3.256
Upper 95% CI 5.113 4.604 6.053 5.71
Raw
Grip Strength Mean 106.8 117.3 165.1 148.7
Std. Error of Mean 13.41 4.144 2.841 14.07
Lower 95% CI 64.1 105.8 152.8 109.6
Upper 95% CI 149.4 128.8 177.3 187.7
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To do…
X 1 (p. 8): typo
X 2 (p. 20): typo
X 3 (p. 21): typo
X 4 (p. 25): Reference fixed
X 5 (p. 27): typo
X 6 (p. 29): Added general paragraph on myopathies
X 7 (p. 30): Added histopathology of OPMD
X 8 (p. 33): Add details and give reference for IM2 cell line
X 9 (p. 36): All (not gene) strategies in title of figure
X 10 (p. 38): Give details of the route of administration and frequency of
Trehalose administration
X 11 (p. 39): Check ref 87 and if necessary modify statement on apoptosis
X 12 (p. 45): Give a better description of the metabolome in different
muscle diseases. Add a figure to explain.
X 13 (p. 46): Explain why chose GCMS not LCMS
X 14 (p. 47): Re-write as clear hypotheses, aims and objectives.
X 15 (p. 52): ”Add details of the mouse model and how it was made. Give
references State that only male mice were used for experiments Give
details of the breeding strategy and what genotypes the litters will be
expected to be. Clarify that normal controls were littermates of A17
mice
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X 16 (p. 54): Add time of day of studies in sections 3.4 and 3.5
X 17 (p. 55): State why weekly, why dose chosen and add that it is a murine
antibody
X 18 (p. 55): Add time of day of studies in sections 3.4 and 3.5
X 19 (p. 55): State whether the person doing the analysis and behavioural
studies was blinded as to the strain/treatment of each mouse. State
which experiments were not analysed blinded
X 20 (p. 57): Add time of day of studies in sections 3.4 and 3.5
X 21 (p. 57): State whether the person doing the analysis and behavioural
studies was blinded as to the strain/treatment of each mouse. State
which experiments were not analysed blinded
X 22 (p. 57): State any work that was not done by candidate and who it
was done by
X 23 (p. 58): Say what overall cross sectional area is and add reference for
the formula.
X 24 (p. 58): State whether the person doing the analysis and behavioural
studies was blinded as to the strain/treatment of each mouse. State
which experiments were not analysed blinded
X 25 (p. 58): Euthanised – add by schedule 1 procedure
X 26 (p. 58): Here and elsewhere – replace rpm with g; added centrifuge
make
X 27 (p. 59): How far apart were the sections? Give details of how the
sections were cut and placed on slides.
X 28 (p. 59): typo
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X 29 (p. 59): Add the DAPI concentration
X 30 (p. 60): Were both left and right leg muscles analysed for each exper-
iment (separately, or pooled)?
X 31 (p. 60): Give details of how they were counted
X 32 (p. 60): State whether the person doing the analysis and behavioural
studies was blinded as to the strain/treatment of each mouse. State
which experiments were not analysed blinded
X 33 (p. 60): State whether the person doing the analysis and behavioural
studies was blinded as to the strain/treatment of each mouse. State
which experiments were not analysed blinded
X 34 (p. 61): State whether the person doing the analysis and behavioural
studies was blinded as to the strain/treatment of each mouse. State
which experiments were not analysed blinded
X 35 (p. 62): “Samples were analysed…” – clarify this sentence
X 36 (p. 63): State whether the person doing the analysis and behavioural
studies was blinded as to the strain/treatment of each mouse. State
which experiments were not analysed blinded
X 37 (p. 64): Add references for Kernel density and the technique used
X 38 (p. 65): Define Feret’s diameter, give references and describe the
technique
X 39 (p. 67): State that FVBmice were littermate controls
X 40 (p. 67): Give more detailed explanation of the mouse model – too
much atrophy, too much loss of mass leading to drop in force
X 41 (p. 67): Give some precision on howmuch and each fibre type.
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X 42 (p. 67): Explain why 12 week start point and 10 weeks duration were
chosen
X 43 (p. 67): Sex of mice needs to be stated (here and throughout)
X 44 (p. 68): This and all other figures – state exact number of mice in
each group
X 45 (p. 68): And elsewhere (e.g. page 65) – state the age of the mice at
the time of each analysis. Do a flow chart for each experiment, to clar-
ify whether different mice were used for each figure, or whether some
or all were the same mice. Add details of what was measured from
what muscle of each mouse and which were used for which behavioural
assay. State if any of the in vivo experiments were repeated (e.g. page
63, 65, 67)?
X 46 (p. 69): Data ARE (not is); corrected at all known instances
X 47 (p. 73): Added kernel graph
X 48 (p. 78): Clarify “5 muscle samples from all groups” ; changed to 5
muscle samples from all groups were stained for bovine PABPN1 after
a KCl wash, and 5 random fields were imaged
X 49 (p. 78): State if any of the in vivo experiments were repeated (e.g.
page 63, 65, 67)? State if these were the same mice as used in previous
experiments (refer to new flow chart)
X 50 (p. 78): Howmany measurements/day?
X 51 (p. 81): Say why open field study was used
X 52 (p. 81): Clarify - 1 hour over 4 days – does this mean 1 hour a day, or
15 minutes a day?
X 53 (p. 81): Amend legend to say if it is SD or SEM
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X 54 (p. 87): typo
X 55 (p. 87): typo, all instances corrected
X 56 (p. 88): What is the reason for using collagen VI to quantify fibro-
sis?
X 57 (p. 92): Explain why you chose 42 weeks
X 58 (p. 92): Do a flow chart for each experiment
X 59 (p. 97): table added, here and all instances
X 60 (p. 99): Added kernel graph
X 61 (p. 103): Clarify “5 muscle samples from all groups” ; changed to 5
randomly selected muscle samples from all groups were stained for
bovine PABPN1 after a KCl wash, and 5 random fields were imaged
X 62 (p. 107): Clarify - 1 hour over 4 days – does this mean 1 hour a day,
or 15 minutes a day?
X 63 (p. 112): Mention that, since myostatin has different effects on dif-
ferent fibre types, one could look at diameter of fibres of different fibre
types. Say why soleus was not included.
X 64 (p. 112): Are there evidence and references that open field test corre-
lates with 6 minute walk test? If not, clarify this statement
X 65 (p. 116): check and state numbers of mice analysed
X 66 (p. 116): Explain why FVB + RK35 were not includedWere these the
same, or different mice than previous experiments?
X 67 (p. 117): Explain in legend what = and no change mean
X 68 (p. 124): Explain VIP scores
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X 69 (p. 138): typo
X 70 (p. 139): Give brief explanation of Ckmt-1
X 71 (p. 139): Add missing reference: footnote
X 72 (p. 142): Comment on relationship of serum and muscle metabolome
explain that muscle metabolome is the missing link
X 73 (p. 144): 9 general groups of NMDs
X 74 (p. 145): Add that there is a decrease in life expectancy
X 75 (p. 147): Comment on the body weights and fibre diameters at weeks
22 and 52 and that they suggest that the disease is not progressive
X 76 (p. 148): Discuss that it might have been useful to do fibre types and
intensity of SDH+ fibres
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